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Dynamic Digital Optical Tomography for Cancer Imaging and Therapy Monitoring 
Molly Flexman 
 
Diffuse optical tomography is a non-invasive imaging technique that uses near-infrared light to 
create three-dimensional images of tissue.  This dissertation presents the design and validation 
of an instrument for rapid optical imaging using digital detection techniques.  In addition to a 
detailed description of the instrument, three studies are presented: a clinical study detecting 
breast cancer using dynamic optical imaging; a pre-clinical study monitoring early tumor 
response to anti-angiogenic therapy; and a clinical study monitoring individual patient response 
to neoadjuvant chemotherapy.  These studies show that diffuse optical tomography is a 
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Chapter 1 : Introduction 
Breast cancer affects approximately 1 in 8 women in the United States and the incidence 
throughout the world is increasing [1]. While mammography is still the current standard of 
care, its shortcomings have led to the exploration of novel imaging modalities to improve the 
sensitivity and specificity and to provide screening alternatives for young women, women at 
high risk, and women with dense breast tissue. Over the past ten years, research in the field of 
diffuse optical tomography (DOT) for breast cancer has grown substantially. DOT shows 
significant promise in both detecting tumors and predicting their responsiveness to treatment 
due to its strong sensitivity to physiologically relevant parameters such as hemoglobin, fat, and 
water [2]. 
1.1 General goals and specific aims 
 The goal of this thesis is to develop and validate a new DOT system that can perform 
simultaneous measurements of both breasts at fast imaging speeds for use in dynamic imaging 
studies.  The instrument is built upon digital detection techniques that leverage a digital-signal-
processor (DSP) design to acquire and process large amounts of data quickly, with high 
sensitivity, and a large dynamic range.  This system opens up a new realm of breast imaging 
studies focusing on the hemodynamic signature of the breast in response to an external 
stimulus.  Clinically, there are two main areas where DOT could make an impact in the current 
state of breast cancer management.  Firstly, in breast cancer screening, the non-ionizing, low-






screening, secondary screening, or the more frequent imaging required for high-risk groups.  
Secondly, there is a growing need for real-time feedback during chemotherapy treatments to 
adjust the timing and treatment type according to the individual patient's response.  In 
investigating the role that DOT may play in breast cancer management we will pursue the 
following specific aims:  
 
Aim 1: Develop and characterize a DOT breast imaging system that uses digital 
detection techniques 
Challenge: To capture enough data to image both breasts simultaneously and fast 
enough to capture dynamic features. 
Approach: We will employ digital detection techniques including multiple digital signal 
processor (DSP) chips for processing data.  Configured in a master-slave architecture 
these DSP chips can streamline data collection while minimizing cost, improving 
scalability, and maintaining low noise levels. 
Impact: This will be the fastest DOT system to simultaneously image both breasts in a 3D 
geometry.  This will enable studies focused on detecting breast cancer based on the 
hemodynamic response to a stimulus.  
 







Challenge: To identify dynamic features that can be used to detect breast tumors in 
response to a breath hold. 
Approach: We will identify optimal time points during the imaging sequence for 
separation of tumor/non-tumor regions.  We will also explore differences in the 
transient response of tumor regions as compared to healthy tissue. 
Impact: This pilot study will provide a basis for further studies looking at the dynamic 
signature of breast cancer. 
 
Aim 3: Explore the use of DOT for imaging early vascular response to drug therapy in a 
pre-clinical tumor model 
Challenge: To determine if DOT can distinguish responsive from non-responsive tumors 
within a few days of beginning therapy. 
Approach: Two tumor types will be studied: a responsive Ewing Sarcoma and a non-
responsive Neuroblastoma. We will aim to differentiate between the two tumor types 
using DOT imaging performed at baseline and 1, 3, and 5 days following treatment.  
Impact: Anticipating tumor response to therapy can enable more tailored treatment 
schedules that reduce toxicity and lower cost, thereby improving patient outcomes.  
This pre-clinical model will provide a basis for Specific Aim 4. 
 
Aim 4: Investigate the use of DOT in monitoring and predicting chemotherapy 






Challenge: To use DOT to predict if a breast tumor will respond to neoadjuvant 
chemotherapy treatment.   
Approach: We will image each patient at scheduled intervals over several months of 
chemotherapy.  We will correlate the response seen in DOT imaging to actual tumor 
response. 
Impact: DOT can help inform clinical decisions about treatment schedules and drug 
effectiveness on a patient-specific basis.  Ultimately this could reduce toxicity, lower 
costs, and improve patient outcomes. 
 
Exploring these specific aims will introduce new state-of-the-art technology to the field 
of DOT that will facilitate future studies using dynamic changes to detect breast tumors.  This 
technology will be used for studies that could help enhance traditional breast cancer screening 
and improve the quality of care for patients undergoing chemotherapy treatments.  
1.2 Breast Cancer 
Breast Cancer Management 
Breast cancer affects approximately 1 in 8 women in the United States and the incidence of 
breast cancer throughout the world is increasing [1].  Breast cancer currently accounts for 28% 
of all new cancers diagnosed in women, with almost 40,000 deaths caused by breast cancer 
each year [3].  However, from 1975 to 2000 there was a 24% reduction in breast cancer deaths 
due to screening mammography and adjuvant therapy [1, 4].  It is clear that breast cancer 






opportunities for improving breast cancer care and outcomes, there are a number of steps 
during the screening, diagnosis, and treatment where one can look to improve upon the 
current techniques.  An overview of the steps involved in breast cancer management is shown 
in Fig. 1-1.   
 







 Following an abnormal screening mammogram, or a palpable mass detected by a self or 
clinical breast exam, the patient typically undergoes secondary screening.  Secondary screening 
includes diagnostic mammography, ultrasound (US) or magnetic resonance imaging (MRI).  US 
and MRI are less sensitive to breast density and can provide additional information to 
differentiate between benign and malignant masses.  In cases where the MRI and US imaging is 
inconclusive, the patient may be referred for nuclear imaging, which includes positron emission 
mammography (PEM, also known as positron emission tomography PET) or breast-specific 
gamma imaging (BSGI).  Both of these imaging modalities are based on the same technology, 
but use different radiotracers to identify cancer cells based on their increased uptake of the 
tracer. 
 If secondary imaging indicates that there is a possible malignancy in the breast, then a 
biopsy is performed for a pathological assessment of the cells of the suspicious region.  The 
biopsy needle must be guided into the correct region of the breast and this is usually 
accomplished by either ultrasound-guided biopsy, stereotactic biopsy (x-ray guided), or MRI-
guided biopsy, depending on which modality has the best visualization of the tumor.  The 
imaging and biopsy results combine to form the diagnosis.  In cases of locally advanced breast 
cancer, involving a large tumor that has not metastasized to any other region in the body, the 
patient may be referred for neoadjuvant therapy prior to surgery.  Surgery may include a 
lumpectomy or mastectomy.  Following surgery the patient may undergo a number of adjuvant 
therapies including radiation, hormone therapy, treatment with monoclonal antibodies, and 






 Breast cancer management combines a large amount of information from a variety of 
sources in order to improve patient outcomes.  New technologies must consider how they can 
best fit into and improve the entire process.   
Breast Cancer Pathology 
Breast cancer is a generic term that covers a wide range of pathologies.  Understanding the 
various types of breast cancer is important in preparing new imaging strategies.  Breast cancer 
typically begins with a mutation to an epithelial cell lining the ducts and/or the lobules.  Ductal 
carcinomas make up the majority of detected breasts cancers, but lobular carcinomas, which 
make up 5-15% of breast cancers, are significantly harder to detect with traditional screening 
methods due to the fact that they often create single cell strand-like growths as opposed to 
masses and tend to be multifocal in the breast [5].   
 Ductal Carcinoma in situ (DCIS) is characterized by the proliferation of large, cohesive 
malignant cells from the epithelial lining of the duct or lobule, but where there is no evidence of 
invasion.  Approximately 20% of diagnosed breast cancers are caught prior to invasion [5], and 
mammography is the primary imaging modality for diagnosis of DCIS by identifying 
microcalcifications.  However, mammography is not very sensitive to DCIS and is unable to 
evaluate the extent of the DCIS.  MRI imaging has shown promise in visualizing DCIS, but has 
variable sensitivity to DCIS, with published studies showing sensitivities ranging from 16-73% 
[5].  This may be partially attributed to the fact that DCIS is highly heterogeneous and can exist 
in both mass and non-mass form.   DCIS also ranges from low-grade to high-grade classification.  






features as well as necrosis.  Low grade DCIS is characterized by uniform cells without necrosis 
and in its mildest form is identified as Atypical Ductal Hyperplasia (ADH).  Lobular Carcinoma in 
situ (LCIS) and Atypical Lobular Hyperplasia (ALH) are pre-invasive lobular carcinomas and are 
rarely detected by screening as they do not form masses.  LCIS is rarely associated with 
calcifications, is almost always multifocal, and is more frequently bilateral than DCIS.  Invasive 
Ductal Carcinoma (IDC) and Invasive Lobular Carcinoma (ILC) are cancers where the malignant 
cells have invaded out of the ducts or lobules into the surrounding normal tissue.  Breast cancer 
spreads three ways: direct invasion, through the lymphatic system, or via the blood vessels.  
Primary tumors are ultimately responsible for only 10% of deaths from cancer, making 
metastatic tumors in remote sites in the body the primary cause of death [6].  In breast cancer 
the most likely locations of metastases are bone marrow, lungs, liver, and brain. 
 Growing tumors require increased access to nutrients and oxygen, which they obtain by 
creating new vasculature via a process known as angiogenesis.  Angiogenesis is evident even in 
preinvasive cancers; high-grade DCIS is associated with a rim of microvessels around the ducts 
to supply the proliferating tumor cells [7].  As the tumor continues to grow and invade, it 
increases the amount of surrounding vasculature.  Studies have shown that the vascular density 
of a tumor correlates with disease-free-survival [6].  In addition, due to the fact that the pro-
angiogenic factors are continuous and abundant in the tumor region, the vasculature fails to 
create an efficient and mature network.  As a result, tumor vasculature is typically irregular, 






and visualizing the vascular features of tumors can help differentiate benign from malignant 
masses, predict outcomes, and provide additional information about the tumor physiology.  
Breast Cancer Imaging 
The most commonly applied modality for breast cancer screening is x-ray mammography.  This 
screening technique is widely used due to its ease of administration and relatively good 
sensitivity and specificity given its low cost.  However, its use of ionizing radiation limits the 
frequency with which this modality can be employed.  Furthermore, mammography has shown 
to be less reliable for young women and women with dense breasts, to cause patient 
discomfort, and its high false positive rate means that after 10 years of screening 1 in 2 women 
will have had at least one false positive mammogram [8, 9].     
 As an alternative to x-ray mammography, magnetic resonance imaging (MRI) has proven 
to be a powerful tool in secondary imaging and in monitoring high-risk women, but its high cost 
and low specificity hinders its use as a screening modality [8].  In addition, breast MRI typically 
uses an injected contrast agent and has some contraindications (pacemakers, claustrophobia).  
Dynamic contrast-enhanced MRI (DCE-MRI) uses the kinetic uptake curves of the suspicious 
region to differentiate between benign and malignant lesions based on the vascular perfusion, 
vessel density, and leakiness.  MRI can also be used to assess the extent of disease in already 
detected cancers, and is being investigated for monitoring chemotherapy treatment. 
 Ultrasound imaging (US) is commonly used as a second-line diagnostic tool to 
differentiate masses detected with x-ray mammography, but operator variability and low 






cysts from tumors, can be used to estimate tumor size, and is commonly used to guide biopsies.  
Recently, automated whole breast ultrasound (AWBU) has been explored as a way to 
standardize breast ultrasound imaging for use in screening applications.  This technique is still 
in early stages of research. 
Diffuse optical tomography (DOT) is a non-ionizing modality that is sensitive to 
physiologic changes and may be able to address some of the shortcomings of other breast 
imaging modalities [2, 10].  Nuclear imaging techniques including PEM and BSGI have gained 
attention for their ability to detect small tumors, their high sensitivity, and the ability to 
visualize ductal and lobular carcinomas.  A comparison of some of the available breast imaging 
modalities is presented in Table 1-1 [11], below.  This table is by no means comprehensive, as 
there is also ongoing research into a variety of imaging techniques including diffusion-weighted 
MRI, ultrasound elastography, thermography, electrical impedance imaging, and more.  The 
extensive effort that is currently committed to finding new breast imaging modalities to 
improve breast cancer management is indicative of the importance of this field, and the impact 
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Y +good at identifying small tumors 
+good sensitivity for DCIS, ILC 
-~40 minutes/exam 
-high false positive rate 
-injection of radiotracer 
*Approximate cost based on similar techniques. 
1.3 Diffuse Optical Tomography (DOT) 
Over the last decade, DOT has emerged as a novel biomedical imaging modality that may be 
able to address some of the shortcomings of other breast imaging modalities [2, 10]. DOT uses 






breast tissue.  By illuminating the tissue from various spatially distributed source positions and 
measuring the transmitted and reflected light at a number of detector positions surrounding 
the sample, DOT generates 3D spatial maps of the absorption (μa, typically 0.01-1 cm
-1) and 
scattering (μs‘, typically 10-100cm
-1) of tissue.  The reduced scattering coefficient (μs‘) is 
commonly used to characterize both the scattering (μs) and the anisotropy (g) of the tissue as 
shown in Eq. 1.1.  Anisotropy is a measure of the directionality of the scattering (in isotropic 
scattering the light is deflected to all angles equally, whereas anisotropic scattering favors a 
specific angular range). 
    
              (1.1) 
By illuminating the sample with multiple wavelengths of light and using the known 
absorption spectra of optically-relevant tissue chromophores, we can extract the concentration 
of those chromophores.  Fig. 1-2 shows the absorption spectra of the four primary optical 
absorbers in the breast: oxygenated (HbO2) and deoxygenated hemoglobin (Hb), fat, and water 
[15-17].  Fig. 1-2 illustrates why the near-infrared (NIR) wavelength window from 650-900 nm is 
ideal for tomographic imaging of tissue: the absorption of blood is significantly lower than at 
the lower visible wavelengths, but the absorption of water and fat is still quite low (it increases 







Figure 1-2. Optical absorption of oxy-hemoglobin (HbO2), deoxy-hemoglobin (Hb), water (H2O), 
and fat plotted versus wavelength, showing the 650-900 nm NIR window ideal for optical imaging 
of tissue. 
 
 For a tissue comprised of Nc absorbing chromophores the total absorption of the tissue 
at a given wavelength, μa(λ), can be described by Eq. 1.2, where Ci is the concentration of the i-
th chromophore and ԑi is the molar extinction coefficient of the i-th chromophore at that 
wavelength.  Ci is the only unknown in Eq. 1.2, since μa(λ) is measured experimentally and ԑi is 
known (see Fig. 1-2).   By measuring the absorption coefficient at Nc wavelengths, Eq. 1.2 
produces four equations with four unknowns, allowing us to solve for the concentrations of the 
optically absorbing chromophores (Ci). 
       ∑        
  
       (1.2) 
DOT differs from x-ray imaging in a number of important ways.  Firstly, x-ray imaging 
uses shorter, higher energy wavelengths of electromagnetic radiation whereas DOT uses 






imaging than x-ray mammography as it doesn't expose the tissue to harmful high-energy 
radiation.  However, the use of safer, lower energy electromagnetic radiation (light) comes at a 
cost.  Electromagnetic waves are subject to scattering by structures of a similar size to the 
wavelength.  This means that near-infrared light is subject to scattering by cellular and sub-
cellular structures (such as mitochondria).  As a result, unlike high-energy x-rays that pass 
through the tissue in relatively straight lines with little scattering, near-infrared light will pass 
through the tissue in a scattered, more diffuse distribution.  The propagation of some initial x-
ray intensity (I0) through tissue can be modeled by the Beer-Lambert law, Eq. (1.3), and the 
absorption (μa) within the tissue can be reconstructed using the inverse radon transform.   
        
           (1.3) 
The Beer-Lambert law requires a known path length (dx) for the electromagnetic wave passing 
through the tissue.  In optical imaging, the path length depends heavily on the number of 
scattering events and will vary for each photon exiting the tissue (Fig. 1-3).  As a result, 
modeling the propagation of light in tissue is significantly more complicated and prevents the 
use of a direct inversion scheme to solve for the absorption and scattering coefficients of the 
tissue.  Reconstructing optical properties (namely absorption and scattering) is a 
mathematically ill-posed problem that is computationally expensive and is the subject of 








Figure 1-3.  Illustration of the effect of scattering events on the path length.   
Shown are an example path through tissue for (a) an  x-ray beam and (b) near-infrared light.  The 
multiple scattering events of light make it difficult to know the optical path length of the 
photons. 
 
A second significant difference between DOT and x-ray imaging is the source of contrast.  
X-ray imaging relies predominantly on the photoelectric absorption of energy by atoms with a 
high atomic number.  In tissue, this means that calcium (atomic number of 20) is a primary x-ray 
absorber, which is why microcalcifications are a source of contrast in detecting breast tumors 
using mammography.  In DOT, contrast is derived from the primary absorbers and scatterers of 
light at a given wavelength.  In the red to near-infrared wavelength range the primary 
absorbers of the breast are blood (oxy- and deoxy-hemoglobin), water, and fat.  All four of 
these chromophores have been shown to be valuable in detecting and characterizing breast 
tumors [21].  Increased blood is a hallmark of growing tumors that require increased 
vascularization to continue to receive adequate nutrient supply and remove waste products [6].   
Growing tumors also push away the surrounding adipose tissue, resulting in decreased lipid.  
The water content may be related to the cellularity and corresponding aggressiveness of the 
tumor.  Water and lipid are also correlated to breast density, a known breast cancer risk factor.  
Furthermore, light is sensitive to scattering changes in tissue. Researchers have shown that 






denser nuclei, can be used to detect breast cancer [22, 23].  Specifically, increases in scattering 
power and scattering amplitude can differentiate certain types of cancer from healthy tissue 
[24].  Overall, diffuse optical tomography is rich in contrast that is not readily available to any 
other imaging modality. 
1.4 Instrumentation for Diffuse Optical Tomography 
DOT is a relatively young technology that has yet to be commercialized on a large scale.  
Instrumentation for DOT is typically designed by investigators for use in specific applications.  
Many research groups have made significant advances in the field of DOT breast imaging, 
focusing on a variety of designs for instrumentation [24-39].  These designs fall into three broad 
categories based on the type of light illumination: time-domain (TD), frequency-domain (FD), 
and continuous-wave (CW).   
TD systems inject a short light pulse (full-width-half-maximum typically less than 0.1 ns) 
into the breast and measure the time-dependent transmitted intensities.  These systems 
provide a wealth of information about the optical properties of the tissue, however, data 
acquisition typically takes 3-5 minutes and the systems are comparably expensive.  Taroni et al. 
have shown an 80% sensitivity in detecting breast lesions with a 5-7 wavelength time TD system 
in a retrospective study of 194 patients [29].  In particular, they showed that while strong 
absorption of blood at the short wavelengths is a hallmark of tumors, it is low scattering across 
wavelengths, and low absorption around the lipid peak (905-916 nm) that allows for the 
differentiation of cysts.  Rinneberg et al. also showed sensitivity and specificity between 80% 






 Another type of instrumentation, known as frequency-domain (FD), uses amplitude-
modulated light instead of a short light pulse to probe the breast tissue.  These systems operate 
at one or more source-modulation frequencies and gather data on both the amplitude and 
phase of the light that passes through the tissue.  FD instrumentation is typically less expensive 
than TD instrumentation and allows for faster data acquisition than TD systems.  Using this 
technology Choe et al. showed the ability to differentiate between benign and malignant 
tumors in 47 subjects with a sensitivity and specificity of 98% and 90% [26].  Analyzing data 
from 60 healthy patients, Srinivasan et al. conducted one of the most comprehensive studies on 
the properties of normal breast tissue using a 6-wavelength FD system [32], and have shown 
promising results in small populations of breast cancer patients [24]. 
 The third category of DOT instrumentation does not rely on a time-varying light source, 
and instead injects a steady-state beam of light into the breast.  Known as continuous-wave 
(CW) systems, the instrumentation measures the change in the amplitude of the light as it 
passes through the breast, which results in simpler, more affordable technology.  While no 
phase information is acquired, this approach allows for faster data acquisition than in FD or TD 
systems, which makes it possible to study intrinsic time-varying dynamic signals.  Several groups 
have made successful use of CW instrumentation for breast cancer detection including Liang et 
al. who showed sensitivity and specificity of 82% and 71% in 33 patients [33] and van de Ven et 






 In addition to these three classes of optical tomography imaging systems (TD, FD, and 
CW), a number of promising hybrid systems have been developed that combine DOT with other 
imaging modalities such as x-ray mammography [27], ultrasound [35, 36], and MRI [25, 38]. 
1.5 Dynamic Optical Imaging 
Regardless of the type of instrumentation, all categories of DOT systems rely on endogenous 
contrast generated by the physiology of the tissue.  Most studies have focused on the steady-
state changes that can be observed in malignant tissue, notably, increase blood due to tumor 
angiogenesis, increased scattering due to tumor cellularity, or decreased oxygen saturation due 
to tumor hypoxia.  However, there are also transient features that can be used to identify 
malignant tissue. 
Tumor vasculature is known to be tortuous and disorganized, hyperpermeable, and lack 
proper vasomotor function [41].  Tumor cells consume large amounts of oxygen which, coupled 
with poor oxygen delivery, leads to tumor hypoxia.  These changes not only affect the steady 
state appearance of the malignant tissue, but also affect the hemodynamic response of the 
cancerous tissue, providing additional information that can assist with the diagnosis.  Some 
common sources of dynamic contrast used to evoke a hemodynamic response include a 
respiratory maneuver [42], the application of pressure to the breast [27, 39, 43], the respiration 
of carbogen [44], and the injection of indocyanine green (ICG) [38, 45, 46].  
 The existing systems used in dynamic imaging studies are limited in three-dimensional 
spatial resolution, temporal resolution, or dynamic range.  Almost all of the systems image only 






a different stimulus.  Further, the clinical application of dynamic imaging is still relatively recent, 
and hence most published work focuses on case studies and small patient populations. 
1.6 Optical Imaging of Neoadjuvant Chemotherapy 
Neoadjuvant chemotherapy (NACT), chemotherapy given prior to surgery, is the standard of 
care for locally advanced breast cancers that have not metastasized to other regions of the 
body.  It can reduce tumor size, thereby allowing for breast conserving surgery in patients who 
would have otherwise have required a mastectomy [47].  It also provides clinicians with 
valuable information on the tumor responsiveness to treatment.  Following NACT the patient 
undergoes surgery, at which point the pathological effect of the treatment can be assessed.  A 
complete pathological response (pCR) occurs when no residual tumor cells are observed in the 
pathological specimen obtained during surgery.  Studies have shown that pCR correlates with 
the more traditional cancer endpoints of 5-year and 10-year disease-free-survival [48, 49].  
However, only 3-27% of women achieve a pCR after months of NACT [50].  Developing a way to 
monitor the progress of the therapy would make it possible to detect non-responders early in 
treatment and then adjust the therapy to improve response and overall survival.  
 The low pCR rate for NACT has been the impetus for studies looking to predict individual 
patient response to neoadjuvant chemotherapy.  There is currently no modality that is ideal for 
assessing the tumor response to NACT.  Physical exam, mammogram, ultrasound, and magnetic 
resonance imaging (MRI) are based on measuring tumor size changes and are insensitive to 
early response.  In a retrospective study of 141 women, Chagpar et al., found that size 






tumor size after NACT (correlation coefficients of 0.42, 0.42, and 0.41 respectively) [51].  PET-
CT, has shown promise in predicting response to NACT; however, in addition to high cost 
($1000 per study) [52], the disadvantage of successive PET-CT imaging is the exposure of 
patients to radioactive isotopes and ionizing radiation (30 mSv for a CT scan compared to 0.1 
mSv for a chest  x-ray).   
 DOT has the potential to make an impact in NACT monitoring due to its low cost, lack of 
ionizing radiation or isotopes, and fast imaging speeds.  In addition, it is sensitive to hemoglobin 
and the corresponding vascular changes, which occur early on during treatment and could be a 
more reliable way of predicting the tumor response.  Preliminary work by groups using 
handheld diffuse optical spectroscopy systems [53, 54], ultrasound guided tomography [55], 
and 3D diffuse optical spectroscopy [56, 57] has shown that DOT may be a promising technique, 
but further investigation is needed.  In particular, there is a need for studies using full 3D DOT 
implementations and larger patient groups with better controlled drug types and schedules. 
1.7 Overview of this Thesis 
This work aims to improve the understanding of dynamic imaging by developing novel 
instrumentation for use in cancer imaging studies.  Here, we present a new CW optical 
tomographic breast imaging system designed for dynamic optical breast imaging.  This new 
system uses digital detection techniques with multiple digital-signal-processor (DSP) chips 
arranged in a master-slave configuration to maximize the processing throughput, reduce noise, 
and provide a system design that can be scaled to accommodate a variable number of 






 The clinical use of the new optical tomography system is demonstrated in two breast 
cancer studies.  The first study uses dynamic DOT to identify breast tumors by their 
hemodynamic response to a breath hold.  The second study uses DOT to monitor the response 
of breast tumors to neoadjuvant chemotherapy over the course of 5 months.  The neoadjuvant 
chemotherapy monitoring study is complemented by a pre-clinical study looking at the early 
vascular response (<5 days) to anti-angiogenic therapy in a mouse tumor model.  And finally, 







Chapter 2 : Instrument Design 
This chapter introduces a novel CW optical tomographic breast imaging system designed for 
dynamic optical breast imaging.  To overcome the inherent difficulty in obtaining high frame 
rates while collecting large amounts of data, we expand upon the concept of digital-based 
detection previously introduced by our group [58].  This new system extends the digital 
detection performance by using multiple digital signal processing (DSP) chips arranged in a 
master-slave setup to maximize the processing throughput, reduce noise, and provide a system 
design that can be scaled to accommodate a variable number of detectors and wavelengths. 
2.1 System Requirements 
A number of requirements were important in designing the dual-breast dynamic optical 
tomography system.  These requirements are listed in order of importance: 
A. Speed: To perform dynamic imaging of vascular changes the temporal resolution of 
the system should be on the order of 1 Hz. 
B. Channels: A large number of source-detector channels are necessary to provide 3D 
spatial coverage of both breasts. 
C. Sensitivity and Dynamic Range: The system must be sensitive enough to detect light 
that has been attenuated by up to 10 cm of tissue.  However, it must also be able to 
detect light that has only passed through 1 cm of tissue.  A large dynamic range 
allows for both small and large source-detector separations. 
D. Linearity: The system must maintain a linear response over the complete dynamic 






E. Stability:  As dynamic experiments will take place over an interval of time, the 
system should have a stable response over that time. 
F. Size: The system should be compact for use in a clinical setting. 
G. Scalability: The system should be able to scale with the number of detector 
channels, wavelengths, and sources to facilitate future design. 
2.2 Benefits of Digital Design 
To accomplish these design requirements, we implemented a system that uses digital 
techniques for the optical detection.  Digital signals rely on a sequence of high and low voltages 
to encode a binary number.  Analog signals use a voltage level to indicate the number.  Digital 
signals are much less sensitive to fluctuations in the voltage level (due to changes in 
temperature, power supply) and to noise introduced on the signal (due to external 







Figure 2-1.  Example of an analog and digital representation of the value 5.   
(a) The digital signal transmits high-low-high as 10V-0V-10V to encode the number 5 in binary 
format, while the analog signal is transmitted as a level 5 volts.   
(b) In the case of ±10% noise the digital high-low-high signal becomes at worst 9V-1V-9V which.  
If we assume that anything above 7V triggers a ‘high’ and anything below 3V triggers a ‘low’ 
signal then the digital signal will be unchanged and interpreted as high-low-high, encoding the 
value 5.  However, in the analog domain, the ±10% noise direct affects the level of the signal, 
resulting in a range of results from 4.5 to 5.5.   
(c) In the case of 10% droop in the driving voltage, the binary signal changes to 9V-0V-9V, still 
resulting in high-low-high, or 5.  However, the analog signal will decrease due to the droop in the 
driving voltage, resulting in a value of 4.5. 
 
By bringing the detected signal into the digital domain close to the point of detection, 
the amount of noise introduced onto the signal as it is transmitted back to the host computer is 
reduced.  Moving into the digital domain also facilitates the use of increasingly sophisticated 
digital hardware including integrated circuits (ICs), digital-signal-processors (DSPs) and 






achieve the same or similar performance to the equivalent analog hardware with a significantly 
smaller footprint.  The design described here incorporates multiple DSP chips in a master-slave 
configuration to streamline the signal detection and reduce noise. 
2.3 Instrument Overview 
The system uses four near-infrared wavelengths to illuminate the tissue through 32 source 
fibers on each breast and simultaneously collects the transmitted and reflected light from 64 
detector fibers on each breast.  The instrument is made up of four main components, as shown 
in Fig. 2-2.  The following chapters will discuss each of these components in further detail. 
 
Figure 2-2. Schematic of the dynamic optical tomography breast instrument. 
 
The Input Unit is responsible for generating the light used to illuminate the tissue.  The 
system uses four wavelengths of near-infrared light that are generated by laser diodes (LD) and 
modulated at two different radio frequencies.  The four wavelengths are combined into two 
streams of light that are sequentially switched between various optical fiber positions on the 
target tissue.  The design of the input unit is discussed in Chapter 3. 



































































































The Breast-Fiber Interface is the physical component that brings the optical fibers in 
contact with the tissue.  The configuration varies depending on the type of tissue being imaged 
and the experimental design.  Two fiber-tissue interface designs are discussed in Chapter 8. 
The Detection Unit measures and conditions the transmitted and reflected light from 
the tissue before passing it onto the Host Computer.  As each source fiber sequentially 
illuminates the tissue, all detectors surrounding the tissue measure the light intensity.  The 
signal is detected with a photodiode (PD) prior to amplification by a trans-impedance amplifier 
(TIA) and programmable gain amplifier (PGA), low-pass filtered (LPF), and then digitized with an 
analog-to-digital converter (ADC).  The signal is then processed in the digital domain by a 
master DSP (mDSP) and three slave DSPs (sDSP).  To coordinate the system timing and data 
throughput the mDSP relies on a master complex programmable logic device (mCPLD) and slave 
CPLD (sCPLD). The final signal is deposited into data buffers that coordinate with data 
acquisition cards (DAQ) to transmit the data to the Host Computer. In addition, the Detection 
Unit, via the mCPLD, communicates directly with the Input Unit to coordinate the timing of the 
system.  The detection unit is discussed in detail in Chapters 4 and 5. 
The Host Computer communicates with the instrument hardware and provides a 
graphical user interface (GUI) through LabVIEW to control the instrument and collect data.  The 
software control of the system is described in Chapter 6. 
An overview of the system, along with the characterization of the system performance, 







Chapter 3 : Input Unit Design 
3.1 Multi-wavelength Illumination 
The input unit is responsible for generating the light that illuminates the target.  The system 
uses four wavelengths of near-infrared light at 765 nm, 808 nm, 827 nm, and 905 nm generated 
by continuous-wave laser diodes controlled by laser drivers.  The intensity of each laser is 
modulated at either 5 kHz or 7 kHz.  The four wavelengths are passed through two optical 
combiners to create two streams of light, with each stream containing two colors of light 
modulated at different frequencies.  The two light streams are input to a 2x32 optical switch 
that is responsible for sequentially switching the light into the 32 optical fibers that surround 
the tissue.  Optical fibers bifurcate to simultaneously illuminate the left and right breast with 
the same input light.  An overview of the generation of the input light is shown in Fig. 3-1.   
 
Figure 3-1.  Schematic of the light input unit.   
The light is generated at two different modulation frequencies by four laser diodes (LD).  Two 
optical combiners bring the four wavelengths into two streams of light that are input to the 2x32 
optical switch (OS).  The optical switch sequentially redirects the light to each of the 32 output 







Modulating the laser light intensity is an important feature of the input unit as it allows 
for simultaneous illumination of the target with multiple wavelengths at the same time, and 
also improves the rejection of ambient light.  Due to the fact that each stream must be 
detected with the same hardware, the same amount of gain must be applied to all wavelengths 
of the stream.  In cases where the attenuation through the tissue is significantly different at the 
various wavelengths it can be difficult to find one gain setting to accommodate all four 
wavelengths, thus our design uses two streams of light with two wavelengths in each stream as 
opposed to combining all four wavelengths into a single stream.   
3.2 DDS Modulation 
Each modulation frequency is generated by a direct digital synthesis (DDS) chip 
(AD9854, Analog Devices Inc.) and passed through a series of filters as well as offset and 
amplitude adjustment stages prior to being input to the laser driver controller.  A DDS chip is an 
inexpensive solution that is compact and can generate a more stable frequency than other 
commercial laser drivers.  In this system we use a pre-programmed fixed reference signal on 









Figure 3-2.  Diagram of the circuitry for generating the modulation waveform. 
Highlighted are the DDS synthesis, pre-amplification, filtering, and post-amplification stages. 
 
Fig. 3-2 shows a circuit diagram of the components responsible for generating the 
modulated current that is used to modulate the intensity of the laser driver.  The DDS chip 
generates a sinusoidal waveform (IOUT1), that develops a 10 mA 0.5 V peak-to-peak signal with 
12 bits of resolution across an LC filtering stage (as specified in the application notes for 
AD9854 [59]).  This digital signal cannot fully capture the smoothly varying sinusoid, and instead 
approximates the sinusoid with a staircase-like waveform with 2m available levels where m is 
the number of bits of resolution.  This effect is exemplified in Fig. 3-3.  This approximation 
introduces white noise onto the signal.  IOUT1 must be amplified to a suitable level, filtered to 







Figure 3-3.  Graph demonstrating the effect of quantization on an analog signal.   
Here we show a sinusoid quantized with 2
3
 bits of digital resolution.  Note the staircase effect 
that the quantization produces – resulting in white noise that is present along with the sinusoidal 
frequency. 
 
The first amplification stage (AMP1) uses an operational amplifier (EL5203IS, Elantec) 
whose R2/R1 ratio determines the amount of gain applied (in this case R1=3.3 kΩ, R2=15 kΩ, 
and ~4.5x gain is applied).  AMP1 amplifies the signal in preparation for the filtering stage.   
The low-pass filtering consists of two 4th order Butterworth filters (LTC1563, Linear 
Technology) whose cutoff frequency and filter characteristics are determined by a number of 
resistors, as specified in the application notes [60].  The purpose of the filtering stage is to 
remove some of the white noise introduced onto the modulation signal through quantization.  
Specifically, the filtering must improve the signal-quantization-to-noise-ratio (SQNR) of the 
modulation signal so that it is not the limiting factor in our system.  The detection electronics 
make use of 16 bits of resolution, but our input DDS synthesizer only uses 12 bits of resolution.  






by low-pass filtering the signal to remove the noise contained in the high-frequency spectrum 
of the signal.  The cutoff frequency of the low-pass filter is selected as 12.5 kHz, well above our 
5 kHz and 7 kHz modulation frequencies, and exactly matches the anti-aliasing filter used in the 
detection unit.  For a detailed discussion of the SQNR considerations please refer to [56]. 
Following the filtering stage, the signal must be amplified to control the laser intensity.  
A laser driver regulates the laser output power according to the driving input voltage to the 
driver.  Therefore the voltage offset and amplitude of the modulated signal must be 
considered, since they will set the output power and the lowest part of the signal must stay 
above a 1.5 volt threshold that will keep the laser driver “on”.  Operating in a constant current 
mode, the laser driver modulates the input current to the laser with a coefficient of 200 mA/V.  
The amplitude of the input signal to the driver is primarily controlled by the final amplification 
stage (AMP2) according to ratio of R4/R3.  The offset, originally derived from the DDS, is also 
amplified according to the AMP2 gain.  In this design, it is not explicitly controlled.  This feature 
could be introduced by replacing the ground connection at the positive input to AMP2 with a 
voltage divider circuit that would precisely set the offset of the signal. 
The modulation signal synthesis and conditioning is all performed on a printed circuit 
board (PCB) of a standard 3U height and 16 cm length for ease of use with commercial 
enclosures.  Each board contains the circuitry to generate two distinct modulation frequencies, 
and the system uses two of such boards to drive the four laser drivers.  The four-layer PCB has a 
top and bottom copper layer for part placement and routing, one dedicated inner ground layer, 






on-board voltage regulators to generate +3.3 V and ±5 V power lines.  The board connects to a 
backplane via a standard 96-pin connector (650473-5, Tyco Electronics).   
A photograph of the board is shown in Fig. 3-4.  The detailed schematic, board layout, 
and bill of materials (BOM) for the DDS board are included in Appendix A.  
 
Figure 3-4.  Photograph of the DDS board with the key functional components outlined in white. 
 
3.3 Microcontroller Design 
The output frequency and operating settings of the DDS chips are controlled by a 
programmable microcontroller (AT89S8252, Atmel) that sits on the backplane of the Input Unit.  
The microcontroller receives a 3.3 V power supply and an input 10 MHz clock (M_CLK) 
generated by a crystal oscillator (SG8002, Epson).  There is a master reset (M_RST) that is 






principally used for debugging purposes.  The key microcontroller inputs and outputs and their 
connection to the DDS chips is outlined in Fig. 3-5.   
 
Figure 3-5.  Outline of the connections between the microcontroller (µCTLR) and the direct digital 
synthesis (DDS) chips. 
 
 With an 8-bit Atmel 8501 architecture the microcontroller also has 12 Kbytes of In-
System Programmable Flash memory and 2 Kbytes of EEPROM data memory.  The program for 
the device is written in C++ through Keil µVision and programmed directly onto the 
microcontroller using an EEPROM programmer (in our case a BK Precision 864).  The 






reprogrammed at any time by removing it from the socket, programming it, and then returning 
it to the socket.  The microcontroller program is included in Appendix B. 
 The microcontroller has 32 bidirectional digital input/output lines configured into 4 
ports (P0-P3) with 8 bits each.  In our configuration, P0 is unused, P1 is configured for write 
(WR/) and update clock (UCLK/) active low signals (as indicated by the “/” following the signal 
name), P2 is configured for the address lines and the reset (RST) active high signal, and P3 is 
configured as data lines.  All four DDS chips share the address, data, and RST lines, but have 
individual WR/ and UCLK/ lines that allow for individual programming of each DDS chip.  A 
summary of this configuration is in Table 3-1. 
Table 3-1. Configuration of microcontroller I/O ports and pins. 
Port Bits Configuration 
















The microcontroller program consists of two parts: initialization and frequency 
programming.  The initialization sets the mapping of the pins as shown in Table 3-1, and then 
initializes the DDS registers for the correct mode of operation.  Specifically, this involves setting 
the mode of operation to single mode (as opposed to chirp or frequency shift keying) and an 






updated as opposed to a periodic update pulse internally generated by the DDS chip).  Both of 
these settings are updated by writing 0x00 to address 0x1F.  By default, the DDS implements a 
feature known as the inverse sinc function to compensate for amplitude roll-off in high 
bandwidth signals, something that is not relevant for our low-bandwidth, single-tone 
frequency.  This feature uses a lot of power, and so we disable it by writing 0x40 to address 
0x20.  There are many other features that can be enabled by writing to the respective registers, 
as outlined in the DDS AD9854 datasheet [59], but those features exceed our design 
requirements.   Once the initialization is complete, the modulation frequency is programmed to 
the appropriate registers.  The modulation frequency is specified as a 48-bit frequency tuning 
work (FTW) that is defined according to Eq. 3.2. 
                                            (3.2) 
The FTW number is typically a decimal number that must be rounded to the nearest 
integer and then converted to a binary number.  For our modulation frequencies of 5 kHz and 7 
kHz the FTWs are 0x20C49BA5E3 and 0x2DE00D1B71 respectively.  The FTWs are programmed 
as 6 sequential 8-bit writes to 6 DDS registers (0x04 to 0x09).  The phase offset of the signal is 
not important to our application and thus is left at the default of 0.  Upon a low pulse of the 
UCLK/ signal, the DDS begins outputting the sinusoid at the programmed frequency.  Prior to 
the UCLK/ pulse the DDS output consists of a default DC (0 Hz) signal of approximately 0.5 V.  








Figure 3-6. Timing diagram for the microcontroller initialization and programming of the DDS 
chips. 
 
The microcontroller sits on the backplane of the input unit.  The backplane is the anchor 
of the input unit and is comprised of a two-layer PCB that routes all of the signals between the 
DDS cards and the laser controllers.  The backplane is designed for use with standard 
enclosures.  The input unit is powered by a two 12 V switching power supplies (GLM75-12, 
Condor) configured to provide a +12 V and -12 V line.  Switching power supplies are known to 
be noisy, with background noise of up to 120 mV, however, as originally implemented by Lasker 
et al. [56] and reproduced here, we use a capacitive and balun choke filter on the power lines 
entering the backplane to reduce the noise to around 5 mV.  The schematic, board layout, and 








3.4 Light Generation 
Light at four wavelengths (765, 808, 827, and 905 nm) is generated by continuous-wave 
high power laser diodes (HPD-1010-HHLF-TEC, High Power Devices, Inc).  Each laser diode is 
controlled by a laser driver controller (ITC110, Thorlabs Inc.) and intensity modulated at either 5 
kHz (765 nm and 808 mm) or 7 kHz (827 nm and 905 nm).  Two wave division multiplexers (Oz 
Optics Ltd.) combine the four colors of light into two separate streams: one stream that 
combines 765 nm modulated at 5 kHz and 827 nm modulated at 7 kHz, and one stream that 
combines 808 nm modulated at 5 kHz and 905 nm modulated at 7 kHz.  Each light stream is fed 
into a 2x32 optical switch to control the sequential illumination of various positions around the 
tissue. 
The specifications for each laser diode, including the maximum input current, the 
maximum power, the maximum voltage, and the spectral response of the diode are included in 
Appendix D.  It is important that the driver for each laser diode is adjusted according to these 
specifications.  This should be done with the use of the ITC1xx Operation Manual.  With the 
help of the display module (ITC100D, ThorLabs Inc.) potentiometers P1-P7 can be adjusted for 
each laser driver and corresponding laser diode.  Specifically P1 should be set to the laser diode 
limit current, P2 can set the laser current, and P3 and P4 can be used to set the thermo-electric 
cooler (TEC) properties. 
Fig. 3-7, shows a photograph of the input unit, as seen from above.  The power supply, 








Figure 3-7. Photograph of the input unit, as seen from above.   
The power supply, DDS boards, laser drivers, optical combiners, and laser diodes are all visible. 
 
3.5 Optical Switching 
The optical switching is performed by a 2x32 Sercalo Rack System Solution (RS-FSPA-
2x1x32-62FCPC) optomechanical switch.  The switch begins by illuminating the target at one 
source position with the first wavelength set (765 nm & 827 nm) and then the second 
wavelength set (808 nm & 905 nm) before moving onto the next source position.  It continues 
this source switching until all programmed source positions (up to 32 per breast) have 
illuminated the target. The switching is customizable so that the system can run with only two 
wavelengths twice as quickly since it doesn't need to repeat the measurements at each source 






The optical switch accepts wavelengths from 700 to 1650 nm and takes less than 7ms to 
settle when switching between positions.  Control of the switch position is accomplished 
through a 36 pin Centronics connector.  The timing to control the switch, specified by the 
Sercalo Operating Manual, is outlined in Fig. 3-8, along with the pin positions for the connector.  
In our design we implemented a set-up time 16 µs and a hold-time of 26 µs to match the values 
observed by probing the Sercalo control software, as opposed to the > 10 µs set-up time and > 
1 ms hold time specified in the manual. 
 
Figure 3-8. Optical switch details. 
Shown are (a) the connector pinout and (b) pin descriptions along with (c) the digital 
programming timing. 
 
An optical switch, which relies on a MEMS based switch network that uses micro-
machined silicon mirrors to redirect light between the selected output fibers, is preferred to a 
mechanical switch in this case (often involving a rotating mirror that reflects the incoming light 
into the sequential output fibers) for a couple reasons.  Optical switches are quieter and more 






switches that can be digitally controlled and that have good temporal response for fast 
switching between source positions. 
3.6 Optical Fibers 
32 optical fibers (Fiberoptic Systems Inc.) connect to the optical switch by fixed connection (FC) 
connectors.  The fibers bifurcate to simultaneously illuminate both the left and right breast.  
Each source fiber converges with a detector fiber, so that a single fiber tip can perform both 
illumination and detection.  This accounts for 32 of the fibers per breast.  The other 32 fibers 
are solely used for detection.  The 64 total detection fibers return back to the detection 
module.  
3.7 Light Intensity 
The intensity of light that is used to irradiate tissue is limited by the American National 
Standard Institute (ANSI) and recommended by the Occupational Safety and Health 
Administration (OSHA) of the US Department of Labor.  According to these standards (ANSI 
Z136.12000 pg 48, Table 7) the maximum permissible exposure (MPE) before tissue damage 
occurs is given by Eq. 3.3 where λ is the light wavelength in nm. 
                                    (3.3) 
In this system, the light intensity is well below the ANSI standards and is essentially 
limited by the input power to the switch.  Sercalo recommends limiting the input intensity of 
light into the switch to 100 mW.  As such, the output power from the laser diodes is currently 
optimized to give 100 mW of light out of the optical combiners (and into the switch).  Loss 






bifurcation of light to the left and right breast, and accompanied by a 50% loss through the 
optical fibers, bringing the output power from the optical fiber to approximately 12.5 mW 
shared between the two wavelengths in that light stream.  This means each wavelength of light 







Chapter 4 : Digital Detection Techniques 
4.1 Detection Unit Overview 
The role of the detection unit is to quantitatively measure the amplitude of the light that is 
emitted from the tissue surface.  As described in the previous chapter, the light is radio-
frequency modulated, and so the detection unit must extract the amplitude from the 
modulated detected signal.  There are three factors that make the design of this unit 
challenging. 
1. Sensitivity: There is considerable attenuation as light passes through the tissue, making 
it essential that the detection electronics be very sensitive to low light intensity. 
2. Dynamic Range: While many of the signals will be very small, detectors located in close 
proximity to the source will be exposed to a high light intensity.  The detection unit 
must be able to accommodate both these low and high intensities. 
3. Speed: For dynamic imaging the system must collect data very quickly, while still 
accommodating the large number of sources and detectors needed to cover 3D breast 
geometries. 
 
The detection electronics are specifically designed to address these challenges.  The 
detection unit begins by converting the incident light into an electric current using a 
photodetector.  It then amplifies and converts that current to a voltage, filters the signal, 






filtering in the digital domain.  All of these stages, outlined in Fig 4-1, will be described in detail 
in the following sections. 
 
Figure 4-1.  Block diagram of the detector board electronics. 
The light is detected with a silicon photodiode (SiPD), amplified in two gain stages: the trans-
impedance amplifier (TIA) and the programmable gain amplifier (PGA), filtered to remove the DC 
offset (RC-HP) and filtered to prevent aliasing prior to quantization of the signal using an analog-
to-digital converter (ADC). 
4.2 Analog Detection, Amplification, and Filtering 
The detection unit begins with the optical fibers that bring light from the surface of the tissue 
back to the detection electronics.  A custom connector uses a set screw to hold the fiber in 
alignment with a silicon photodiode (SiPD) (S1337-33BR, Hamamatsu) that converts the 
incoming photons into electrons (and a corresponding electrical current).  The S1337-33BR SiPD 
provides a response of 0.5-0.6 A/W in the 750-900 nm range with a fast response time (0.2 µs).  
We chose to use a photodiode due to the highly linear response it provides across a large range 
of incident light intensities.  In addition, other optical detection devices such as avalanche 
photodiodes and photomultipliers require very large supply or bias voltages, which is 
undesirable in a clinical device.  
 A photocurrent is induced across the device when an incident photon dislodges an 
electron in the SiPD.  The next step is to convert this photocurrent into a voltage, while also 






shown in Fig. 4-2a, produces a voltage that is equal to Vout=-Iin*Rf.  By changing the value of Rf it 
is possible to change the amplification of the incoming signal, thus providing a way to increase 
the dynamic range so that both very small and very large signals are accommodated.  However, 
Rf cannot be increased without consideration of the frequency response of the filter.  In this 
design we want to insure that any signals modulated in the 3-9 kHz range can be detected with 
less than 1% of ripple in the pass-band.  As such, we must insure that the frequency response of 
the TIA adheres to this requirement.  The TIA will pass all frequencies up until a cutoff 
frequency fc=1/(2πRfCf).  To insure a flat pass band for our core frequency range we choose fc to 
be greater than 60 kHz (this is to insure minimal dropout at our upper core frequency of 9 kHz – 
see Appendix E for bode plots of the magnitude, phase, and transient response of this RC filter).  
As the feedback resistance Rf increases, the corresponding feedback capacitor Cf must similarly 
decrease in order to maintain the same fc.  This introduces a problem at high values of Rf 
because parasitic board capacitance is typically around 1-2 pF and the smallest capacitors 
available are similarly ~1pF.  To overcome this issue, we use a bandwidth extension technique 
originally demonstrated by Michel et al. [61] and first applied to optical detection techniques by 
Lasker et al. [58].  The circuit diagram for a bandwidth-extended TIA is shown in Fig. 4-2b.  With 
this modified design, Vout=-IinR1 and the cutoff frequency is fc=1/(2πR2C2) where R2 << R1 and 







Figure 4-2. Trans-impedance amplifier (TIA) schematic. 
Shown are two configurations: (a) a typical trans-impedance amplifier (TIA) with a feedback 
resistor and capacitor and (b) a TIA with a bandwidth-extension feedback circuit. 
 
 
In our design we use three different feedback resistors across the TIA: 10 kΩ, 10 MΩ, and 100 
MΩ. Each of the gain settings used in the TIA amplification stage are outlined in Table 4-1 along 
with the resistor and capacitor values selected for the circuit design. 





10 kV/A No Rf = 10 kΩ 
Cf = 220 pF 
10 MV/A Yes R1 = 10 MΩ 
R2 = 10 kΩ 
C1 = 15 pF 
C2 = 220 pF 
C3 = 15 nF 
100 MV/A Yes R1 = 100 MΩ 
R2 = 10 kΩ 
C1 = 1.5 pF 
C2 = 220 pF 







 The operational amplifier (op-amp) used for the TIA (AD8610A, Analog Devices) is 
specifically chosen for this application due to its low bias current and noise.  The bias current of 
this device is ~2 pA which allows us to measure photodiode currents in the tens of picoamps.  In 
addition, the AD8610A has excellent voltage noise performance of 6 nV/Hz-1/2 and 5 fA/Hz-1/2 
which means that with a 100 MΩ resistor the noise generated from the op-amp is: 
                      
    
√  
 (√        )                (4.1) 
Whereas the thermal noise of the 100 MΩ resistor is: 
         √            (4.2) 
 √                                               
        
The noise generated by the op-amp is still well below the thermal noise of the resistor.  In both 
Eq. 4.1 and 4.2 the frequency used is 12.5 kHz which is the bandwidth of our acquired signal, as 
specified by the cutoff frequency of the low-pass anti-aliasing filter.  Notice that in Eq. 4.2 it is 
important that temperature be controlled as it can lead to an unwanted increase in the thermal 
noise.   
The output signal from the TIA is high-pass RC filtered to remove any DC offset.  As we 
are solely interested in the amplitude of the modulated signal, the DC offset is not important, 
and can limit the amount of gain that can be applied to the signal in the PGA gain stage.  In 
addition, the high-pass filter reduces low-frequency noise including power-line noise (at 60 Hz).  
We choose a cutoff frequency of ~500 Hz which provides a flat passband for our 3-9 kHz core 






noise suppression.  The RC high-pass filter also determines the settling time of the output of the 
TIA stage – an important factor for the timing of our detection unit.  The settling time for this 
filter is approximately 3 ms for the signal to settle to within 99.9% accuracy.  See Appendix E for 
the amplitude, phase, and transient response of the passive RC high-pass filter.  Increasing the 
cutoff frequency of this filter would decrease the settling time and improve the low-frequency 
noise rejection, but would cause the passband to be less flat in our core frequency range, likely 
resulting in rolloff and subsequent loss of signal amplitude at lower frequencies. 
Following the TIA and high-pass filter the signal is passed through a second amplification 
stage, the programmable gain amplifier (PGA) that is used to increase the peak-to-peak 
amplitude of the signal so that it best occupies the full 5V range of the analog-to-digital 
converter (ADC).  In addition, the PGA provides for more gain settings beyond the three levels 
provided by the TIA.  The PGA uses an instrumentation amplifier (INA128U, Texas Instruments) 
where the gain across the amplifier is determined according to G=1+50kΩ/RG where RG is the 
resistance between pins 1 and 8 of the amplifier.  This amplifier has low input bias current (5 nA 
max, which means that even at a gain of 100 with Rin of 4.7 kΩ the offset is only a couple mV, 
thus not causing any risk of saturation of the PGA).  With a gain-bandwidth product of 20 MHz 
the PGA has cutoff frequency of 200 kHz at a gain of 100, which corresponds to only 0.1% signal 
loss at 9 kHz (the upper limit of our core frequency range).  For the PGA stage we use resistor 
values of 47 Ω, 487 Ω, 5.6 kΩ, 10 MΩ to accomplish gain of approximately 1000, 100, 10, and 1, 
respectively.  Although we provide the option to apply 1000 times PGA gain, in reality the noise 






By providing options for the amount of gain applied at each amplification stage, we 
enable a broad range of signals that can be detected – from very small signals that require a lot 
of amplification to large signals that require very little amplification.  In order to select which 
feedback resistors will be used to set the amplification for a given channel, we use a 
combination of multiplexers and switches.  When switching the feedback resistance across the 
TIA, care must be taken with regards to switching and settling time of the detected signal.  For 
this reason we use two reed relays (Coto Technologies) that have fast settling times and 
moderate current across them (10 mA @ 5V supply). Both the TIA and PGA have 8:1 
multiplexers (MUXs) (ADG608BRZ, Analog Devices) whose output is selected based on 3 bits, 
referred to in our design as the ‘gain bits’ that can be controlled by the user.  Table 4-2 shows 
the gain bit control of the amplification settings available in our design. 
Table 4-2.  Gain settings and corresponding TIA and PGA amplification. 
Gain 
Setting 





(V/A) 2 1 0 
1 0 0 0 10 k 1 10 k 
2 0 0 1 10 k 10 100 k 
3 0 1 0 10 k 100 1 M 
4 0 1 1 10 M 1 10 M 
5 1 0 0 10 M 10 100 M 
6 1 0 1 10 M 100 1 G 
7 1 1 0 100 M 100 10 G 
8 1 1 1 100 M 1000 100 G 
 
The gain bits are stored on the detector board in first-in-first-out (FIFO) (IDT72V02, 
Integrated Device Technology) storage registers and when the source position is changed the 
corresponding gain bits are updated across the TIA and PGA via a read from the FIFO.  After 






bottom of the FIFO in preparation for the next imaging sequence.  The optimal gain bits can be 
determined prior to the image acquisition and loaded into the FIFOs for optimal timing of the 
system.  The programming of the gain bit FIFOs is discussed in more detail in Section 5.2. 
Following the TIA and PGA gain stages, the signal is filtered with an 8th order 
Butterworth anti-aliasing filter that removes high frequency components and whose primary 
purpose is to ensure there are no frequencies present above the Nyquist frequency prior to 
digitization.  The signal is sampled by the ADC at 75 ksamples/s which establishes a Nyquist 
frequency of 37.5 kHz.  As a result, we choose a cutoff frequency of 12.5 kHz and a Butterworth 
filter that has a flat passband for the 5 and 7 kHz signals, while also providing strong 
attenuation of any higher frequency noise at risk of aliasing into the passband.  The 8th order 
Butterworth filter is implemented using two filter chips (LTC1563-2IGN, Linear Technologies).  
These filters, in combination with a number of resistors, form an 8th order low-pass Butterworth 
filter with a 12.5 kHz cutoff frequency that has <0.1% attenuation at our upper core frequency 
of 9 kHz, but still offers over 100 dB of noise suppression in our first aliasing range of 67 to 72 
kHz.  The design and analysis of this filter can be performed through LTSpiceIV and FilterCAD 
software provided by Linear Technologies.  The optimal layout for the filter componenets, as 
used in our design, is specified in the LTC1563 application notes [60]. The magnitude and phase 







Figure 4-3.  Magnitude and phase response of the 8th order Butterworth low-pass anti-aliasing 
filter. 
 
 Following the filter, the final analog component of the detection board is the offset 
buffer that centers the signal around 2.5 V for optimal detection by the 0 to 5 V input range of 
the ADC.  The offset amplifier also buffers the signal according to the ADC specifications.  These 
specifications are outlined in the ADC AD7655 Datasheet and include the following 
requirements for the amplifier: low noise, low total harmonic distortion (THD), and a fast 
settling time [62].  Based on these requirements we selected an amplifier (AD8028, Analog 
Devices) with -100 dBc THD, settles to 0.1% in 35 ns, and has good noise performance.  The 







Figure 4-4.  Schematic of the offset buffer that precedes the ADC. 
 
Eq. 4.3 describes the relationship between Vout and Vin.  In our case we do not desire any 
additional amplification, which is accomplished by selecting R1=R2=R3=R4=R5=20 kΩ.  This gives a 
relationship Vout = Vref - Vin.  By setting Vref=2.5 V we convert Vin from a zero-bias signal with 5 V 
peak-to-peak amplitude to Vout, a 2.5 V biased signal (the center point of the ADC) with a 5 V 
peak-to-peak amplitude.  This allows Vout to span the full 0 to 5 V input range of the ADC.   
     
    
    
     
  
  
        (4.3) 
4.3. Analog-to-Digital Converter (ADC) 
Following the offset buffer we are ready to transition from the analog domain to the digital 
domain.  To do this we must convert a continuous, smoothly varying signal, into a finite number 
of samples that adequately capture the shape of the signal.  Resolution in both x (time) and y 
(amplitude) are both important.  Resolution in time is determined by the sampling rate of the 






determined by the number of bits that the ADC can capture in its digital sample.  More bits 
allows for more resolution in approximating the analog signal.   
 
Figure 4-5.  Diagram outlining the challenge of digitally sampling an analog signal.   
Here the sin(2x) analog signal is shown in solid grey, the digital samples are shown as black x 
markers, and the reconstructed waveform using the digital samples is shown in dashed black for 
(a) a sampling period of π/4 and m=3 (8 quantization levels); (b) a sampling period of π/16 and 







The 16-bit ADC used in our design provides 216=65536 levels of quantization, and given that we 
have a supply range of 5V, the ADC provides a resolution of 76 µV (~0.0015%).  Fig. 4-5 
illustrates how both sampling frequency and resolution both play a role in adequately 
describing the analog signal in the digital domain.  As the sampling period decreases and the 
number of bits (and corresponding levels of quantization) increase, the digital representation of 
the signal gets closer to the true analog equivalent.   
In our design we use a four channel, 16-bit, successive approximation register ADC 
(AD7655, Analog Devices) that samples at a maximum rate of 1 Msps.  Fig. 4-6, below, is a 
functional diagram for the ADC showing the significant pins.   
 
Figure 4-6.  Functional block diagram of the ADC7655 [62]. 
 
The ADC has four inputs and can quantize two inputs at a time (INA1 and INB1 or INA2 
and INB2).  Selection of the input channels is performed using the A0/ pin.  To acquire a digital 
sample of the analog input, the CNVST/ signal must be held low for at least 5 ns, following 
which the BUSY signal will go high and 2 µs later the digital sample will be available.  We choose 






can be read (controlled by CS/,RD/, and CLK) from the serial data line (SDOUT) with the data 
from Channel B followed by the data from Channel A (this order is determined by the A/B pin 
which is pulled low in our design).  Outputting the data serially allows for significantly less data 
lines to be routed from the ADC to the other boards for processing of the digital signal.  The 
timing digram for converting and reading the data from the ADC is shown in detail in Fig. 4-7. 
 
Figure 4-7. Timing diagram for converting and sampling the digital signal from the ADC. 
 
In our system the ADC samples the data from each detector channel at 75 kHz.  The ADC 
timing is synchronized with the rest of the digital electronics through the master CPLD and DSP.  
This is described in more detail in the following chapter. 
4.4 Detector Board Design 
There are 16 detector boards used to capture the 128 detector channels in the system.  Each 
board houses 8 channels that have their own analog circuitry feeding into two 4-channel ADCs.  
The four-layer PCB has a top and bottom copper layer for part placement and routing, one 
dedicated inner ground layer, and one inner layer for power planes.  Each detector board is 






the necessary 3.3 V, 2.5 V, +8 V, -8 V, +5 V, and -5 V lines that are used by the ICs on the board.  
The initial gain stages are covered by custom-made copper shields to reduce noise.  The shields 
attached directly to the board by screws and are soldered to the ground plane.  The board 
connects to a solid 6U/4HP front panel (Vero Technologies) that holds the optical fiber 
connectors.  The boards connect to the backplane of the detection unit via two 96-pin 
connectors (650473-5, Tyco Electronics).  Fig. 4-8 shows a photograph of a detector board.  The 
detector board BOM, schematic, and layout are included in Appendix F. 
 
Figure 4-8.  Photograph of the detector board with the key functional components outlined in 
white. 
Key components include the power regulation, gain bit FIFOs, the ADCs, and the components of 
each of the 8 detector channels: the location for the silicon photodiode (SiPD) and fiber 
connector (not shown in this photo), the TIA and PGA amplification stages, the multiplexers 







Chapter 5 : Master-Slave Digital Signal Processor Architecture 
5.1 Master-Slave Architecture 
One of the key challenges in fast optical tomography for breast imaging involves designing a 
system that obtains measurements from a large number of sources and detectors without 
sacrificing the imaging speed. In our design, this is accomplished by implementing a master-
slave DSP architecture that involves multiple DSP chips for fast simultaneous processing of all 
128 detectors.  The master DSP (mDSP) chip is the single DSP that coordinates the behavior of 
the system, including the other slave DSP (sDSP) chips.  It handles all of the handshaking with 
the host computer and works with the master CPLD (mCPLD) to control the timing of the optical 
switch, gain bits, and acquisition of the signals from the ADCs.  The mDSP relies heavily on the 
mCPLD to control the timing of all of the signals related to shifting and setting the gain bits, 
controlling the conversion and sampling from the ADCs, and sending out the address signals to 
control the source position of the optical switch.  
The mDSP also relies on a slave CPLD (sCPLD) whose job is to multiplex the incoming 
data from the 32 detector ADC chips (each ADC is responsible for digitizing 4 detector channels) 
and routing it to the DSP chips for processing.  This multiplexing is controlled through a chip 
select (CS) signal that keeps the CPLDs, ADCs, and DSPs in sync.  Each DSP acquires two 
simultaneous serial streams of data through the A and B serial ports.  The mDSP is referred to 
as the master because it controls the operation of all the components in the system.  The other 
three DSP chips (sDSP1, sDSP2, sDSP3) are referred to as “slave chips” because they can only 






master-slave configuration helps simplify the control of the system and keeps the data 
acquisition for all DSP chips in unison. This configuration also allows for easy scaling of the 
system for a larger number of sources, wavelengths, or detectors which is achieved either by 
reprogramming the existing DSPs or by adding additional slave DSP chips. 
Each pair of DSP chips share an output data buffer.  Following demodulation of the 
detected signal, the amplitude is written to the data buffer, where it is held until the host 
computer performs a read of the data buffer, via a data acquisition card (DAQ).  An overview of 
the detection unit, including the way in which the master and slave DSPs and CPLDs combine to 
rapidly process large amounts of detected data, as shown in Fig. 5-1, below. 
 
Figure 5-1.  Overview of the detection unit. 
The interaction between the Detection Board, the DSP Master Board, the DSP Slave board, and 






5.2 Digital Signal Processor (DSP) States 
The behavior of the DSP chips is controlled through Visual DSP++ code written according to the 
Analog Devices standard.  This code is compiled and programmed onto one Electrically Erasable 
Programmable Read-Only Memory (EEPROM) (M29W040B90K1E, ST Microelectronics) per DSP.  
The DSP code is included in Appendix G.  The master and slave code is compiled from the same 
source, with a global define (#DEFINE MASTER_DSP) to distinguish the master DSP-specific 
portions of the code.  As the DSP is powering up or coming out of reset, it loads the 
programming code from the EEPROM into its internal memory (via 8-bit reads over the external 
address and data lines).  After the EEPROM program is loaded into memory, the mDSP begins 
executing the program, starting with an initialization sequence that allocates memory, 
configures registers and interrupts, and allocates I/O ports (Appendix G: initializeDSP.c, 
myIRQ.c).  Interrupt signals play an important role in alerting the DSP program to important 
inputs or outputs.  Table 5-1 contains a summary of the interrupts used in the mDSP program, 
along with their function.  Note that the sDSP chips are only concerned with input from the ADC 
and output to the output buffer, thus they only use SPORT0 and DMACh10 interrupts. 
Table 5-1.  Description of interrupts used in the DSP program. 
Interrupt Triggered By: Cause DSP to: 
RST A low signal on Pin E2, RESET/ Return to start of main program 
IRQ0 A low signal on Pin H2, IRQ0/ 
Wake up from Standby and read the command from the 
host PC encoded on DIO_PC0 and DIO_PC1 
SPORT0 
Serial Port 0  has received all of 
the data from the ADCs. 
Disable SPORT0.  Proceed to next source position in 
Imaging State 
SPORT1 
Serial Port 1 has finished sending 
gain bits. 
Disable SPORT1.  Proceed to next source in Gainbit state. 
EP0I 
DMA Channel 10 has finished 
writing the demodulated data to 
the output buffer. 
Disable DMACh10.  Proceed to next operation in Imaging 
Bits State. 
EP1I 
DMA Channel 11 has received all 
of the gain bits from the host PC. 
Disable DMACh11 operation.  Proceed to next operation in 






TIMEXP 7 ms timer has expired. 
Disable the timer.  Alert mCPLD and mDSP that 7 ms timer 
has elapsed by outputting TIMEXP. 
 
The DSPs communicate with the outside world through a number of channels: 
input/output flags, Serial Port 0 (SPORT0), Serial Port 1 (SPORT1), External Port 0 (DMACh10), 
and External Port 1 (DMACh11).  Flags are the simplest interface, consisting of 9 digital pins that 
can be configured as either inputs or outputs.  The flags used by the mDSP and sDSP are shown 
in Table 5-2. 
Table 5-2.  Flags used by the mDSP and sDSP. 
Flag Input/Output Function 
Master DSP Flags 
Flag0 Input DIO_PC0: Instruction from the host PC. 
Flag1 Input DIO_PC1: Instruction from the host PC. 
Flag2 Input 
DIO_PLD0: High when the mCPLD is in Standby.  Important 
for ensuring mDSP and mCPLD are synchronized. 
Flag3 Input 
DIO_PLD1: Used by the mCPLD to acknowledge 
instructions from the mDSP 
Flag5 Output 
DIO_IMST/: Instructs the mCPLD and sDSPs to go into 
Imaging State. 
Flag9 Output 
DIO_LED/: Turns on the Idle LED whenever the mDSP is in 
Standby. 
Slave DSP Flags 
Flag2 Input 
DIO_PLD0: High when the mCPLD is in Standby.  Tells sDSP 
to leave Imaging and return to Standby State. 
Flag3 Input DIO_PLD1: Currently unused by the sDSP. 
Flag5 Input DIO_IMST/: Instructs the sDSP to go into Imaging State. 
 
There are two types of interfaces used for data transfer: serial ports (SPORT0 and 
SPORT1) and external, parallel ports (DMACh10 and DMACh11).  SPORT0 receives the serial 
data from the ADCs, SPORT1 sends the gain bits to the mCPLD, DMACh10 sends the 
demodulated data to the output buffer, and DMACh11, receives the imaging parameters and 






1. Instruct the port where to store the data (for incoming data) or where to begin 
reading the data to send out (for outgoing data) 
2. Tell the port how many words of data to send or receive 
3.  Enable the port.   
Once the port is initialized and enabled it conducts the data transfer independently and 
will trigger an interrupt (see Table 5-1) upon completion of the transfer.  The serial ports have 
two data lines that use the same clock (A and B).  The word size for each port is determined as 
part of the DSP initialization: SPORT0 uses 16-bit words, SPORT1 uses 32-bit words, DMACh10 
uses 8-bit external words with 32-bit internal words, and DMACh11 uses 16-bit internal words 
with 32-bit external words (Appendix G: Initialize_DSP.c).  The word count written to the 
register specified in Table 5-3 must match the word size of the port.  Each port is initialized as 
either an input or output port.  Table 5-3 outlines the registers that are updated for data 
transfers on each of the data ports.  A full description of the registers and functionality of the 
ports can be found in [63]. 
Table 5-3.  Relevant registers for the data transfer ports. 
Port Function Rx/Tx 
Address 
Word Count Enable 
Address Word Size 



















Send demodulated data 
to output buffer. 







parameters and gain bits 
from host computer. 










The state machine for the mDSP is comprised of four states: Standby, Imaging 
Parameters, Gain Bits, and Imaging.  After initialization the DSP sits idle in Standby waiting for a 
command (encoded by DIO_PC0 and DIO_PC1) to arrive from the host computer.  Following the 
completion of each state the mDSP returns to Standby.  In the Imaging Parameters State the 
host PC sends the mDSP the number of sources, detectors, and wavelengths to be used in the 
current experiment.  In the Gain Bits state the mDSP receives the gain bits from the host PC and 
transmits them via the mCPLD to the detector boards.  In the Imaging state the mDSP 
coordinates the acquisition of data from the ADCs on the detector boards, demodulates the 
data, and sends the result to the host PC via an output buffer.  Unlike the mDSP, the sDSPs have 
only two states: Standby and Imaging.  The sDSP sits idle in the Standby State until it receives a 
signal (DIO_IMST/) from the mDSP to begin processing incoming data from the ADCs.  The sDSP 
then returns back to Standby when DIO_IMST/ has returned high, and the mCPLD has returned 
to Standby (indicated by DIO_PLD0=1).   Fig. 5-2 shows a state machine diagram detailing how 
the (a) mDSP and (b) sDSPs transition between the various states. 
 
Figure 5-2.  State machine for the (a) mDSP and (b) sDSP. 
Also shown are the transitions between the four main states: Standby, Imaging Parameters, Gain 
Bits, and Imaging.  Transitions out of the Standby state are controlled by the values of DIO_PC1 







This is a low-power state where the DSPs sit idle waiting for an interrupt (IRQ0) in the case of 
the mDSP, or a flag (Flag5: DIO_IMST/) in the case of the sDSPs.  When the mDSP receives the 
IRQ0 interrupt it checks DIO_PC0 and DIO_PC1 to determine which state it should enter.  When 
the sDSP sees DIO_IMST/ go low, it enters the Imaging State and begins processing data.  When 
the DSPs are in the Standby State the IDLE LED is on (Appendix G: LED.c). 
Imaging Parameters State 
The first state that must be entered following reset is Imaging Parameters (Appendix G: 
ImParameters.c).  In this state, the host computer sends the mDSP the global parameters for 
the current experiment.  These global parameters are src, the number of sources (in binary 
representation from 1 to 32); det, the number of detectors per breast (in binary representation 
from 1 to 64); and wl_set, the number of wavelength sets (wl_bit=0 corresponds to one 
wavelength set and wl_set=1, wl_bit=1 to two wavelength sets and wl_set=2).  These 
parameters are all encoded into a single 32-bit data transfer on DMACh11, as illustrated in Fig. 
5-3.   
 
Figure 5-3.  Encoding of the imaging parameters into a single 32-bit DMA transfer. 
 
To send the imaging parameters to the DSP, the host PC initiates a data write through 






(SN74LVC574ADBR, Texas Instruments) onto the DATA[16:32] lines of the mDSP.  The latch 
clock is a delayed version of REQ.  The mDSP reads the data on DATA[16:32] on the falling edge 
of DMAR1/.  DMAR1/ is a 50 ns delayed version of REQ to allow time for the data to arrive at 
the mDSP DATA[16:32] lines.  This timing is outlined in Fig. 5-4, where tp is the delay from REQ 
to DMAR1/ (50 ns), tlatch is the time it takes for the latched data to appear on the DATA[16:32] 
lines (<8 ns), tpw is the pulse width of the REQ signal and tperiod is the interval between REQ data 
transfers.  The 32-bit transfer is comprised of two 16-bit words.  The Imaging Parameters state 
sets up DMACh11 to expect a 2 word write (see Table 5-3).  Once DMACh11 receives 2 words it 
triggers an interrupt EP1I that informs the program that the data has been received and can be 
read from the address specified in register IIEP1.  Following the completion of the Imaging 
Parameters state the mDSP returns to the Standby state. 
 
 
Figure 5-4.  Timing diagram for DMACh11 data transfer from the host PC to the mDSP. 
 
Gain Bits State 
As described in Chapter 4, there are 3 gain bits for each detector channel that encode the 






to each detector channel, source position, and wavelength set.  As such there are 
3*128*32*2=24,576 bits that must be correctly transferred from the software interface onto 
the detection boards.  The software interface allows the gain bits to be set manually, or to be 
automatically detected through an iterative routine, described in Section 6.3.  Determining the 
gain bits prior to imaging and storing the values locally on the detector boards speeds up 
switching the gain bits with each source position. 
In the Gain Bits State three main operations occur:  the gain bits are received from the 
host computer via DMACh11, the imaging parameters are passed to the mCPLD via SPORT1, 
and the gain bits are streamed from mDSP to the mCPLD via SPORT1 and from the CPLD onto 
the Detector Boards (Appendix G: Gain_Bit.c).  The first part of this transfer occurs from the 
host computer to the DSP.  This transfer occurs over DMACh11 as described in the Imaging 
Parameters State (see Fig. 5-4).  DMACh11 is programmed to expect 3*src*wl_set*128/16 
words of data.  The factor of 128 is due to the fact that in our design, regardless of the number 
of detectors used in the experiment, the full set of gain bits must be transmitted. 
  Once the mDSP receives the gain bits from the host PC it must coordinate with the 
mCPLD to arrange for the transfer of the gain bits to the Detector Boards.  The first step is to 
put the mCPLD into the Gain Bits state.  This is accomplished by performing a write on SPORT1.  
The one-word write of zeros causes the frame sync signal (FS) to pulse high, instructing the 
CPLD to go into the Gain Bits state.  Once the mCPLD is in its Gain Bits state it indicates this by 
setting DIO_PLD1 high for two clock cycles.  The mDSP waits until it sees this flag pulse high 







Figure 5-5. mCPLD Gain Bit state machine. 
 
 Once both the mDSP and mCPLD are in the Gain Bits State the mDSP must tell the 
mCPLD how many sources and wavelength sets to use in this experiment.  Note that the mCPLD 
is oblivious to the number of detectors.  The src and wl_set values are transmitted to the 
mCPLD via a one-word SPORT write similar to the lower 16-bits of the DMA encoding shown in 
Fig. 5-3.  When the mCPLD sees the FS go high it moves from the Init sub-state into the 
GetSource sub-state and receives the number of sources and wavelength sets from the mDSP.  
The mCPLD knows it is finished receiving the data when the FS signal goes low, and then 
proceeds to the ShiftGB sub-state.  As the mCPLD moves into the ShiftGB sub-state it pulses 
DIO_PLD1 high to confirm to the mDSP that it has received the number of sources and 
wavelength sets. 
 Next, the mDSP loops through each source position and wavelength set and sends the 






detectors on SPORT1B.  As long as the frame sync (FS) signal is high, the mCPLD passes the 
incoming bits from SPORT1A onto GBL and from SPORT1B onto GBR, which are the data lines 
that connect from the mCPLD to the detection boards.  Synchronized with the data bits is a sync 
clock (SCL) that shifts the gain bits through a series of shift registers (TC74VHC595, Toshiba) 
located on the detector boards.  Each of the 8 detector boards containing 8 channels that 
require 3 gain bits to encode their amplification, resulting in 192 gain bits per breast that must 
be programmed for each source position.  These gain bits arrive from the mDSP and are output 
to the detector boards via the mCPLD along with a synchronized shift register input clock (SCK). 
With each input clock (SCK) the shift register reads in the value present on its serial input (SI).  
The shift register output clock (RCK) causes the values stored in the register to be latched onto 
the output ports (QA through QH).  Fig. 5-6 shows the timing diagram for the gain bit shift 
register as well as the logic diagram detailing the operation of the chip.  Since the timing of RCK 
and SCK must be carefully synchronized with the long series of gain bits that must be shifted 
through the registers, the Master DSP Board provides the ability to introduce from 0 to 40 ns of 
delay onto each clock through the use of jumpers (SCK: J3,J4, RCK: J5,J6).  Each jumper position 







Figure 5-6.  Shift register timing and operation. 
Shown are (a) the timing diagram and (b) the logic diagram [64] for the operation of the shift 
register responsible for daisy-chaining the gain bits through the detector boards.  The timing 
diagram shows the tail end of the gainbit shifting of 192 gain bits. 
 
There are three shift registers on each board that continue passing the gain bits along 
for 192 pulses of SCK.  The input to the first shift register on a given Detector Board comes from 
the Detector Board before it (or from the mCPLD for the first board) and the output of the last 
shift register is connected to the input of the next board (with the exception of the last of the 8 
boards).  This means that the last gain bits to be sent out from the mDSP and mCPLD are the 








Figure 5-7.  Diagram showing the gain bits shifting through the detector boards for the left and 
right breast. 
 
 Once the gain bits have been shifted through the registers they are latched onto the 
shift register outputs by RCK in preparation for writing the values into three 1k x 9-bit FIFOs 
(IDT72V02, Integrated Device Technologies) on each detector board.  RCK is triggered each time 
the mCPLD passes from the ShiftGB sub-state into the UpdateFIFO sub-state  Each time the 
mCPLD enters the Gain Bit state it resets the FIFOs to clear their contents and to prepare to 
write the new set of Gain Bits.  During the UpdateFIFO sub-state the gain bits are written into 
the FIFOs from the shift registers using a write (W) command from the mCPLD and the values 
are stored in the FIFO for use during the imaging sequence.  Each row of the FIFO contains the 






complete, there should be src*wl_set entries in the gain bit FIFO.  The connections between the 
shift registers and the FIFOs for each detector board are shown in Fig. 5-8. 
 
Figure 5-8.  Shift register and gain bit FIFO connections on the detector board. 
 
 The mCPLD progresses from the UpdateFIFO sub-state into the Loop sub-state.  In the 
Loop sub-state it checks if all of the sources and wavelength sets have been programmed with 
gain bits.  If it still has more sources and wavelength sets to cover it returns to the GetSource 
sub-state.  Otherwise it returns to the Init sub-state and leaves the Gain Bit state and returns to 
the Standby state.  After returning to Standby the DIO_PLD0 flag goes high, informing the mDSP 
that it, too, can return to Standby state.  
Imaging State 
The Imaging State is where the mDSP acquires the data from the Detection Boards and 
performs the digital lock-in detection to extract the amplitude of the waveform, which is then 
passed to the host PC through an output buffer (Appendix G: Imaging.c).  The Imaging state 






DIO_IMST/ low.  The mDSP will loop through each source for both wavelength sets and perform 
the following sequence:  
1. Switch the source position. 
2. Wait for the 7 ms timer to expire. 
3. Acquire 150 samples from the detector channels. 
To optimize the timing, the mDSP performs the demodulation of data from the previous source 
position and sends the result to the output buffer, while waiting for the source to settle. 
The mCPLD plays a central role in the imaging state, and its behavior is governed by the 
state machine shown in Fig. 5-9, shown below. 
 
Figure 5-9. mCPLD Imaging State Machine. 
 
 The mCPLD enters the Imaging state by the active low signal DIO_IMST/ and 
immediately progresses from the Init sub-state to the Switch sub-state.  Once in the Switch sub-






PS6) that behave according to Fig. 3-8.  The mCPLD then progresses to the Wait sub-state to 
allow the optical switch time to settle at its new position.  Upon entering Wait the mCPLD 
triggers a read from the Detector Board FIFOs to apply the gain bits for the current source 
position across the TIA and PGA amplification stages.  While in Wait, the mCPDL outputs 
DIO_PLD1 to tell the mDSP to start the 7 ms timer.  The mDSP initializes the timer to 0xAAE60, 
which is hexadecimal representation for 700,000 cycles of the 100 MHz internal DSP clock to 
give 7 ms.  When the timer expires it asserts TIMEXP, which alerts the mCPLD that it can move 
out of Imaging.Wait, pass through the Update sub-state (where it updates the source position 
counter, but doesn’t use it until the next time it enters the Switch sub-state), and into the 
Convert sub-state.  In the Convert sub-state the mCPLD waits for 2.4 µs.  During the entire 
Imaging.Convert State the CVST/ signal to the ADCs is held low, causing the ADCs to convert the 
analog input into a digital value.  Once the 2.4 µs has elapsed, the F_CNVT signal goes high, 
pushing the state machine into the SendData sub-state.   
While in SendData, the mCPLD samples the data from all of the ADCs and works with the 
sCPLD to route the data from the ADCs to the correct DSP for processing.  The read port of the 
ADC is held low, which allows the chip select (CS/) to act as the read enable.  The data from the 
32 ADCs in the system is collected through the careful data multiplexing controlled through four 
chip select signals CS1/ CS2/, CS3/, and CS4/.  In the SendData sub-state each chip select signal 















The chip select also coordinates the correct routing of the incoming data from the ADCs to the 
correct DSP for processing, via the sCPLD.  The routing of the chip selects and sampled data 
from the 16 boards (Right Breast: Boards 1-8, Left Breast: Board 9-16) is shown in Fig. 5-10.  
Only one chip select is held low at any given time, which means that the inverted value (!CS/) 
will only ever be high for one CS/ and corresponding data line at a time.  The data is routed by 
the sDSP as follows: 
Right Side 
mDSP_D0A = (!CS1/ and IND1c) or (!CS2/ and IND3c) or (!CS3/ and IND5c) or (!CS4/ and IND7c) 
mDSP_D0B = (!CS1/ and IND2c) or (!CS2/ and IND4c) or (!CS3/ and IND6c) or (!CS4/ and IND8c) 
sDSP1_D0A = (!CS1/ and IND1d) or (!CS2/ and IND3d) or (!CS3/ and IND5d) or (!CS4/ and IND7d) 
sDSP1_D0B = (!CS1/ and IND2d) or (!CS2/ and IND4d) or (!CS3/ and IND6d) or (!CS4/ and IND8d) 
 
Left Side 
sDSP2_D0A = (!CS1/ and IND1a) or (!CS2/ and IND3a) or (!CS3/ and IND5a) or (!CS4/ and IND7a) 
sDSP2_D0B = (!CS1/ and IND2a) or (!CS2/ and IND4a) or (!CS3/ and IND6a) or (!CS4/ and IND8a) 
sDSP3_D0A = (!CS1/ and IND2b) or (!CS2/ and IND3b) or (!CS3/ and IND5b) or (!CS4/ and IND7b) 
sDSP3_D0B = (!CS1/ and IND2b) or (!CS2/ and IND4b) or (!CS3/ and IND6b) or (!CS4/ and IND8b) 
 
 Once the data from all of the ADCs has been transmitted to the DSPs (indicated by 
F_SD=1 in the mCPLD), the mCPLD must return to the Imaging.Convert State to take the next 
sample.  This time it will sample the other two ADC ports (the A1 and B1 ports).  The mCPLD will 
continue cycling between the Convert and SendData sub-states until 150 samples have been 
acquired from both the A0&B0 and A1&B1 ports of the ADCs (300 samples total).  Once all 300 
samples are acquired (indicated by F_SMPL) the mCPLD is ready to go back to the Switch sub-
state to cause the switch to move to the next source position.  And the cycle continues until 
data for all sources and wavelength sets has been acquired (F_IMG=1). 
When 150 samples have been acquired from all detector channels for the last source 






state will also transition to Standby, triggering the DIO_PLD0 to indicate to the mDSP that the 
imaging frame is complete and it has returned to Standby.  In addition, as the mCPLD exits the 
Imaging state, it pulses the FIFO retransmit signal (FIFO_RT/) to the gain bit FIFOs on the 
Detector Boards.  This causes the read pointer to return to the first entry (the gain bits for 
source 0, wavelength set 1) in preparation for the next imaging frame (which will start back at 
source 0, wavelength set 1 and must read the corresponding gain bits from the FIFOs). 
 The DSP chips are unaware of the intricacies of the data acquisition from the ADCs.  
They program the SPORT0 register to expect 150 16-bit words of data from 16 detector 
channels on each D0A and D0B port.  Once this data is received the SPORT0 interrupt is 
triggered, alerting the Imaging state that it can proceed.  However, it doesn’t immediately use 
the newly sampled data.  First, it confirms that the mCPLD is not inStandby (it shouldn’t be,  but 
if for some reason it is, the mCPLD leaves the Imaging state and returns to Standby) and then 
waits to see the DIO_PLD1=1, indicating that the mCPLD is in Wait state and needs the mDSP to 
start the timer.  
 While the mDSP is waiting for the timer to expire, it has 7 ms during which it can 
demodulate the data it just received for the previous source.  The details of the digital 
demodulation are discussed in Section 5.5.  The digital demodulation takes in 150 samples for 
each channel and computes the amplitude as a 32-bit floating point number.  Once all channels 
have been demodulated, the mDSP programs the DMACh10 to write the data to the output 
buffer. Two DSPs share one dual 9-bit output buffer.  As a result, the DMACh10 outputs each 






and write the values to the demodulation buffer.  This means that the 7 ms settling time of the 
optical switch is the delay most critical to the system timing. 
Once the data has been acquired for all sources and wavelength sets the mDSP must still 
send the data for the final source and wavelength set.  Once that is complete, the mDSP waits 
for the mCPLD to transmit DIO_PLD0 which indicates that it is in Standby before returning to its 
own idle state Standby to await the next instruction from the host computer.  In the case of the 
sDSPs, which are oblivious to the number of sources and wavelength sets, they continue 
iterating in Imaging until they see the mCPLD return to Standby, as indicated by DIO_PLD0, at 
which point they transition back to Standby. 
The DSPs acquire 150 samples from each of the 128 detectors over a period of 2 ms 
which results in each detector being sampled at 75 ksamples/s.  To collect a complete sample 
on one serial input port, the DSP must wait for the ADCs to convert the sample for A0&B0 and 
will then read the two 16-bit values from 4 ADCs (one for each chip select).  Next, the DSP must 
wait for the ADCs to convert the sample for A1&B1 and then read the two 16-bit values from 
the 4 ADCs.  This means that the sampling time is 2*(t_cnvst + 16*2*4*t_read_clk), where 
t_cnvst must be at least 1.75 µs and t_read_clk is dictated by the CPLD clock, which is 30 MHz, 
so in this case t_read_clk=33.33 ns.  By this calculation, the fastest sampling rate possible is ~83 
kHz.  To allow for ample conversion time, while also obeying the constraints for digital lock-in 
detection outlined in 5.5, we choose a sampling rate of 75 kHz.  To maintain this sampling rate 
we lengthen t_cnvst to 2.4 µs.  The detailed digital logic signals and timing to acquire data for a 







Figure 5-11.  Digital signals for acquiring image data for a source and wavelength set. 
 
The overall sequencing and timing to acquire a complete frame in the imaging state is 







Figure 5-12.  Timing sequence for the acquisition of a complete image. 
 
5.3 DSP-CLP Coordination 
 The mDSP and mCPLD work closely together to synchronize the timing of the events in 
the system and to control the other chips.  The mCPLD is used to communicate the control logic 
to the detection boards, but the mDSP closely controls the mCPLD and is responsible for the 
timer that counts the 7ms required for the optical switch settling.  The intricate way in which 
the mDSP and mCPLD work together to progress through the various states of setup and data 







Table 5-4. State by State Description of the PC, mCPLD, and mDSP Interaction 
State Description 
Standby mDSP is idle waiting for a signal from the host computer. 
mCPLD is idle waiting for a signal from the mDSP. 
Imaging 
Parameters 
1. mDSP receives CMD:01 from the host computer telling it to go into the Imaging 
Parameters state. 
2. The host computer sends the number of sources, detectors, and wavelengths to 
the mDSP via DMACh11. 
3. mDSP returns to Standby. 
*mCPLD remains in Standby. 
Gain Bits 1. mDSP receives CMD:10 from the host computer telling it to go into the Gain Bit 
download state. 
2. PC sends the gain bits for each source-detector pair to the mDSP on DMA Ch11. 
3. mDSP tells the mCPLD to go into Gain Bit state by transmitting an empty word on 
SPORT1A. 
4. mDSP sends the mCPLD the # of sources and wavelengths as a word on SPORT1A. 
5. mDSP sends the gain bits to the mCPLD via SPORT1A (Left Breast) and SPORT1B 
(Right Breast).  mCPLD passes them directly onto the detection boards along with 
the control signals for the shift registers and FIFOs. 
6. mCPLD returns to Standby and sets DIO_PLD0=1. 
7. mDSP returns to Standby. 
Imaging 1. mDSP receives CMD:11 from the host computer telling it to acquire one frame. 
2. mDSP tells mCPLD to go into Imaging State by setting DIO_IMST=0. 
3. mCPLD tells the optical switch to move to the next position.  Updates the gain bits 
by triggering a read from the detection board FIFOs.  Waits for the TIMEXP signal 
from mDSP.  Outputs DIO_PLD0=1 while waiting for TIMEXP=1. 
4. mDSP waits to see DIO_PLD0=1 to start the 7ms timer.  While waiting for the 
timer to expire it runs the lock-in detection and sends data from previous source 
back to the PC via DMA Ch10.  When the 7 ms has elapsed it sets TIMEXP=1. 
5. mCPLD acquires 150 samples from all detectors. 
6. mDSP receives 150 samples from 16 detectors on SPORT0A and from 16 detectors 
on SPORT0B.  
7. mCPLD asserts DIO_PLD0=1 to show it has finished acquiring data. 
8. mDSP returns to step 3 until all sources and wavelength sets are acquired. 
9. mCPLD returns to Standby and sets DIO_PLD1=1. 
10. mDSP returns to Standby. 
 
5.4 Data Sample Reordering 
The 150 data samples are received in a time-multiplexed fashion from the ADCs according to 
the chip selects (CS1-CS4/) and the ADC Channel select (A0/).  Table 5-5 shows the order in 
which the samples are acquired.  Each DSP is responsible for 32 detector channels (housed on 4 






the ADC Channel Select (A0/) chooses which pair of channels to read from the four-channel 
ADC.  Each read from the ADC samples two channels that are output serially to the DSP.  The 
ordering of the data samples captured in the DSP memory following the acquisition of one 
source position measurement is shown in Table 5-5.   
Table 5-5.  Order in which the samples are received by the DSPs from the ADCs. 


















































































































*Shown in grey are the samples belonging to Detector 4 on D0A and Detector 8 
on D0B.  Note that they are separated by 16 rows. 
 
In order to perform the demodulation (Appendix G: Demodulation.c) for a given detector 
channel, the algorithm must first extract all 150 samples that belong to each detector channel.  
It does so sequentially by looping through the data memory (IDA and IDB) extracts each of the 
150 samples which are stored at 16 row intervals.  The loop starts with row 0 and loop through 
all 16 possible starting offset rows (index i loops from 0 to 15). 
for i from 0 to 15 //each possible starting offset row 
 for j from 0 to 149 //find each of the 150 samples 
datMatA[j] = (double) IDA[i+16*j]; 
datMatB[j] = (double) IDB[i+16*j]; 
 
  end 
OUTPUT[(Det_Hash[i]] = demodulate(datMatA); 
OUTPUT[(Det_Hash[i+16]] = demodulate(datMatB); 
 end 
 
Once the DSP has extracted the 150 samples from the IDA and IDB memory banks, it 
now has a complete waveform for one detector from each channel (datMatA and datMatB).  
At this point it can perform the demodulation to compute the amplitude of the waveform.  
Then, when writing the result to the output array (an array that contains 32 elements - one for 
each detector channel), it carefully matches the data extracted from memory to the actual 
detector value according to the following hash table according to Table 5-5.  The hash table 
references detector values from 0 to 31. 
 







5.5 Digital Lock-in Detection 
Each DSP is responsible for demodulating the incoming data to extract the amplitude of the 
signal.  The digital lock-in detection algorithm employed by this system was previously 
described in detail by Masciotti et al. [65].  The key feature of the algorithm is that it uses a 
simple averaging filter to extract the amplitude of the signal, but requires a specific relationship 
between fm, the frequency of the signal (7 kHz and 5 kHz in this system), and Ns, the number of 
samples acquired, as shown in Eq. 5.1. 
   
   
  
      
  
 
      (5.1) 
 Using the relationship given in Eq. 5.1 the digital demodulation can be implemented as 
derived in [65] and shown in Eq. 5.2 where Data is a 1x150 array of the samples from the 
detector channel containing the measurement from one wavelength set that contains two 
wavelengths: one modulated at 5 kHz and one modulated at 7 kHz.  InPhaseRef is a 150x2 array 
of a 5 kHz and 7 kHz in-phase waveform with 150 samples taken at 75 kHz.  Quad is a 150x2 
array consisting of a 5 kHz and 7 kHz quadrature waveform, shifted by ¼ of the phase period, 
with 150 samples taken at 75 kHz.  Both InPhaseRef and QuadRef are stored on the DSP.  The 
Scaling  parameter is used to convert the final amplitude from an integer ranging from 0 to 216-
1 into a relative voltage ranging from 0 to 5 V, so Scaling in our system equals 13107. 
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Performing the lock-in detection digitally using a DSP chip as opposed to using 
traditional analog circuitry not only reduces the amount of hardware required for 
demodulation, but also provides a more robust solution with better noise performance [66, 67].  
Simply by reprogramming the DSP chip it is possible to adjust the lock-in frequency, filtering, 
and the number of detectors.  In addition, DSP-based demodulation is less sensitive to analog 
component tolerances that can vary with temperature and age as well as between detector 
channels [68]. 
5.6 Coordinated Data Transfer 
The demodulated amplitude for each detector is stored as a 32-bit floating point number that 
must be transferred to the host.  This transfer takes place through output buffers that are 
located on the Master and Slave DSP Boards.  The DSP writes the data to the output buffer, 
triggering a read request to the host PC.  The host PC then asynchronously chooses to read the 
result from the output buffer.  
Each pair of DSP chips (mDSP & sDSP1 and sDSP2 & sDSP3) share an 8,192 x 9-bit dual 
synchronous FIFO (IDT 72851, Integrated Device Technologies) through which the data is sent 
back to the host computer.  Each DSP must break up the 32-bit floating point number into four 
8-bit writes to the FIFO.  These writes are accomplished through the DMACh10, which is 
programmed to transmit 32 32-bit words according to its internal counter (CEP0) and 4*32=128 
8-bit words according to its external counter (ECEP0).  A full tomographic data set consists of 4 
writes/detector * 32 detectors * 32 sources * 4 wavelength = 16,384 writes.  The output buffer 






flexibility in the event that the host PC cannot immediately service the read request from the 
output buffer.   
Any data sitting in the output buffer FIFO causes the empty flag (FIFO_EF/) to deassert, 
thereby triggering a request to the host PC.  The host PC then grants the request and triggers a 
read to the FIFO, which sends the data to the host PC, via a Data Acquisition Card (DAQ).  As 
such, the FIFO is essentially a data buffer that is responsible for holding the data until the host 
computer is ready. The control signals from the host PC are passed to the detector hardware 
through a DAQ (PCI-6503, National Instruments) that has a 24-bit digital I/O interface.  The data 
from the DSP chips is acquired by the host PC through a second DAQ (PCI-6533, National 
Instruments) that provides 32 digital data lines that are individually configurable as inputs or 
outputs, grouped into four 8-bit ports.  Each group of 8-bit ports is devoted to one DSP in order 
to handle the data transfer to the host computer.  The connections between the DAQ cards and 







Figure 5-13.  Overview of the connections between the DSPs, Output Buffers, Glue Logic Board, 
and DAQs. 
 
Any data present in the output buffer causes the FIFO_EF/ signal to go low, initiating the 
burst-transfer protocol.  The burst-transfer protocol, controlled by the DAQ, is a protocol that 
uses acknowledgement (ACK) and request (REQ) signals in addition to sharing a clock (PCLK).  
The Glue Logic Board contains the hardware that synchronizes the FIFO_EF/ signal with the 
PCLK line to generate the REQ signal to the DAQ.  The DAQ responds by asserting the ACK signal 
to indicate it is ready to acquire the data.  Data transfer occurs on the rising edge of the PCLK 
signal (which is connected to the FIFO_R/ pin) until the data buffer is empty and FIFO_EF/ goes 
high.  The PCLK is generated by the DAQ and can be controlled through the user interface (it is 






handshaking signals for the data transfer and also provides connectors for the two DAQ cables, 
and the cable to the optical switch.  The Schematic, Board Layout, and BOM for the Glue Logic 
Board are included in Appendix I. Fig. 5-14 contains the timing diagram for the burst transfer of 
the data from the output buffer to the host PC. 
 
Figure 5-14.  Timing diagram for the burst-transfer protocol from the DSP output data buffers to 
the host computer.  
 
 For each source, the DSP dumps the demodulated result for 32 channels of data at 2 
wavelengths as a series of four 8-bit writes into the output buffers.  Ideally, the host PC should 
empty the output buffer in time for the DSP to write the data from the next source position. 
This gives the host PC 9 ms to retrieve the data (7 ms of source settling, plus another 2 ms while 
the DSP is acquiring the data from the ADCs).  It takes approximately 1.7 ms to demodulate the 
data, which leaves 7.3 ms to transfer the data to the host PC.  The PCLK determines how quickly 
this data transfer takes place.  We use a PCLK of 60 kHz, which allows us to transfer the data in 
4.3 ms (1/60 kHz * 32 channels * 4 transfers/channel * 2 wavelengths).  The PCLK speed can be 
increased if more channels or wavelengths are added to the system, but a slower PCLK 
improves the data acquisition stability my reducing the likelihood of race conditions on the 






5.7 Master DSP Board Design 
The mDSP, mCPLD, and sDSP1 are all mounted on the Master DSP printed circuit board, shown 
in Fig. 5-15.  The board is the same height and size as the detector boards, and can connect to a 
standard 6U/4HP front panel (Vero Technologies)  The boards connect to the backplane of the 
detection unit via to 96-pin connectors (650473-5, Tyco Electronics).  The four-layer PCB has a 
top and bottom copper layer for part placement and routing, one dedicated inner ground layer, 
and one inner layer for power planes.  The Master DSP uses on-board voltage regulators to 
convert the incoming 5 V and 12 V lines into 1.8 V, 3.3 V, and 5 V.  The board also has both a 
digital and analog ground planes.  There are two clocks on the Master DSP Board: a 30 MHz 
clock for the CPLD (PLD CLK) and a 25 MHz clock for the DSP (DSP CLK).  The CPLD and EEPROM 
chips can all be removed from the board for reprogramming the behavior of the system.  The 







Figure 5-15.  Photograph of the Master DSP board with key functional components outlined in 
white. 
 
5.8 Slave DSP Board Design 
The sCPLD, sDSP2 and sDSP3 are mounted on the Slave DSP printed circuit board, shown in Fig. 
5-16.  The board is the same height and size as the Detector and Master DSP boards, and can 
connect to a standard 6U/4HP front panel (Vero Technologies)  The board connects to the 
backplane of the detection unit via two 96-pin connectors (650473-5, Tyco Electronics).  The 
four-layer PCB has a top and bottom copper layer for part placement and routing, one 
dedicated inner ground layer, and one inner layer for power planes.  The Slave DSP uses on-
board voltage regulators to convert the incoming 5 V and 12 V lines into 1.8 V, 3.3 V, and 5 V.  
The board also has both digital and analog ground planes.  There is one clock on the Slave DSP 






Master DSP board to ensure both CPLDs are synchronized. The CPLD and EEPROM chips can be 
removed from the board for reprogramming the behavior of the system.  The Slave DSP Board 
schematic, bill of materials, and layout are included in Appendix K. 
 
Figure 5-16.  Photograph of the Slave DSP board with the key functional components outlined in 
white. 
 
5.9 Detection Backplane and Enclosure 
The Detection Backplane is a PCB board whose primary role is to connect all of the boards of 
the Detection Unit (16 Detector Boards, 1 Master DSP Board, 1 Slave DSP Board, 1 Glue Logic 
Board).  In addition, the Detection Backplane provides the connector (PCIH47M400A1, 
Positronic) for a 400 W Compact Peripheral Component Interconnect (cPCI) Power Supply 
(cPWR-59401, Chroma) that provides voltage rails +5 V (50 A), +3.3 V (50 A), +12 V (12 A), and -






of most cPCI power supplies, we supplement the -12 V line with a 1 W external power supply 
(MW1212-760, Elpac).   
The Detection Backplane also provides connectors for two quiet fans (SF12025C, 
Vizo/Vantec) that require 12 V and provide 38 cubic feet of air flow per minute (CFM).  The 
Detection Backplane also contains a power resistor for each of the voltage lines (FPS2-T220, 
Reidon) to ensure that even when no boards are plugged in, the minimum current is still drawn 
from the cPCI supply.  The Detection Backplane is 10.3 inches by 16.925 inches and is 
compatible with a 19 inch x 6U Elma Enclosure.  The BOM, Layout, and Schematic for the 
Detection Backplane are included in Appendix L.  Fig. 5-17 shows how the various PCB boards 
are connected to the Detection Backplane to make up the Detection Unit. 
 
Figure 5-17.  Diagram of the physical configuration of the PCBs that make up the Detection Unit. 
 
 The Detection Backplane is a very long PCB that routes signals as far as 17 inches.  Over 
this long distance, the reflections and termination of the line may impact the digital signals.  






this fluctuation can incorrectly triggering the signal.  In our system this can cause issues shifting 
in the gain bits as well as reading of the ADC data.  To reduce digital reflections, the following 
lines were updated with an RC line termination (typically with a ~1 MΩ resistor and a ~10 pF 






Chapter 6 : Software Interface 
The software interface gives the user control over the operation of the system, automatically 
computes the optimal gain bits for an experiment, and displays real-time imaging data.  The 
software interface communicates with the electronics via two DAQs, and consists of a graphical 
user interface (GUI) written in LabVIEW (LabVIEW 6.0, National Instruments).  The user 
interface is comprised of a series of tabs that compartmentalize the various operations: 
Experiment Setup, Imaging Parameters, Gain Bits, and Imaging.  Upon launching the GUI the 
user must input the parameters to be used for the experiment including: the number of 
sources, detectors, and wavelengths to be used for each breast (Fig. 6-1). 
 
Figure 6-1.  User interface launch screen. 
The launch screen accepts the parameters for the experiment including the number of sources, 
detectors, and wavelengths for each breast. 
 
6.1 Imaging Parameters 
The Experiment Parameters tab provides advanced options for the control of the system.  
These features are primarily used for the development and debugging of the system, and are 






be controlled through this tab, as well as the output ports to the mDSP (such as DIO_PC0, 
DIO_PC1, SOFT_RST/, etc).  In addition, the user can adjust the lower and upper signal 
thresholds (Smin=0.2 V and Smax=1.5 V), and can modify the timing of the automatic gain bit 
detection routine.  Any LabVIEW and data acquisition errors that occur can be seen on this tab.  
A screen shot of Imaging Parameters tab is shown in Fig. 6-2. 
 
Figure 6-2.  Screen shot of user interface Imaging Parameters tab. 
 
6.2 Experiment Setup 
The Experiment Setup tab gives the user with the ability to change the number of sources, 
detectors, and wavelengths for an ongoing experiment.   In addition, the gain bits can be saved 
to a text file, or loaded from a text file.  This is an important feature that allows the same gain 






each measurement on the Gain Settings tab is also modifiable through this tab (Navg, typically 
set to 3).  The tables on the right side of the tab inform the operator of the detectors that do 
not have measured values in the optimal range.  Finally, in the event of a problem with the 
detection electronics, this tab allows the user to perform a soft reset of the hardware.  
Following the soft reset the user must end the program and restart.  A screen shot of the 
Experiment Setup tab is shown in Fig. 6-3. 
 
Figure 6-3.  Screen shot of the user interface Experiment Setup tab. 
 
6.3 Gain Settings 
The Gain Settings tab is one of the more important tools provided by the user interface.  By 
pressing the “CONFIRM” button the system uploads the gain, takes 3 measurements (as 
specified on the Experiment Setup tab), and displays the result for each source-detector pair for 
each wavelength set.  If the measured signal for a given source-detector pair is below the lower 






indicator is red, and if the value falls in the optimal range (Smin<S<Smax) then the indicator is 
green.  This allows the user visually assess the performance of the current gain bits.  The 
amount of gain for each source-detector pair at each wavelength set can be manually 
controlled by a slider.  With each increment of the slider the gain applied to the source-
detector channel increases by a factor of 10.  Both wavelengths belonging to a Wavelength Set 
must share the same gain setting (the wavelengths are not demodulated and separated until 
after the analog gain stages).  The user can switch between Wavelength Sets as well as the Left 
and Right breast via tabs on the Gain Settings page.  A screen shot of the Gain Settings tab is 







Figure 6-4.  Screen shot of the user interface for Gain Settings tab. 
 
A key feature of the Gain Settings interface is the “AUTO” button that calls a routine 
that automatically detects the optimal gain settings for each source-detector pair for each 
wavelength set and breast.  This is important, since for 2 breasts, each with 64 detectors, 32 
sources, and 2 wavelength sets, there are over four thousand gain settings that must be 
programmed.  Without the “AUTO” feature, the user would need to adjust over 4000 gain bits 






the gain across the channels, takes the average of Navg=3 samples at that gain setting, and then 
evaluates if that gain setting provides a signal above the minimum threshold (Smin).  If the signal 
for a channel is within the optimal range, then the LabVIEW records that gain setting, and no 
longer updates the gain bits on that channel for the rest of the iterations.  By no longer 
increasing the gain bits on channels that are already at an acceptable level, we avoid 
unnecessarily saturating those channels with too much gain.  In the next iteration the routine 
applies the next highest gain setting, acquires Navg samples, and records the channels that are 
now within the optimal range.  The routine continues looping until it has tested all of the gain 
settings, at which point it ends and displays the optimal gain setting and signal received at the 
gain setting for each source-detector channel at both wavelength sets and for both the left and 
right breast. 
 The automatic gain routine begins with the lowest possible gain setting and gradually 
increments the setting until the signal reaches the optimal range for the detected signal.  This is 
important design because saturation or clipping of the detected sinusoidal waveform can occur 
if too much gain is applied to a detector channel.  Clipping of the sinusoid will cause the DSP to 
measure signal power at our modulation frequencies of 5 kHz or 7 kHz frequency, despite the 
fact that the amplitude of the signal is ‘bigger’.  When demodulated, a clipped sinusoid signal 
has a lower value than an unclipped sinusoid with a smaller amplitude.  For this reason, it is 
important that the user be aware of the fact that detector values that are too high, or that are 







6.4 Data Acquisition 
Prior to acquiring the data for an experiment, the gain bits should be optimally set on the Gain 
Settings tab.  Next, the imaging can be performed through operations on the Data Acquisition 
tab.  This tab allows the user to specify the number of frames to acquire and the location where 
the data should be stored.  The data is stored according to the name entered in the ‘File Name’ 
with _Left and _Right appended for the data from the left and right breast, respectively.  The 
extensions .wl1, .wl2, .wl3, and .wl4 are also appended to the files corresponding to the data 
acquired at 808 nm, 765 nm, 905 nm, and 827 nm wavelengths.  Each imaging frame is written 
to the files as a separate row.  Each frame, or row, contains 32x64 space-separated values 
written in the following order, where S1D1 represents source 1 detector channel 1: 
S1D1 S1D2 … S1D64 S2D1 S1D2 … S2D64 … S32D64 
The user can start, stop, and pause the imaging using the SCAN, PAUSE, and STOP 
buttons located on the Data Acquisition tab.   The data acquired from the left and right breasts 
is displayed on two tabs that can be easily switched between during the experiment to monitor 
the data acquisition from each breast.  The data for all the detectors for one source position 
and one wavelength is displayed on the graph.  Sliders below the graph allow the user to 
display different source positions and wavelengths.  In some cases it is useful to display only 
some of the detector channels – these can be selected from the checkboxes to the right of the 







Figure 6-5.  Screen shot of the user interface the Data Acquisition tab. 
 
While the user operation of the Data Acquisition tab is relatively straightforward, the 
LabVIEW interface plays an important role in processing the incoming data from the system.  As 
described in Section 5.7, the data in the output buffers on the DSP boards is stored as 4 8-bit 
writes.  These 8-bit writes are read from the dual FIFO output buffer as a 16-bit value 
combining the data from mDSP and sDSP1 and as another 16-bit value combining the data for 






numbers for each of the channels.  Fig. 6-6 shows how the incoming data for a single source is 
unpacked in the LabVIEW (Scan_2_mx.vi whose block diagram is included in Appendix M). 
 
Figure 6-6.  Diagram showing the unpacking of data arriving from the DSP.   
This diagram shows the data collection from a single source. 
Chapter 7 : System Overview and Performance 
In Chapter 2, a number of system requirements were specified: Speed, Number of Channels, 
Sensitivity and Dynamic Range, Linearity, Stability, Size, and Scalability.  Here we discuss how 
each of these requirements was satisfied by the design of the digital optical tomography breast 
imaging system.  The performance of the system is tested in phantom experiments involving 







The speed of acquisition is an essential parameter for dynamic imaging experiments.  The 
temporal response of the system is limited by the settling time of the optical switch and the 
number of source positions and wavelengths that it must switch between.  The switch requires 
7 ms to settle after switching positions, followed by 2 ms to acquire the data for all detectors at 
that source position.  This brings the imaging time to 9 ms per source position.  Since we image 
the two wavelength sets sequentially, the imaging rate also depends on the number of 
wavelength sets.  Consequently the fastest the system can image is to collect one frame in 
0.009 seconds with one source and 2 wavelengths (111 Hz).  Or, with 32 sources and 2 
wavelengths it can acquire a frame in 0.288 seconds (3.5 Hz).  Finally, the slowest configuration 
is to use all 32 sources and 4 wavelengths in which case it takes 0.576 seconds to acquire one 
frame (1.7 Hz). 
7.2 Channels 
The system has 32 source positions, 64 detector positions, and 4 wavelengths per breast.  This 
provides a total of 16,384 data points per image frame.  A rough estimate for a C-cup breast 
assuming a 6 cm radius and a half-sphere shape for the breast indicates that the system has 
one detector every 4 cm2. 
7.3 Sensitivity and Dynamic Range 
The dark noise is the measured signal when no incident light is present, and thus 
represents the smallest measurement that can be reliably performed with the system.  Fig. 7-1 






measurements across all detectors indicated by the error bars.  As expected, with increasing 
amplification in the PGA stage and eventually in the TIA stage we see increasing noise present.  
At the lower gain stages we see noise levels below 50 μV, but as the gain increases we see 
increasing noise until at the highest gain stage of 10 GV/A we observe an RMS dark noise of 22 
mV.  The slightly higher noise at the 1 M versus the 10 M setting represents the fact that the 1 
M setting uses less TIA gain and more PGA gain, whereas the 10 M setting uses more TIA gain 
and less PGA gain.  While TIA gain improves the signal to noise ratio (SNR), PGA gain does not.  
This finding demonstrates that increasing the gain at the TIA stages is preferred over increasing 
the gain at the PGA stage. 
 
Figure 7-1.  Logarithmic plot of the root mean squared (RMS) dark noise for each detector gain 
setting.   
Error bars represent the standard deviation of all detectors. 
 
The Noise Equivalent Power (NEP) is an indication of the detector sensitivity to light and 
can be computed for an SNR of unity using the dark noise of the highest gain setting.  Taking 
the mean of the root-mean-squared (RMS) detector noise at the highest gain setting and using 






NEP is approximately 4.5 pW RMS.  The NEP represents the smallest light signal that can be 
detected.  The largest light signal that can be detected uses the full detector range for the 
lowest gain setting, which in this case is to detect a 2.5 V peak-to-peak voltage on the 10 kV/A 
gain setting.  Using these values we can calculate the dynamic range of the system to be 108 (or 
158 dB). 
Using the Beer-Lambert Law specified in Chapter 1 (Eq. 1.3) we can estimate the 
amount of light that will arrive at the detector after passing through 10 cm of breast tissue.  
Assuming typical optical properties of breast tissue (μa=0.1 cm
-1 and μs’=10 cm
-1) we can 
calculate the light intensity arriving at  a detector separated by 10 cm from an input source of 5 
mW as shown in Eq. 7.1.  Here we roughly account for the effects of scattering on the path 
length by using      √           .  Our calculation shows that our sensitivity (4.5 pW) is 
still two orders of magnitude better than the sensitivity of light required to detect 5 mW of light 
through 10 cm of breast tissue (138 pW). 
                                      
            (7.1) 
Using the same calculation for the smallest source-detector separation of 1 cm we find that the 
system must accommodate a range of light intensities from 138 pW to 0.8 mW.  This works out 
to a dynamic range of 136 dB.  Our system exceeds that requirement by 24 dB. 
7.4 Linearity 
System linearity was examined by using the same incident light on a detector and then 
measuring the detected voltage across all possible gain settings.  This was repeated four times 






relationship across the gain settings is generally maintained.  We expect to see a 10x gain factor 
between each gain setting measuring the same signal.  An exponential fit of the data in Fig. 7-2 
should give an equation of e-2.3 in a perfectly linear 10x relationship between gain settings.  For 
the curves below we see good linearity with fits of e-2.31 (R=1), e-2.27 (R=0.9999), e-2.30 (R=1), and 
e-2.02 (R=0.9955) for S1 through S4.  We expect the decreased linearity at the highest gain 
settings (reflected by S4), since those settings also introduce higher noise levels. 
 
Figure 7-2.  Linearity across all gain settings measured through four otpical samples (S1-S4)..   
Each sample reflects the same input intensity measured across multiple gain settings. 
7.5 Coefficient of Variation and Long Term Stability 
The coefficient of variation (CV), shown in Eq. 7.2 is calculated here for a static breast-
shaped phantom with breast optical properties over a period of 5 minutes (500 frames) with 
the full number of sources and detectors.   
    
 
 
               
 
  
    (7.2) 
Fig. 7-3 shows the mean of the CV calculated for all detectors at the given gain setting for each 
wavelength.  Up until 100 MV/A the CV is as low as 0.15% for some wavelengths but by the 






calculated according to Eq. 7.2 giving us an average SNR of 51 dB for the lowest gain setting and 
30 dB for the highest gain setting. 
 
Figure 7-3.  The mean CV of the detectors at each gain setting for each wavelength. 
Errors bars represent the standard deviation across source-detector pairs. 
 
To assess the long term stability of the system we measured the same static breast 
phantom over 40,000 frames (~38 minutes). Taking the mean of measured values at frame 1 
and calculating the percentage change between that and the mean at frame 40,000 there is a 
0.7% change in the measured value. 
7.6 Size 
The electronic components and software interface described in the previous chapters are 
combined into a single system that is contained in a custom-made portable cart, as shown in 
Fig. 7-4.  The instrument cart measures 104x79x66 cm and is on wheels so that it can be moved 
around in a clinical setting.  All of the electronics are completely encased by semi-transparent 







Figure 7-4.  Photograph of the instrument. 
Shown are (a) the portable cart enclosing all the electronics and (b) the cart with the doors open 
to display the various electronic components. 
 
 There are four shelves inside of the cart that hold the various modules of the system.  
The top shelf holds the optical switch, the shelf below it contains the input unit, the largest 
middle shelf contains the detection electronics, and the bottom shelf holds the host computer 
(Fig. 7-4b).  The optical fibers emerge from the opposite side of the cart (not shown) and can be 
configured in a number of geometries, as discussed in Chapter 8. 
There are two power lines in the cart that provide power to the computer on the 
primary line, and the rest of the electronics on the secondary line.  The secondary line has an 
emergency stop button and can be turned on and off without affecting the computer.  The 
secondary line also provides power to a 12 V DC power supply that powers two fans (4212, 
ebmpapst) that each provide 50 CFM.  One fan brings cool air into the cart while the other fan 






the noise generated by the fans was not ideal for use in the clinical setting.  The noisier, higher 
CFM fans should be used for studies that require running the system for more than 3 hours. 
7.7 Scalability 
An ideal instrument design will provide the flexibility for a number of experimental applications, 
and for the scaling of the system for future applications.  Already our system provides the 
ability to image with 1 to 32 sources and 1 to 64 detectors with 2 or 4 wavelengths.  In addition, 
the use of digital components provides a scalable design that can be adjusted to accommodate 
more sources, wavelengths, and channels without a significant design effort.  More sources can 
be introduced be adding laser diodes and using the Input Unit microcontroller to program a 
unique frequency within the 3-9 kHz band.  The DSP chips can be programmed to demodulate 
at any frequency, and can accommodate any number of wavelengths and sources.  To increase 
the number of detectors the master-slave architecture can be expanded to include an 
increasing number of slave DSP chips and DAQ cards, without affecting the processing time or 
significantly increasing the size of the system.  
7.8 Phantom Measurements of Absorbing Inclusions 
To test the ability of the instrument to identify an absorbing inclusion, similar to a tumor 
located inside the breast, we performed a series of phantom experiments with an Intralipid and 
Ink solution as the background breast-like tissue, and with a scattering silicon and ink solid cube 
to mimic a tumor.  The background intralipid was mixed to approximate breast optical 
properties of μa=0.1 cm
-1 and μs’=8 cm
-1 by combining 40 mL of 20% Intralipid (Baxter) with 3 






suspended in the background mixture.  The lightest cube had a slightly higher absorption and 
scattering than the background mixture, the medium cube had 2x the absorption of the lightest 
cube, and the dark cube had 3x the absorption of the lightest cube.  A photograph of the three 
inclusions are shown in Fig. 7-5. 
 
Figure 7-5.  Photograph of the absorbing inclusions used in the phantom experiments. 
Shown from left to right are the light, medium, and dark inclusions. 
 
25 frames of data were acquired and averaged for both the background reference as well as the 
background with each inclusion and the results were reconstructed using the diffusion 
approximation, as discussed in detail in Section 9.3.  The results of the phantom reconstructions 
are shown in Fig. 7-6.  The inclusion is identified as a region of increased absorption in all three 
cases.  The darkest inclusion has a reconstructed absorption of μa=0.2 cm
-1, while the middle 
inclusion has μa=0.16 cm
-1 and the lightest inclusion has μa=0.12 cm
-1.  These values agree with 
the known ratios of ink introduced into each inclusion. 
 
Figure 7-6.  Phantom experiment with DOT images shown for three inclusions of increasing 
absorption. 
The images show the absorption profile (in cm
-1
) of a (a) the lightest inclusion, (b) the medium 






7.9 System Summary 
Table 7-1 summarizes the system performance.  The cost to produce the prototype instrument 
is approximately $100,000, but future iterations and mass production would significantly 
decrease that cost.  As such, the digital optical breast imaging system is a fairly low-cost, 
portable, non-ionizing, clinically translatable imaging system. 
Table 7-1.  Summary of the digital optical breast imager parameters. 
Parameter Value 
Sources 32 per breast, 64 total 
Detectors 64 per breast, 128 total 
Wavelengths 
<5 mW at 765 nm, <5 mW at 808 nm, 
<5 mW at 827 nm,  <5 mW at 905 nm 
Temporal Response 
111 Hz (1 source, 2 wavelengths), 
3.5 Hz (32 source positions, 2 wavelengths), 
1.7 Hz (32 source positions, 4 wavelengths) 
Dynamic Range ~ 10
8
 (158 dB) 
Noise Equivalent Power ~ 4.5 pW RMS 
Dark Noise Amplitude 
<10 µV RMS (at lowest gain setting), 
<22 mV RMS (at highest gain setting) 
Long Term Stability 0.7% over 40 minutes 
System Size 104 cm x 79 cm x 66 cm 
Power Consumption 3.5 Amps @ 120 V AC 
 
Table 7-2 presents a comparison between the new digital breast imaging system and the 
small animal digital imaging system presented by Lasker et al. [58].  The most important 
difference between the digital breast imaging system described in this thesis and the small-
animal digital imaging system lies in the dramatic increase in sources, detectors, and 
wavelengths for the application to breast imaging, bringing the number of data points collected 
per frame from 1024 in the original system to 16,384 in the breast imaging system.  Despite this 






In fact, the decrease in imaging speeds comes primarily from the increased number of sources 
and wavelengths, and not from the 4 fold increase in detectors.  This is accomplished by the 
new master-slave architecture implemented for simultaneous data detection and 
demodulation from 128 detectors.  In addition, despite the large increase in detectors, sources, 
and wavelengths, the size of the entire breast imaging system (including the cart) is only slightly 
larger than the original digital imaging system.  This is due to more compact digital detection 
boards (8 channels per board as opposed to 4) as well as the master-slave DSP-based 
architecture that can scale effortlessly with the number of detectors.   
 The breast imaging system uses less low gain settings and adds more high gain settings 
to handle the larger imaging volumes.  This accounts for the lower dynamic range as well as the 
fact that the higher gain settings lead to slightly higher dark noise and CV%.  Overall, the system 
performance is similar between the two systems as they are based upon the same detection 
techniques - both have coefficients of variation of less than 1% for most gain settings and have 
very low dark noise (<50µV for most gain settings).   




Digital Breast Imaging 
System 
Mode of Operation CW CW 
Sources 16 64 
Detectors 32 128 
Wavelengths 1-2 1-4 
Total Data Points 1024 16,384 
Frame Rate 8.9-140 Hz 1.7-111 Hz 
Dynamic Range ~180 dB ~160 dB 
Dark Noise 20-400 µV 10 µV-22 mV 
CV (%) 0.05-0.5% 0.3-3% 
Number of DSP Chips 1 4 






7.10 Future Improvements 
During the design, validation, and clinical use of the system there were certain features that 
would be valuable to include in future implementations of this design.  In many cases the value 
of these features wasn’t apparent until the device was built and in use, preventing us from 
implementing them in this version of the device. 
 The first feature that would be valuable for use in debugging and in calibrating the 
system is software control of each individual laser diode.  Due to the fact that two wavelengths 
are present on each wavelength set, it is impossible to measure the intensity of one wavelength 
without unplugging the laser driver from the input backplane, which is clearly not an ideal 
solution.  In addition, software control of the laser diodes would allow the user to turn laser 
diodes for wavelengths not required for the experiment.  This feature could be fairly simply 
implemented by passing 4 additional signals from the host pc, via the DAQ1, routed through the 
backplane to a connector that would bring the signals to the input unit.  The laser diode on/off 
signal could then be input directly to the ON pin of the relevant laser driver. 
 Detecting signal saturation due to too much amplification is an essential feature that 
should be included in the next design of the system.  When signals saturate they provide 
incorrect demodulated values that can often be difficult to detect.  Unfortunately, the only 
place where saturation or clipping can be detected is prior to demodulation on the DSP chip.  I 
believe this could be made possible through an algorithm that looks for repeated samples at 
the maximum or minimum values.  If this situation is identified the DSP should transmit a 






to saturation.  The implementation of this feature would require significant planning and 
possible changes to the hardware design of the DSP to Host PC data transmission 
 A simple enhancement to this system would involve the addition of an even lower 
amplification setting for the TIA. Currently the lowest setting is 10 kV/A, and in some situations 
this low gain setting still risks saturation for the co-located source-detector fibers.  It would be 
suitable to add a 1 kV/A gain stage.  This would have the added benefit of further increasing the 
dynamic range of the system. 
While 4 wavelengths of light provides an improvement over previous 2-wavelength 
systems, adding an additional 2 wavelengths to bring the system to 6 wavelengths would 
provide even more spectral information to better resolve the optical chromophores in the 
breast, specifically water and fat.  These wavelengths could be incorporated into the current 
system by adding 2 laser diodes and accompanying drivers.  The light from each laser could be 
combined into each of the two current light streams, but with modulation frequencies at 3 kHz.  
Each light stream would contain a 3 kHz, 5 kHz, and 7 kHz modulated wavelength to be 
demodulated by the DSP in the detection unit.   
 Although the system is portable and can be moved between the lab and the clinic, the 
cart is very heavy, and moving the system could be made much easier by transitioning to a 






Chapter 8 : Breast-Fiber Interface 
One of the goals in designing the digital optical tomography system for breast imaging was to 
image the breast via direct contact in a fully 3D geometry.  This allows the imaging to be 
performed without compression and without the use of a matching fluid, two features that are 
clinically desirable.  Imaging the breast in a fully 3D geometry provides more angles for 
measurements through the breast, improving the 3D resolution and removing the need for 
compression that other geometries necessitate (specifically parallel plate geometry).  However, 
designing a clinically translatable breast-fiber interfaced is challenging for a number of reasons: 
1. Accommodating a range of breast sizes: There is a very large range of breasts sizes that 
the interface must accommodate – from A to DDD+. 
2. Getting close to the chest wall: It is difficult to get the breast away from the stomach 
and to allow the interface to get under the breast and close to the chest wall. 
3. Making good contact with the breast:  If the interface allows the fibers to conform 
entirely to the patient’s breast then the contact with the breast will be good, but it 
becomes very difficult to know the positioning of the individual fibers.  If the fibers are 
in a rigid geometry it is easy to know the positioning, but it becomes harder to make 
good contact with the breast.  Both issues are important: without good contact with the 
breast the imaging may miss regions of the breast or introduce artifacts to the images.  
Inexact source-detector positions introduce artifacts to the reconstructions and can 






In the studies described in the following chapters two different breast interfaces were 
tested.  Each interface addresses the tradeoffs listed above in slightly different ways.  The first 
interface described is an articulating-finger interface that has more degrees of freedom for 
making contact with the breast and is ideal for dynamic studies where knowledge of the exact 
fiber positioning is not as important.  The second interface is a translating-ring interface with 
precise positioning that is suitable for longitudinal studies and absolute imaging where it is 
more important to know the precise fiber positioning for repeatable measurements. 
8.1 Articulating-Finger Fiber-Breast Interface 
The articulating-finger fiber-breast interface was designed and built by the Optical Tomography 
group at the State University of New York Downstate Medical Center.  The patient can be 
imaged in either a standing or seated position.  The interface uses two adjustable arms that 
bring 64 fibers in contact with each breast.  There is a flat bottom plate that comes up under 
the breast, bringing 4 rows of 8 fibers each (32 total fibers including 32 detectors and 16 co-
located sources).  The top part of the interface is comprised of eight articulating fingers, each 
holding 4 optical fibers that can be individually adjusted to make gentle contact with top part of 
the breast.  32 fibers make contact with the top of the breast including 32 detectors and 16 co-
located sources.  The angle of the articulating fingers can be increased to accommodate larger 







Figure 8-1.  Photograph of the breast imaging system and the articulating-finger fiber-breast 
interface. 
 
 The articulating-finger interface provides a fast way to make good contact with breasts 
from a C-D cup.  The interface is not optimized for smaller breasts (A-B cup), where the breast is 
not large enough to cover the optical fibers on the lower plate.  Conversely, for very large 
breasts, it is difficult to bring the interface in close proximity to the chest wall, and the fibers 
only cover a limited portion of the breast. 
 One important consideration in using the articulating-finger interface is that due to the 
flexibility of the interface, it is difficult to know the precise location of the optical fibers.  As 
such, the interface does not lend itself to the generation of a unique finite element meshes for 
each individual patient.  In addition, due to the grasping nature of the interface, the articulating 
fingers must be released to remove the breasts, prohibiting the use of an optical reference 
imaged under the same settings as the breast that can be to calibrate the system for absolute 






optical signal is used to solve for changes in the optical chromophores in tissue.  All 
measurements are normalized to a baseline breast measurement, which significantly reduces 
the importance of the mesh and fiber positions.  Fig. 8-2 shows the finite element mesh used 
for all patients imaged with the articulating-finger interface.  The mesh uses typical fiber 
positions and tissue boundary for a C-cup breast.  The mesh contains ~6500 voxels. 
 
Figure 8-2.  Finite-element mesh used to approximate the breast geometry for the articulating-
finger interface.   
There are 4 rows of 8 fibers on the bottom plate and 4 articulating fingers with 4 fibers each 
covering the top of the breast.  Red dots indicate fiber positions. 
 
8.2 Translating-Ring Fiber-Breast Interface 
A second fiber-breast interface was designed specifically for the longitudinal imaging required 
to monitor tumor response to therapy.  This interface was designed to accommodate a large 
range of breast sizes, while allowing for the precise repositioning of the interface at each 
imaging time point.  In addition, the interface allows for precise localization of the fibers, and a 
liquid optical reference can be placed into the interface after imaging the patient, allowing for 
better calibration.  The precise fiber positioning and use of an optical reference allow for 






 The design consists of four rings of increasing diameter (4, 8, 12, 16 cm).  As the rings 
increase in size, they contain more positions for source and detector fibers (8, 12, 16, 28).  
Further, the angle of the fibers changes as the ring size increases (60˚, 45˚, 30˚, 15˚).  This 
variable angle helps to keep the fibers normal to the breast tissue.  With the exception of the 
smallest ring, the rings can be removed to accommodate breast sizes from A (smallest 2 rings 
used) to DDD (all 4 rings used).  In addition, the rings can translate vertically to conform to each 
patient's breast.  This translation is accomplished manually and secured by spring plungers that 
interact with shafts that have holes every 5mm.  Two shafts attach to each ring and hold it in 
place.  Each optical fiber is held in place by a shaft collar that secures to the metal part of the 
fiber tip. 
This new interface was designed for optimal patient comfort, and thus provides a 
number of adjustable features.  The separation between the left and right breast can be 
changed, as can the height of the rings.  In addition, each set of rings is attached to a camera 
mount (Manfrotto 229 Super Pro Head) which provides three degrees of freedom for aligning 
the ring structures with the patient's breasts.  The camera mounts used in this design have 
recordable positioning indicators so that in longitudinal studies, precise positioning can be 
maintained across imaging time points.  The device is currently constructed for imaging of the 
patient in a seated position, similar to a massage chair.  The patient sits on a stool and leans 
over the rings while holding onto a set of handlebars.  The handlebars also serve as a strain 
release for the optical fibers.  There is a foam head rest where the patient can rest her chin or 






wheels.  A photograph of the digital optical breast imaging system with the optical fibers 
connected to the translating ring interface is shown in Fig. 8-3, below. 
 
Figure 8-3.  Photograph of the translating ring breast interface. 
 
 The rings were designed and prototyped with the help of Keith Yeager and the facilities 
provided through the Biomedical Engineering Machine Shop.  Our fabrication technique 
involved a 3D printed design infiltrated with plastic.  The design of the rings was done using 
Solidworks and then printed using a 3D Printer (310 Plus, ZCorp). Creating the rings through the 
use of a 3D Printer not only simplifies the manufacturing process, but also allows for more 
sophisticated geometries than cannot be easily machined.  The printed parts were left to dry in 






Infiltration of the rings was performed with an ultra-low viscosity liquid plastic casting 
resin (Smooth-Cast 310, Smooth-On, Inc.) with a 20 minute pot life and 2-4 hour demold time.  
The plastic is naturally white, but can be dyed grey or black using Ultra-Black dye that is mixed 
into the liquid plastic.  To infiltrate the rings, the liquid plastic was mixed thoroughly in a pan 
deep enough to cover each ring, and then the ring was submerged into the liquid.  The entire 
pan was then placed into a vacuum chamber for 3-5 minutes to improve the infiltration of the 
plastic through the ring.  After removing the pan from the vacuum chamber the extra plastic 
was blown off of the ring using pressurized air.  The ring was then placed back into the vacuum 
chamber for 2-3 minutes and then blown off with pressurized air one more time.  This process 
helped to avoid excess plastic pooling on the surface of the rings.  The rings were then left to 
dry and harden overnight.  The final result is a very strong plastic material that can be 
machined, drilled, sanded, and painted.  In this application, we chose not to paint the rings, and 
simply sanded them by hand to a smooth and comfortable surface for the patient. 
A key benefit of the translating ring interface is the precise localization of the optical 
fibers.  The position of the optical fibers never changes in the x or y dimensions.  However, as 
the rings are adjusted, the fiber positions translate accordingly in the z direction.  In addition, if 
the largest ring is removed, then those fibers are excluded from the mesh and subsequent 
image reconstruction.  For each patient, a unique mesh was generated in GiD according to the 
ring positioning.  The mesh extended 2 cm beyond the last ring to account for the presence of 
the chest wall.  A sample mesh involving three of the translating rings is shown for a patient 







Figure 8-4.  Sample finite-element mesh to approximate the breast geometry for the translating-
ring fiber-breast interface. 







Chapter 9 : Dynamic Optical Imaging of Breast Cancer 
To investigate the performance of the system in a clinical setting, we gathered preliminary 
imaging data from 21 subjects including 3 healthy subjects and 18 subjects with breast masses.  
The goal of the study was to explore the use of dynamic imaging techniques to detect and 
characterize breast tumors.  Previous studies looking at the dynamic response of breast tissue 
to a stimulus have shown promising preliminary results, but have been limited to case studies 
of only a few subjects [39, 42-44].  Here we aim to more completely explore the rich spatial and 
temporal dataset that dynamic imaging provides in a larger subject group containing healthy 
breasts and well as breasts with benign and malignant masses. 
9.1 Experimental Protocol 
In this study, which was compliant with the Health Insurance Portability and Accountability Act 
(HIPAA) and approved by the Columbia University Institutional Review Board (IRB-AAAD7133), 
written consent was obtained from all 21 subjects who were compensated for their 
participation. The subjects were asked to stand in a comfortable position while the breast 
interface was brought into contact and adjusted for each breast.  Each fiber-bearing finger of 
the interface was adjusted until gentle contact with the breast was established for all fibers, 
starting with the outer fingers and progressing to the central fingers.  During this time the 
patient was asked to identify any fibers that were causing discomfort, and such fibers were 
then readjusted. 
Prior to the measurements, each participant was trained on how to perform a valsalva-






also informed about the importance of minimizing motion during the imaging sequences. The 
valsalva maneuver is a commonly used tool in a number of clinical diagnoses including many 
cardiac and brain abnormalities [69].  It involves a prolonged expiratory effort that results in 
increased intra-thoracic pressure which results in decreased venous return to the heart.  It is 
expected that this decrease in venous return will correlate to a measureable increase in 
hemoglobin levels in the breast tissue as shown by Schmitz et al. [42].  Hemoglobin levels are 
relevant to the detection of breast cancer because they provide contrast between normal 
tissue vascularization and increased, disorderly tumor vascularization. 
In order to minimize the patient’s discomfort and the risk of motion artifacts the 
imaging sequence was compressed to be as fast as possible, while still maintaining time for the 
dynamic effects to settle.  The imaging sequence, shown in Fig. 9-1, involved a 60-180 second 
baseline followed by a 30 second breath hold and 90 second recovery which was repeated 
three times.  Three trials were performed in order to achieve one trial with minimal motion and 
suitable breath hold duration; in most subjects the second trial was selected for reconstruction. 
This resulted in a total imaging duration of approximately 10 minutes.  During the breath hold 
the subject was asked to avoid any large inhalation and simply stop breathing, while 
maintaining pressure in the mouth and stomach.  In the event that the patient could not 
complete the 30 second breath hold, she was asked to indicate the end of the breath hold by 








Figure 9-1.  Imaging protocol for the dynamic breath hold study. 
 
9.2 DOT Imaging 
All imaging for this study was performed using the digital diffuse optical breast imaging system 
described in Chapters 2 through 7.  The articulating-finger breast interface described in Section 
8.1 was used to bring the optical fibers in contact with the breast.  With all 32 sources, 4 
wavelengths, and 128 detectors used in this configuration the system acquires data from both 
breasts at a frame rate of 1.7 Hz.  Automatic gain settings were calculated for each patient prior 
to the imaging sequence. 
Imaging Reconstruction Algorithm 
The data collected from the 128 detectors, 32 sources, and 4 wavelengths (16,384 data points) 
are measurements obtained from the surface of the tissue.  A reconstruction algorithm is 
required to transform the surface measurements into three-dimensional images of the 
chromophores throughout the tissue volume.  The surface measurements can be inverted 
according to the Beer-Lambert law (Eq. 1.1) that describes the absorption of electromagnetic 
energy as it passes along a given path through an absorptive medium.  Unlike x-ray imaging, the 
path that light takes as it travels through the tissue is not a straight line between the source and 
detector.  The propagation of light through tissue can be accurately modeled using the 






as breast tissue is well described by the diffusion approximation (DA) to the equation of 
radiative transfer as: 
Xin  0
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where A is related to the reflection due to mismatched refractive indices, )(r

u is the light 
radiation density, and )(r

D is the diffusion coefficient given by  )(3/1 'saD   . The 
solution to (9.1) provides a prediction Pλ=Quλ of the measurement at the medium surface 
where Q  represents a measurement operator that projects the forward solution )(r

u  onto the 
measurable quantity by our digital dynamic imaging system. The basic idea behind DOT imaging 
of tissue chromophores is to exploit the linear correlation between the tissue absorption and 
the concentrations of chromophores (Eq. 1.2). 
The major chromophores relevant to breast imaging are oxygenated hemoglobin 
(HbO2), deoxygenated hemoglobin (Hb), water (H2O), and lipid, whose molar extinction 
coefficients are well documented in the literature [15].  The multi-spectral inverse model can 
directly recover the spatial distributions of chromophore concentrations by using data from all 
wavelengths simultaneously during the reconstruction [70].  In this experimental study, we 
focus on the reconstruction of two major chromophore concentrations, [HbO2] and [Hb], by 
using data from two wavelengths (λ = 765 nm and 835 nm) since these two chromophores are 
closely associated with tumor vascularity and are the chromophores most relevant to a breath 
hold stimulus. 
For each patient a 50-frame data set (~30 s) acquired immediately prior to the onset of 






and deoxygenated hemoglobin ([Hb]) were reconstructed relative to this baseline, and 
therefore all images indicate a change in the concentration of oxygenated hemoglobin 
(Δ[HbO2]%) and deoxygenated hemoglobin (Δ[Hb]%).  Any source-detector channels with 
greater than 15 dB of noise during the baseline period were excluded from the reconstruction 
as this noisy data can cause numerical instability and produce artifacts in the reconstructed 
image.  Further, we assumed typical breast tissue values for baseline [HbO2] and [Hb] of 18 uM 
and 9 uM respectively.  Although these values may not be exact for all patients, we are most 
concerned with the dynamic (therefore relative) changes that the breast undergoes during the 
course of a breath hold, and absolute chromophore values are not necessary for that analysis.  
In fact, one of the advantages of using dynamic biomarkers lies in the fact that they do not 
require absolute chromophore concentrations.  100-frame time sequences were reconstructed 
starting from the onset of the breath hold and lasting through the recovery period.  The total 
reconstruction time for one image frame was approximately 20 mins on a Dual Core Intel Xeon 
3.33GHz processor. 
Image Quantification 
The reconstructed images provide a visual representation of the breast showing the distribution 
of the percentage change in chromophores (Δ[Hb]% and Δ[HbO2]%).  There are many ways to 
quantify the chromophore change in the tumor region.  We chose to select the average 
chromophore value over a 1-cm-radius sphere around the voxel of maximum change.  The 
position of the sphere can change with each image frame.  We chose to enhance a previous 






around that voxel to create a more stable parameter.  By allowing the sphere to move with 
each imaging frame, the algorithm is free to track the tumor in the breast, which is relevant to 
the post-breath hold period where respiratory motion can cause the tumor position in the 
breast to vary slightly with time.  By allowing the sphere to move to the voxel of peak intensity, 
the algorithm does not require any prior knowledge of the tumor location.  Similarly, using a 1-
cm-sphere provides a standard algorithm, as opposed to selecting a variable radius depending 
on prior knowledge of the tumor size. 
9.3 Subject Summary 
Dynamic DOT measurements were performed on 21 subjects over the course of one year.  
Three of the subjects were healthy volunteers, while the other eighteen had a benign or 
malignant mass.  13 of the 21 subjects were post-menopausal with a mean age of 54±10 years 
and a mean BMI of 30±4.  There was no significant difference in the age or BMI between 
healthy, benign, and malignant groups.  14 subjects had a malignant mass in one breast of 
which 4 were invasive ductal carcinomas (IDC), 1 was an invasive lobular carcinoma (ILC), 2 
were ductal carcinomas in situ (DCIS), and 7 were a combination of IDC, ILC, and DCIS.  Three 
subjects had a benign mass in one breast, and one subject had benign masses in both breasts.  
Three subjects with tumor-bearing breasts also had a contra-lateral breast with a benign mass.  
Of the eight benign masses, 1 was atypical ductal hyperplasia (ADH), 4 were fibroadenomas 
(FA), 1 was a cyst, 1 was sclerosing adenosis (SA), and 1 was unbiopsied.  The average mass size 






 All subjects in this study had prior mammograms for comparison.  In most cases 
ultrasound and DCE-MRI images were also available and were used to verify the tumor location 
and size.  A summary of the subjects who participated in the study is shown in Table 9-1. 
Table 9-1.  Summary of subjects and pathologies. 
Subject Age  BMI Cup Pathology Location Size
1 
1 41 22.6 C Healthy - - 
2 61
PM 
32.9 DD Healthy - - 
3 63
PM 
31 C Healthy - - 
4 44 22.4 B 
Poorly diff. IDC + DCIS 
Benign (SA) 
Right, 1:00, 5 cm FN 
Left 2:30, 6 cm FN 
2.7 
0.5 
5 49 29.2 D Moderately diff. IDC + ILC Left 3:00, Posterior 1.9 
6 70
 PM
 28.7 DDD Poorly diff. IDC Right 2:00, 10 cm FN 2.2 
7 63
 PM
 31.5 DDD 
Poorly diff. IDC 
Benign (Cyst) 
Right 1:30, Posterior 
Left 2:00, 5 cm FN 
3 
0.6 
8 41 27.4 D Moderately diff. ILC Right 10:00, Posterior 2.6 
9 58
 PM
 28.7 C IDC + ILC Left 2:30, 10 cm FN 2.1 
10 56
 PM
 30.2 C 








 25.8 C DCIS Right 11:00, 5 cm FN 2.2 
12 64
 PM
 26.7 B 
Moderately diff. IDC + ILC + 
DCIS 
Right 1:00, 3 cm FN 1.4 
13 42 43.1 D 
Moderately diff. IDC + ILC + 
DCIS 
Left 1:30, 13 cm FN 1.3 
14 68
 PM




15 38 30.4 D Poorly diff. IDC Right 9-10:00, 5 cm FN 1.5 
16 58
 PM
 30.4 C DCIS Left 2:00, 6 cm FN 1.8 
17 57
 PM
 28.6 B Poorly diff. IDC+ ILC Right 11:00, 1 cm FN 0.5 
18 42 31 DD 
Benign (FA) 
Benign (FA) 
Left 7:00, 3 cm FN 
Right 5:00, 8 cm FN 
1 
1 
19 47 31.4 C Benign (unbiopsied) Right 7:30,5 cm FN 1 
20 55
 PM
 23.2 C Benign (FA) Right 6:00, 6cm FN 0.7 
21 61
 PM
 28.3 DDD ADH Left 11:00, 3cm FN 1.1 
PM
Indicates the subject is post-menopausal. 
1
Size of the largest dimension of the tumor (in cm). 
2
Extremely dense breasts - precise location and size not known. 
 
With the onset of the breath hold we observe an increase in [Hb] and [HbO2] levels in 
the breast.  Upon resuming normal breathing, the [Hb] and [HbO2] levels return to baseline 
levels.  In tumor bearing breasts, there is a notable difference in the hemodynamic response 






calculated as the spherical average over the peak voxel as described in Section 9.2, for the left 
and right breast of a breast cancer patient (Fig. 9-2a) and a healthy subject (Fig. 9-2b).  Fig. 9-2a 
shows the Δ[Hb]% response over the course of a 20-second breath hold and recovery for a 64-
year old subject with a 1.4 cm tumor in the right breast identified as Subject 12 (S12) in Table 9-
1. The tumor-bearing breast has a greater increase in [Hb] during the breath hold, followed by a 
slower return to baseline values.  Although both the healthy left and tumor-bearing right 
breasts were imaged during the same breath hold, their hemodynamic response is markedly 
different (Fig. 9-2a), as compared with a 63 year-old healthy subject (S3) where both the left 
and right breasts are healthy and have nearly identical responses to a 30-second breath hold 
(Fig. 9-2b). 
 
Figure 9-2.  Percentage change in deoxy-hemoglobin (Δ[Hb]%) over the course of a breath hold 
for (a) a breast cancer patient and (b) a healthy subject. 
Shown here for (a) a 64 year-old subject (S12) with a 1.4 cm tumor in the right breast (solid black 
line) and (b) a 63 year-old healthy subject (S3).  In (a) the breath hold lasted 20 seconds while in 
(b) the breath hold lasted 30 seconds. 
 
Fig. 9-3a shows coronal slices through the left and right breast for multiple points during 
the breath hold and recovery sequence from a 57 year-old post-menopausal woman (S17).  The 






visible during the mid-recovery time point.  In reconstructed images at the mid-recovery time 
point, we observe an enhancement in Δ[Hb]% in the tumor region, as shown in Fig. 9-3b.  There 
is also an enhancement in Δ[HbO2]% (Fig. 9-3c) although it is lesser than that of Δ[Hb]%. 
 
Figure 9-3.  DOT images of the left and right breast for a breast cancer patient shown at four time 
points over the course of a breath hold. 
Shown are (a) Coronal slices looking at the Δ[Hb]% in the Left (top) and Right (bottom) breast at 
four different time points over the course of the breath hold.  There is an invasive carcinoma at 
11:00 in the right breast (S17), which is most visible during the mid-recovery time point.  Coronal 
slices showing (a) Δ[Hb]% and (b) Δ[HbO2]% demonstrate that while an enhancement of 
Δ[HbO2]% is seen in the tumor region, the contrast is not as great as in Δ[Hb]%. 
 
9.4 Mid-Recovery Tumor Visualization 
As illustrated in Fig. 9-3, the mid-recovery time point provides the greatest contrast between 
tumor and healthy breast tissue.  For this reason we chose to investigate the mid-recovery time 
point, 15 seconds following the end of the breath hold, as a means for breast cancer 
visualization and detection.  Fig. 9-4 shows mid-recovery images from a pre-menopausal 38 
year-old female subject (S15) with a 1.5-2cm invasive ductal carcinoma located at 9-10:00 in the 






dimensional slices that are commonly used to display medical images: sagittal, coronal, and 
axial.  For this subject, the tumor is visualized in all three planes by a marked increase in mid-
recovery Δ[Hb]%.  To compare the DOT images to other modalities, we show here 
corresponding mammogram (Fig. 9-4d) and DOT (Fig. 9-4e) axial views.  The tumor region, 
identified by an increased density in the upper outer quadrant in the mammogram, 
corresponds to an increased region of Δ[Hb]% in the DOT image.  Likewise, corresponding 
sagittal views from DCE-MRI (Fig. 9-4f) and DOT (Fig. 9-4g) show the tumor in the mid-upper 
region as an increase area of contrast enhancement corresponding to an increase in Δ[Hb]% in 
the DOT image.  The DOT sagittal image shows the area of enhancement to be approximately 
5cm from the nipple, which agrees with the other modalities.  The region of enhancement in 
the DOT image appears larger than the actual tumor area due to the blurring introduced by the 







Figure 9-4.  Correlation of the DOT Δ[Hb]% images of the mid-recovery time point with DCE-MRI 
and mammogram images. 
Shown are three slices: (a) sagittal, (b) coronal, and (c) axial for a subject (S15) with a 2 cm tumor 
in the Right breast, 5 cm FN at 9-10:00.  A mammogram of the tumor is shown in (d) with the 
corresponding axial DOT slice (e) showing an enhancement of Δ[Hb]% at the mid-recovery time 
point.  A sagittal DCE-MRI slice shows the location of the tumor in (f) with the corresponding DOT 
slice showing a matching Δ[Hb]% enhancement 5 cm from the nipple in (g). 
 
 The increase in Δ[Hb]% at the mid-recovery time point is observed across multiple 
pathologies including IDC, ILC, and DCIS but not in healthy breasts, as shown in Fig. 9-5.  An 
enhancing region can be seen in the correct location for each of the cancerous pathologies (Fig. 
9-5a/b/c/d) but no enhancing regions are visible in the case of a benign pathology (Fig. 9-5e) or 
in a healthy subject (Fig. 9-5f).   Fig. 5a shows coronal slices of Δ[Hb]% for the left and right 
breast of a 44 year-old pre-menopausal woman (S4) with an IDC of 2.7 cm at 1:00 in the right 






post-menopausal woman (S9) with an IDC and ILC of size 2.1 cm at 2:30 in the left breast.  Fig. 
9-5c shows coronal slices of Δ[Hb]% from a 41 year-old pre-menopausal woman (S8) with a 2.6 
cm ILC at 10:00 in the right breast.  The regions corresponding to the tumor locations show an 
increase in Δ[Hb]% as compared to the surrounding healthy tissue and the healthy contra-
lateral breast.  Fig. 9-5d shows coronal slices for a 58 year-old post-menopausal woman (S16) 
with DCIS at 2:00 in the left breast of approximately 1.8 cm.  Similar to an invasive tumor, the 
DCIS is identified by increased Δ[Hb]% following the breath hold.  Fig. 9-5e shows coronal slices 
for a 61 year-old post-menopausal woman (S21) with ADH of size 1.1 cm at 11:00 in the left 
breast.  ADH, a benign pre-cancerous cellular change, appears as a region of minimal 
enhancement of a magnitude also seen in the contralateral breast.  Finally Fig. 9-5f shows a 63 
year-old healthy subject (S3) where both breasts demonstrate a very homogenous level of 
Δ[Hb]% with no regions of pronounced enhancement. 
 
Figure 9-5.  Mid-recovery images showing the Δ[Hb]% for the left and right breast for six different 
pathologies.   
The pathologies shown include (a) an IDC at 1:00 in the right breast (S4); (b) an IDC and ILC at 






2:00 in the left breast; (e) ADH at 11:00 in the left breast; and (f) a healthy subject with no breast 
nodules. 
 
9.5 Quantification of Mid-Recovery Δ[Hb]% 
The tomographic images show that d[Hb]% is elevated in the region of the tumor at the mid-
recovery time point.  Fig. 9-6a shows the average over the 1-cm-radius sphere of peak d[Hb]% 
for healthy subjects (n=6), benign masses (n=8), and tumors (n=14).  At the mid-recovery time 
point healthy breasts have almost returned to baseline (1.6±0.5%), while the tumors still have 
some d[Hb]% lingering through the recovery period (6.8±3.6%).  The benign masses fall 
between the healthy and tumor values (4.9±2.7%).  There is a significant difference in d[Hb]% 
between healthy and tumor-bearing breasts (p=0.0002), as well as between the healthy and 
benign breasts (p=0.014). 
 To standardized the technique for better comparison across subjects, we normalized 
each breast to the peak d[Hb]% in either breast for each subject.  The normalized change in 
deoxy-hemoglobin (d[Hb]n) at the mid-recovery time point is shown in Fig. 9-6b.  Similar to the 
results found in Fig. 9-6a, the healthy and benign breasts have much smaller d[Hb]n 
(Healthy:0.17±0.1, Benign: 0.31±0.22)  while the tumor bearing breasts have a larger fraction of 
d[Hb]n remaining at the mid-recovery time point (0.45±0.27).  There is a significant difference 







Figure 9-6.  Average Δ[Hb]% at the mid-recovery time point for healthy, benign, and tumor-
bearing breasts.   
Shown are the (a) average and (b) normalized average change in Δ[Hb]% for all healthy (n=6), 
benign (n=8), and tumor-bearing (n=14) breasts.  
(*p<0.05, #p<0.01). 
 
9.6 Bilateral Hemodynamic Correlation 
Subjects with healthy breasts (n=3) or benign nodules (n=4) have a very similar hemodynamic 
response to the breath hold in both the left and right breasts, as shown in Fig 9-2b.  This is 
captured by the high correlation of the d[Hb]% profile shown in Fig. 9-7 (Healthy: 0.85±0.2; 
Benign: 0.92±0.05; Combined Healthy & Benign: 0.89±0.13), while subjects with cancer (n=14) 
had a lower correlation between the two breasts (0.68±0.21).  There is a significant difference 
between the combined correlation for all non-cancer subjects (healthy and benign) and cancer 







Figure 9-7.  Average correlation between the transient response of the left and right breast for 
healthy, benign, and tumor-bearing breasts. 
Shown here are the results for subjects with healthy breasts (n=3), subjects with benign lesions 
(n=4), and subjects with breast cancer (n=14).  (*p<0.05, #p<0.01) 
 
9.7 Exponential Fitting of Dynamic Data 
With the onset of the breath hold we observed an increase in the total hemoglobin levels in the 
breast, likely due to impeded venous return to the heart [42].  Upon resuming normal 
breathing, the hemoglobin levels in the breast return to their baseline levels.  While the tumor-
bearing breasts had a similar profile to the healthy breasts, there was a noticeably slower 
return to baseline during the recovery period following the end of the breath hold, as shown in 
Fig. 9-8a.  To capture this difference, we fit an exponential function to the breath hold and 
minimized the root mean squared error between the exponential function and the actual data.  
The exponential function was characterized by the following equation: 
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where t is the time from the onset of the breath hold, τr is the rise time constant and τf is the fall 






hold range (0-30 seconds) where the curve reaches its maximum.  The functions fsd and fsu are 
step down and step up functions, respectively, defined as follows: 
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}  (9.3) 
All exponential fitting was performed on normalized experimental data in order to characterize 
the shape of the curve without considering the amplitude of change, and for this reason, Eq. 9.2 
is normalized to unity at time tBH. 
Fig. 9-8a shows the time traces for the percentage change in deoxyhemoglobin 
concentration Δ[Hb]% from baseline for a healthy (solid black) and tumor-bearing (solid grey) 
breast as well as the exponential fit (dashed lines) over the course of a breath hold.  Fig. 9-8b 
shows the average rise time (τr ) for the healthy (n=6), benign (n=8), and tumor-bearing breasts 
(n=14).  The τr for the tumor-bearing breasts is smaller than for the healthy breasts (Healthy: 
39.7±30.1%; Tumor: 25.2±27.1%; p=0.33).  However, the greatest difference in the tissue 
hemodynamics occurs following the breath hold, as characterized by τf, shown in Fig. 9-8c.  
Tumor-bearing breasts have a much slower washout rate, reflected by the fact that τf is larger 
in the tumor-bearing breasts than in the healthy breasts (Healthy: 14.3±9.5%; Tumor: 
29.9±29.5%; p=0.09).  The benign masses fall in between the healthy and tumor bearing breasts 
for both τr and τf.  Though not statistically significant, this trend confirms the source of the 







Figure 9-8. Exponential fitting of the transient response to a breath hold. 
(a) The change in [Hb] normalized to the peak change for a healthy (solid black line) and tumor 
bearing (solid grey line) breast over the course of a breath hold.  Overlayed are the exponential 
fits for the healthy breast (dashed black line) and tumor-bearing breast (dotted grey line).  
Average (b) Rise and (c) Fall time constants of the exponential fit for healthy, benign, and tumor 
bearing breasts. 
 
9.8 False Negative and False Positive Cases 
In four tumor-bearing breasts, we were unable to visualize the tumor at the mid-recovery time 
point.  Two of these cases (S6, S13) involved large-breasted subjects with tumors near the chest 
wall.  In these cases, it is possible that the fiber interface did not make adequate contact with 






imaging the healthy portion of the breast, reflected in our images that show a healthy profile of 
Δ[Hb]%.  In the third case (S16) suspicious nodules with tumor-like profiles were observed in 
the contra-lateral breast.  These nodules were unbiopsied so it is not clear how our finding 
relates to the pathology.  In the fourth case (S14), the subject had very dense breasts.   
 In one of the breasts with a benign mass (S19) our imaging showed a tumor-like region 
in the corresponding location.  The mass has not been biopsied and the subject is scheduled for 
a follow-up visit in 6 months.  Since the pathology of the mass is unknown we cannot be sure 
that our finding is incorrect. 
9.9 Discussion 
In this study we demonstrated that there are hemodynamic biomarkers of breast cancer that 
can be detected with dynamic optical tomography imaging during a breath hold.  Respiratory 
maneuvers such as a breath hold or valsalva maneuver have been previously explored in brain 
DOT imaging, where an increased blood volume is observed in the region overlying valveless 
cerebral veins that experience hypertension during the respiratory maneuver [72].  While the 
effect of respiratory maneuvers is not as well studied in the breast, increased blood volume has 
been reported in pilot DOT imaging studies of the breast during a valsalva maneuver or breath 
hold [42, 73], which is believed to be caused by increased intrathoracic pressure that is 
transmitted through the vascular tree, resulting in an increased arterial and venous pressure 
[69].  In addition to the increased blood volume during the maneuver, these studies have also 
reported that the change in deoxy-hemoglobin in the breast appears to be more sensitive to 






 The source of dynamic contrast comes from differences in the architecture and 
structure between normal and tumor vasculature.  Growing tumors require increased 
vasculature in order to supply nutrients and oxygen, while also removing waste products from 
the expanding tumor.  Once tumors surpass approximately 200 microns the tumor cells can no 
longer rely on diffusion from the nearby vessels and therefore must recruit new blood vessels 
by releasing pro-angiogenic growth factors.  The newly formed vasculature is tortuous, 
disorganized, and hyper-permeable [6].  There are many shunts and stunted vessels that disrupt 
the normal artery-capillary-vein vascular hierarchy.  Due to this disorganized structure, despite 
increased vasculature, the tumor perfusion remains poor.  Poor perfusion combined with the 
high metabolic activity of tumor cells causes tumors to be more hypoxic than surrounding 
healthy tissue [74]. 
In our study, the hemodynamic response of the tumor tissue differed from that of the 
healthy tissue.  In healthy subjects we saw a rise in [Hb] and [HbO2] levels during the breath 
hold, followed by a rapid return to baseline levels upon the resumption of normal breathing.  In 
tumor regions of the breast we observed an increase in [Hb] and [HbO2] levels during the 
breath hold followed by a much slower return to baseline than in healthy subjects.  This effect 
was most pronounced in the [Hb] levels.  We believe that this sluggish return to baseline is due 
to the combined effect of the disorganized vasculature that affects blood flow in the tumor 
region, as well as the hypoxic nature of oxygen-hungry tumors.  Our results confirm those of 






transient response of tumor tissue [44] and a sluggish recovery of [Hb] levels following a breath 
hold [42]. 
Study Limitations 
While this work included benign masses for analysis, its primary focus was on differentiating 
healthy tissue from malignant masses.  Due to the variety of benign masses sampled, coupled 
with the small sample size, it was not possible to infer strong statistical value from the benign 
subject data.  While the work here shows some promising trends in the benign masses (typically 
falling in between healthy and malignant values), it is clear that a larger, more controlled study 
would be necessary to fully explore these findings. 
In performing one of the largest diffuse optical imaging studies involving a breath hold 
we discovered a few important clinical advantages and disadvantages associated with this 
work.  Some of the clinically advantageous features of our study include the lack of 
compression during imaging, direct fiber contact with the breast which means no coupling fluid 
is required, and the use of endogenous contrast.  The main disadvantage involves the variability 
in breath holds performed by subjects.  One of four false negative subjects also suffered from 
asthma (S6), where poor breath hold execution likely affected the DOT results.  Asthma should 
be considered as a contraindication to future breath hold studies.  Two subjects had large 
breasts with tumors located close to the chest wall.  In those cases, we had difficulty getting the 
tumor region into our optical breast interface due to the size of the breast, resulting in poor 
visualization of the tumor region.  This was one of the factors that led to the design of the 







We conducted a study exploring the hemodynamic changes in the breast during a breath hold 
in 21 subjects (6 healthy breasts, 14 tumor-bearing breasts, and 8 breasts with benign masses).  
Using a newly designed dynamic DOT system that can acquire data simultaneously from both 
breasts at 1.7 Hz, we were able to analyze the transient response of the breast to a breath hold.  
Healthy breasts showed an increase in [Hb] levels during the breath hold followed by a return 
to baseline upon the resumption of breathing.  In tumor-bearing breasts the tumor region could 
be identified by its much slower recovery from the breath hold.  We quantified this slower 
recovery of the tumor by fitting an exponential curve to the breath hold deoxy-hemoglobin 
levels and found that the washout time constant τf was greater for the tumor region than in the 
healthy breast.  In addition, at a time point 15 seconds following the end of the breath hold the 
tumor region can be visualized as an area of increased Δ[Hb]%, while the surrounding healthy 
tissue and contra-lateral breast show a fairly uniform return to baseline values by that time 
point (Healthy: 1.6±0.5%; Tumor: 6.1±3.7%; p=0.007).  Our analysis of the correlation between 
the Δ[Hb]% transient response in the left and right breast showed a very high correlation in 
healthy and benign subjects (0.89±0.13) and poorer correlation in subjects with cancer 
(0.68±0.2).  We believe that these findings reflect the effect of the disorganized tumor 
vasculature on the tissue hemodynamic response. 
 While these optical biomarkers appear to hold some promise in understanding the 
differences between benign and malignant masses, a larger, prospective study with more 






shows that dynamic optical markers have value in identifying breast tumors without the need 
for injected contrast agents or painful compression.  These findings provide a basis for analyzing 
transient responses for the detection of breast cancer in the hopes that this will provide 
another dimension for characterizing tumors to improve sensitivity, specificity, or better predict 







Chapter 10 : Monitoring Tumor Response to Therapy: Pre-Clinical 
The emergence of a number of therapeutic agents over the past 10 years has improved the 
treatment of both advanced and early stage breast cancer in both the pre-surgery 
(neoadjuvant) and post-surgery (adjuvant) settings [75].  However, despite these advances, the 
optimal therapeutic agent for a specific patient cannot be determined a priori.  There is a 
clinical need for patient specific metrics through rapid noninvasive imaging to tailor drug 
treatment by optimizing dosages, timing of drug cycles, and duration of therapy, thereby 
reducing toxicity and cost and improving patient outcome.  The use of non-ionizing radiation, 
coupled with high sensitivity to HbO2 and Hb, short imaging times, and no need for exogenous 
contrast agents make DOT an attractive imaging solution to this problem. 
In particular, treatments that target blood vessel development in tumors have been 
highly effective in subsets of patients and in select types of cancer.  However, the variability in 
efficacy, combined with the high cost and toxicity of these novel treatments suggest that a 
rapid noninvasive means of benchmarking tumor response to therapy would be useful.  In the 
experiment described here, we study how diffuse optical tomography (DOT) can be used for 
monitoring tumor vascularization.  Using two small animal xenograft model systems with 
previously well-characterized responses to vascular endothelial growth factor (VEGF) inhibition, 








10.1 Anti-Angiogenic Drug Therapy 
The field of anti-angiogenic research was pioneered by Judah Folkman who, 40 years ago, first 
suggested that the prevention of new vessel formation could result in tumor dormancy and 
could therefore be a novel cancer therapy [76].  Since that time, there has been considerable 
effort invested in developing new anti-angiogenic agents that have been tested in a number of 
pre-clinical and clinical studies.  The majority of these agents target pro-angiogenic growth 
factors, specifically, the vascular endothelial growth factor (VEGF).  It has been shown that 
VEGF is expressed in almost all human tumors and higher levels of VEGF correlated with 
increased tumor vascularity, growth, invasion and metastasis [77].  The first successful human 
clinical trial showed that an anti-VEGF monoclonal antibody (bevacizumab) substantially 
increased the time to progression in metastatic colon cancer, and led to FDA approval of 
bevacizumab in 2004 [78, 79].  Bevacizumab (BV) is now approved for non-small cell lung 
cancer, metastatic HER2 negative breast cancer, metastatic renal cell carcinoma, and second 
line treatment of glioblastoma [80]. 
 Despite these promising clinical results, the effectiveness of BV is heavily dependent on 
the type of tumor, and it has been shown that different types of tumors can show significantly 
different responses to VEGF blockade [81].  In addition to variability in effectiveness across 
tumor types, another difficulty that anti-angiogenic drugs face is that over time, tumors are 
able to find a way around the VEGF pathway and resume angiogenesis [82].  Furthermore, VEGF 
inhibitors can have significant toxicities, increasing the importance of targeting therapy to 






able to monitor the tumor progression and response to treatment in vivo will be valuable for 
improving effectiveness. 
 Current methods that have been explored for visualizing tumor angiogenesis and drug 
responsiveness include positron emission tomography (PET), magnetic resonance imaging 
(MRI), and ultrasound imaging (US).  PET imaging uses radioactive tracers such as 
fluorodeoxyglucose (FDG) or 15O to look at tumor metabolism or perfusion [84].  MRI studies 
looking at angiogenesis typically focus on dynamic contrast enhanced MRI (DCE-MRI) which 
uses an injected paramagnetic contrast agent to generate maps of blood flow or permeability 
[85].  Ultrasound imaging of angiogenesis typically uses either power doppler to assess the 
larger vessels, or injected microbubbles as a contrast agent to image blood flow in the smaller 
vessels (known as contrast enhanced ultrasound (CEUS)) [86].  PET, DCE-MRI, and CEUS all 
require an injection of an exogenous contrast agent.  Contrast agents can have adverse effects 
[87], increase the time required for imaging protocols, and the injection of these agents 
introduces an additional variable that can be difficult to control in longitudinal studies. 
10.2 Experiment Design 
In this study, we used DOT to monitor two tumor models with previously characterized and 
divergent responses to VEGF inhibition.  Xenografts from the SK-NEP-1 human Ewing family 
tumor cell line [88], are highly responsive to various anti-VEGF agents, with significant loss of 
vasculature and inhibition of growth. In contrast, xenografts from the NGP human 
neuroblastoma cell line continue to grow with only slight restriction and minimally destabilized 






could differentiate between the responder (SK-NEP-1) and non-responder (NGP) tumor models, 
and whether such changes could be detected within days of the start of treatment with the 
anti-VEGF antibody BV. We found that DOT can distinguish responders from non-responders, as 
early as one day after treatment, and confirmed these findings with MRI T2 relaxometry and 
lectin perfusion imaging. Our findings suggest that a DOT can provide a rapid readout of tumor 
responsiveness to VEGF inhibition. 
 106 NGP or SK-NEP-1 cells were injected intrarenally into 4-6 week old NCR female nude 
mice (Taconic, Germantown, NY) as previously described [89, 92] and the resulting xenografts 
were monitored for growth using bioluminescence. At a threshold corresponding to 1-2 g, 
tumors were randomized to control or treatment groups (cohort size 5-6 mice per treatment 
group).  DOT and MRI imaging of the tumors was performed at day 0, 1, 3, and 5.  An injection 
of 0.2 mL of BV (2.5 mg/mL) was administered intravenously via the tail vein following the 
imaging sessions on days 0 and 3.  Albumin was used as a placebo for control studies (Con).  
Animals were euthanized by CO2 inhalation at day 5 after serial imaging studies (DOT and MRI), 
and at days 0, 1, 3, and 5 for lectin perfusion analysis.  All animal experiments were approved 
by the Columbia University Institutional Animal Care and Use Committee (IACUC, AC-
AAAA9639).   
Optical Imaging Protocol 
Optical imaging was performed using a DOT system designed in our laboratory for small animal 
imaging [58].   The small animal imaging system is a scaled-down version of the digital breast 






830 nm) and 32 fibers to detect the scattered and transmitted light through the target. The 
optical fibers surround a cylinder made of white Delrin material with a wall thickness of 1.7 
mm, a diameter of 3.2 cm and a height of 10 cm (Fig. 10-1a). The fibers are arranged in two 
rings separated by 1.25 cm and with an alternating pattern of source-detector-detector-source. 
The animals were suspended vertically in the cylinder and held in place by a nose code that was 
also used to administer anesthesia (isofluorane gas 1-2%).  For each imaging time point the 
spine of the mouse was aligned with the same source fiber and the ears were carefully 
positioned to maintain precise vertical alignment. Intralipid 1% (diluted from Intralipid 20%, 
Baxter Healthcare Corp.) was used as a matching liquid surrounding the mouse to prevent edge 
artifacts. The Intralipid 1% was warmed to 37°C in order to maintain a stable mouse body 
temperature. Either prior to or following the mouse imaging a reference measurement was also 
acquired using Intralipid 1%.  
 Data was acquired at 6.9 Hz with a dynamic range of ~190dB.  300 frames of data (45 
seconds of data) were collected at days 0, 1, 3, and 5 along with a homogeneous reference 
image of Intralipid 1%. The 300 frames were averaged to compute the mean and standard 
deviation data for each source-detector pair and then normalized to the homogenous reference 
prior to reconstruction into 3D images of [HbO2], [Hb], and total hemoglobin concentration 
([THb]).  We assumed that changes in absorption (i.e. [HbO2], [Hb], [THb]) would most strongly 
reflect tumor responsiveness to BV, and thus did not include scattering parameters in our 
reconstruction.  All image reconstructions were performed using a recently developed partial-






equation of radiative transfer as a light propagation model.  The 3D volume mesh used in these 
reconstructions involved approximately 16,000 tetrahedral elements and the total 
reconstruction time for one image was approximately 2 hrs on a Dual Core Intel Xeon 3.33GHz 
processor. 
MRI T2 Relaxometry  
MRI is routinely used for high-resolution anatomical and physiological imaging in numerous 
clinical applications, including determination of tumor size, location, and perfusion [94].  MRI 
studies that visualize hemodynamic parameters typically employ gadolinium-based contrast 
agents [95].  To circumvent the potential complications due to contrast agents, we have 
adapted an approach first introduced by Teicher et al. [96] that uses T2 relaxometry to derive 
information about blood volume without the use of contrast agents. Here we applied this 
approach to determine relative blood volume fractions in tumors. 
 A vertical 9.4 T microimaging system (DRX400, Bruker Biospin, Billerica, MA, USA) was 
used to perform abdominal MR imaging. The mice were anesthetized using isoflurane gas (1-
2%) and their respiration was monitored and gated during the experiment.  All experiments 
were carried out with a single-element 30-mm-diameter birdcage RF coil.  T2-weighted images 
were acquired using 2D axial and coronal rapid acquisition with relaxation enhancement (RARE) 
pulse sequences. Imaging parameters included a pulse echo time of TE = 50 ms, a repetition 
time (TR) varying from 2700 to 3900 ms, an echo train of 8, a matrix size of 128×128, a slice 







 The T2 images were used to calculate the relative blood volume fraction in the tumors. 
Previous studies [97-99] have reported a linear relationship between the changes in the 
transverse relaxation rate (ΔR2) and the changes in deoxy-hemoglobin concentration (Δ[Hb]), a 
marker for blood volume.  The relationship between R2 and [Hb] is linear, as shown in Eq. 10.1. 
   R2 = R0 + k2[Hb] => ΔR2 = ΔR0 + k2Δ[Hb]     (10.1) 
where ΔR0 is the relaxometry contribution of ΔR2 that is not the result of [Hb] changes and k2 is 
a tissue-specific constant.  If we assume that the relaxation rate changes are caused by changes 
in the deoxy-hemoglobin concentration only, then ΔR0 is zero.  To reduce physiological 
variations that could affect R0, we maintained standard scan times and respiratory rates across 
all mice. 
 In a spin-echo sequence the transverse relaxation rate change is related to the signal 
intensity using the logarithmic expression shown in Eq. 10.2. 
    ΔR2 = ln(Spre/Spost)/TE     (10.2) 
where TE is the effective echo time and Spre, Spost are the signal intensities of the region of 
interest (ROI) in the corresponding T2 images before and after treatment respectively. T2 
images were preferred to T1 for the blood volume measurements because they provided 
significantly improved anatomical information [100].  T2 images were also preferred to T2* 
images due the their superior performance in depicting heterogeneous distributions of small-
field disturbances (derived from arterioles, capillaries, and venules) as opposed to large vessels 






The coronal T2 view allowed the selection of a larger region of interest (ROI) within the 
tumors, since the tumors appeared to expand more on the anteroposterior axis than on the 
lateral or dorsoventral axis across the 5 day treatment period.  However, axial T2 images were 
used for the ΔR2 measurements in cases where the depiction of the tumor was not clear in the 
coronal view. The ROI signal intensities were normalized over the signal intensity of the urine 
(reference signal) on the unaffected kidney. In selecting the ROI we chose a region with very 
homogeneous contrast and attempted to avoid large vessels within the tumor as well as 
necrotic and possibly hypoxic regions in the tumor core.  The selected image plane, slice, and 
ROI dimensions remained as consistent as possible across the different days.   The same 
operator processed all the images. 
Lectin Perfusion Studies 
At euthanasia, mice were injected with fluorescein-labeled Lycopersicon esculentum lectin 
(100μg/100μl PBS, Vector Laboratories, Burlingame, CA). Vasculature was fixed by infusing 1% 
paraformaldehyde. 40-μm sections were cut using a vibratome, and digital images were 
subjected to computer-assisted quantitative analysis of tumor vessel architecture [101, 102].  
After binarization, microvessel density (MVD) was estimated by the total number of white 
pixels per field as determined by the method of Wild et al. [101].  The total number of images 
analyzed ranged from 35-67 for SK-NEP-1 and from 51-74 for NGP. 
Statistical Methods 
To assess overall differences between the groups of mice, a linear mixed effects regression 






Institute, Cary, NC). The model estimates linear trajectories for each cohort over time, while 
accounting for comparisons among repeated measurements from the same mice. The intercept 
was treated as a random effect and covariate to account for the differences between mice at 
baseline. The maximum likelihood method was used to estimate the regression coefficients. 
DOT imaging employed a linear model for the [THb] at days 0, 1, 3, and 5, using the slope of 
linear fit for comparison between cohorts. MRI imaging employed a linear model for relative 
signal change at days 1, 3, and 5, using the intercept of the linear fit for comparison between 
cohorts. Comparisons of DOT and MRI parameters between BV-treated and control tumors at 
days 1, 3, and 5 were calculated using unpaired two-tailed Student’s t-tests, with alpha set at 
0.05.  Lectin perfusion data was analyzed with one-way ANOVA and post-analysis with Tukey’s 
multiple comparison test (GraphPad Prism 5.0 Software, San Diego, CA). 
10.3 DOT Imaging Results 
Continuous-wave DOT was performed using near-infrared light to illuminate the target 
sequentially from multiple angles while measuring transmitted and reflected light intensities, 
allowing sensitive detection of changes in concentrations of chromophores (e.g. oxy, deoxy-
hemoglobin, and total hemoglobin). Fig. 10-1d shows 3D volume images of total hemoglobin 
[THb]. Overall, we observed a strong decrease in total hemoglobin [THb] at least once over the 
5 day experimental period in BV-treated SK-NEP-1 tumors. In Fig. 10-1d, [THb] in the BV-treated 
SK-NEP-1 tumors reached a nadir at day 3 and then had partial recovery at day 5. In contrast, in 
control SK-NEP-1 tumors, and both control and BV-treated NGP tumors, [THb] steadily 







Figure 10-1. DOT small-imaging setup and representative 3D reconstructions of total hemoglobin 
concentration ([THb]) for each cohort at day 0, 1, 3, 5. 
(a) The experimental setup showing a mouse surrounded by intralipid in the imaging cylinder 
with the two rings of optical fibers surrounding the tumor region. Also shown are diagrams 
outlining (b) the region of the mouse shown in the 3D volume images and (c) the orientation of 
the mouse and tumor in the 2D axial images.   
(d) 3D [THb] images showing a 2x3 cm cylindrical volume encompassing the tumor-bearing 
portion of a representative mouse from each cohort at days 0, 1, 3, 5.  A steady increase in [THb] 
over the 5 days is noticeable in the SK-NEP-1 Con, NGP BV, and NGP Con cohorts.  In contrast, the 
SK-NEP-1 BV cohort showed a strong decrease in [THb] at days 1 and 3 followed by a rebound at 
day 5. 
 
The observed effects are further illustrated through axial slices taken from the 3D 
reconstruction through the plane of peak [THb].  Fig. 10-2a shows four mice from the BV-
treated SK-NEP-1 cohort and Fig. 10-2b shows four mice from the BV-treated NGP cohort.  At 
some point over the 5 days all BV-treated SK-NEP-1 mice show a drop in [THb], while in NGP 






mice do show mild signs of suppressed vascularization (Fig. 10-2b, rows 3 and 4) due to the 
drug, although the effect is much smaller than in the SK-NEP-1 cohort. 
 
Figure 10-2.  2D axial slices through the plane of peak [THb] for treated (a) responsive and (b) 
non-responsive tumors at day 0,1,3,5. 
Four representative animals from the (a) BV-treated SK-NEP-1 cohort and (b) BV-treated NGP 
cohort are presented here.   
The images are oriented with the tumor at 9:00, as shown in Fig. 10-1c. 
 
 To quantify these effects, a 5 mm3 cube was selected centered around the highest-
intensity voxel, and mean [THb] of the voxels within that cube was calculated. Fig. 10-3 shows 
the mean [THb] over the 5 days with a linear fit generated by a mixed-effects model [103].  For 
SK-NEP-1 tumors, mean [THb] showed a divergent trend between BV-treated and control 
groups with a significant difference in the slope of the linear fit for each group (P=0.02). In 
contrast, for NGP tumors, the mean [THb] increased in both BV-treated and control groups over 







Figure 10-3.  Average [THb] for each cohort plotted over 5 days. 
Shown is the response for the control and treated cohorts for the (a) SK-NEP-1 responsive tumor 
type and (b) the NGP non-responsive tumor type. 
[THb] was quantified in the tumor region by selecting a 5 mm
3
 cube surrounding the peak voxel.  
The slope of the linear fit is significantly different between the SK-NEP-1 BV-treated (BV) and 
control (Con) cohorts (p=0.02). No such significance is seen between the NGP BV-treated and 
control cohorts (p=0.81). 
 
 Fig. 10-4 shows that the percentage change in mean [THb] from day 0 significantly 
distinguished between SK-NEP-1 BV-treated and control groups at day 1 (BV:  18±15%, n=5; 
Con: 19±27%, n=5; P=0.034) and day 5 (BV: -9±22%, n=5; Con: 42±37%, n=5; p=0.034). No such 
distinction was seen in NGP BV-treated and control groups, which showed an overall increase 
by day 5 (BV: 5±14%, n=6; Con: 5±33%, n=6; p=0.99).  Oxy- and deoxy-hemoglobin 
concentrations, [HbO2] and [Hb], followed similar trends to [THb], with BV causing a decrease in 
[HbO2] and [Hb] in SK-NEP-1 but not in NGP (Fig. 10-4a/b).  This finding suggests that a blood 








Figure 10-4.  Average total-, oxy- and deoxy-hemoglobin concentrations, [THb], [HbO2] and [Hb], 
for each cohort over the five days.  
[HbO2] and [Hb] followed similar trends to [THb], with BV causing a decrease in (a) SK-NEP-1 but 
not in (b) NGP tumors. 
(*P<0.05). 
 
10.4 MRI T2 Relaxometry Results 
MRI T2 relaxometry has previously been used to derive steady-state blood flow measures in 
brain [96]. We have adapted this technique to determine relative blood volume in tumors, by 
using the T2 images to determine the transverse relaxation rate (ΔR2). Since the change in the 
transverse relaxation rate (ΔR2) is linearly related to the change in the deoxygenated 
hemoglobin concentration Δ[Hb] [97-99], ΔR2 can be used to determine relative blood volume. 
Fig. 10-5 shows axial examples of T2-weighted MR images taken just before the injection of BV 
(day 0), and 1, 3, and 5 days after the injection. In the BV-treated SK-NEP-1 tumors there is a 
visible increase in the T2 signal intensity (brightness). This indicates that ΔR2, and thus the 
relative blood volume, decreases with BV treatment. In comparison, the T2 signal intensity in 






constant or decreased, indicating that the relative blood volume remained constant or 
increased, respectively. 
 
Figure 10-5. Representative T2 spin-echo axial MR images for each group at days 0, 1, 3, 5.  
The axial slices were obtained at days 0, 1, 3, and 5 after an initial injection with either 
bevacizumab (BV) or albumin control (Con) at day 0. 
 
 Quantifying the transverse relaxation rate (ΔR2), we found that BV caused a rapid (after 
1 day), decrease in the relative blood volume in SK-NEP-1 tumors as determined by a significant 
decrease of 3.47±2.77 s-1 (p=0.021) in the ΔR2 (Fig. 10-6). By day 3 and day 5, the effect of BV 
on the relative blood volume persisted but lessened (reduction of 0.91±2.22 s-1 and 1.1±1.95 s-1, 
respectively). SK-NEP-1 control tumors exhibited no statistically significant changes in the ΔR2. 






statistically evaluate the overall response over the entire five days of the study, we employed a 
linear mixed-effects model [103].  A linear fit to days 1, 3 and 5 demonstrated a significant 
difference between the intercept of the SK-NEP-1 BV-treated cohort and the control group 
(p=0.0014), but no such difference between the NGP BV-treated cohort and the control group 
(p=0.1037). 
 
Figure 10-6. Average change in the transverse relaxation rate (ΔR2) plotted for each cohort over 
5 days. 
The changes in ΔR2 were quantified in a specific region of interest with homogeneous tissue 
contrast within the tumor. The same region was selected throughout the tumor images over the 
five days.  
The slope of the linear fit is significantly different between the SK-NEP-1 BV-treated and control 
cohorts (p=0.0014). No such significance is seen between the NGP BV-treated and control 
cohorts (p=0.1037). 
 
 In addition to the transverse relaxation rate, we quantified the tumor mass from MR 
images.  This was performed by manually outlining the left kidney in the axial T2 images and 
generating 3D reconstructed views of the tumors.  The mass value was estimated from the 
product of the total number of voxels within the boundary of each tumor and the voxel 






SK-NEP-1 mice with BV essentially arrested tumor growth over the 5 day period, compared with 
continued growth in the control tumors (Fig. 10-7).  Growth of NGP tumors was unaffected by 
BV treatment. These results along with the analysis of lectin perfusion studies of the 
vasculature, shown in Section 10.5, verify our DOT classification of SK-NEP-1 as a responder and 
NGP as a non-responder to VEGF blockade therapy. 
 
Figure 10-7.  The temporal progression of the percentage mass volume-changes of the tumors as 
computed by 3D reconstructed T2 MRI views of the tumors.  
BV treatment significantly inhibited tumor growth in SK-NEP-1 xenografts at days 3 and 5 in 
comparison to control, but not in NGP xenografts. 
(*p<0.05). 
 
10.5 Lectin Perfusion Results 
Established SK-NEP-1 and NGP tumors were injected IV with fluorescein-labeled L. esculentum 
lectin, prior to sacrifice at day 0, or after 1, 3, or 5 days of treatment with either the control 






NEP-1 BV-treated tumors by day 1, which persists at day 3 and day 5.  This decrease in 
vascularization is not evident in NGP BV-treated tumors. 
 
Figure 10-8. Lectin perfusion results confirm the vascular responsiveness of SK-NEP-1 and non-
responsiveness of NGP tumors to treatment. 
Representative fluorescent images are shown in (a) for BV-treated SK-NEP-1 and NGP tumors at 
days 0, 1, 3 and 5.  A noticeable decline in vasculature is observed by day 1 in SK-NEP-1 BV-
treated mice, but not in NGP BV-treated mice.  
There is a significant drop in MVD (b) in SK-NEP-1 BV-treated tumors at days 1, 3, 5 (**p<0.001) 
compared with day 0 control tumors, and with a significant difference in MVD between Con and 
BV-treated tumors at days 1, 3, 5 (#p<0.001).  NGP BV-treated mice show a drop at day 3 
(*p<0.01) with a rebound at day 5 and no significant differences between Con and BV-treated 
tumors on any day. 
 
 Quantified changes in lectin perfusion studies of tumor vasculature were consistent with 






microvessel density (MVD) in BV-treated SK-NEP-1 tumors decreased by 65% at day 1, 74% at 
day 3, and 77% at day 5 (p<0.001, each) and differed significantly from control SK-NEP-1 tumors 
at days 1, 3, and 5 (p<0.001, each). MVD decreased by 51% in BV-treated NGP tumors at day 3 
(p<0.01) followed by a rebound back to baseline levels at day 5.  There was no significant 
difference between control and BV-treated NGP tumors at any day. 
10.6 Discussion 
Biologically targeted agents hold promise for increasing effectiveness of cancer treatment, yet 
optimizing their use may require the development of new assessment strategies. In this set of 
preclinical studies, we have demonstrated that it is possible to clearly distinguish responder 
from non-responder tumors within 5 days of BV treatment (Fig. 10-3). Changes in total 
hemoglobin identified by DOT at early imaging time points correlates to changes in microvessel 
density (as observed by lectin perfusion imaging) and relative blood volume (as observed by 
MRI T2 relaxometry).  The DOT images show a significant decrease in total hemoglobin in the 
tumor region over the five days, but no significant change in the blood oxygen saturation (Fig. 
10-4), leading us to believe that a blood volume reduction is the leading cause for this 
observation.  This is confirmed by the change in relative blood volume observed in BV-treated 
SK-NEP-1 by the MRI T2 relaxometry studies (Fig. 10-6). 
 The results shown here underscore the importance of visualizing the tumor vascularity 
non-invasively for longitudinal studies.  In both the DOT (Fig. 10-3) and MRI (Fig. 10-6) 
quantification of tumor [THb] and blood volume there are signs of rebounding effects in the BV-






and provides valuable insight into the temporal dynamics of the vasculature in response to anti-
angiogenic therapy.  Further work would be necessary to correlate how these observed 
transitive responses relate to changes in the vascular structure, namely normalization of vessel 
architecture [104, 105].  In addition, the incorporation of other optical imaging techniques such 
as diffuse correlation spectroscopy (DCS) [106] and contrast-enhanced optical techniques [107] 
could enhance this work by further quantifying the changes in tumor perfusion and 
oxygenation due to BV treatment.  More sophisticated image classification algorithms could 
also provide alternative ways of quantifying tumor response and could extend this work to use 
multiple image parameters to discriminate responders from non-responders, similar to work 
that has been performed using optical images for classification in rheumatoid arthritis [108] and 
breast cancer [109]. 
DOT's advantages lie in its low cost, short imaging times, and use of non-invasive and 
non-ionizing radiation. In addition, with no need for exogenous contrast agents, DOT is well 
suited to longitudinal studies that require repeated imaging.  Our findings open the door for a 
number of non-invasive, longitudinal, pre-clinical studies, to improve our understanding of the 
subtleties of anti-angiogenic agents in an effort to increase the efficacy of these drugs.  Further, 
this study provides pre-clinical background as the optical imaging field looks to translate these 
findings into therapy monitoring in the clinic [2]. 
Overall, these results suggest that the development of rapid, imaging-based 
assessments for human patients is feasible.  Coordinated clinical use of DOT data could provide 






For individuals with nonresponsive tumors, alternate regimens could be considered without 
waiting for overt therapeutic failure to occur, avoiding needless toxicity. Alternatively, those 
patients whose tumors demonstrated responsiveness could remain on treatment. Lastly, given 
the high cost of biologically-targeted therapies like BV, such early assessment of drug 







Chapter 11 : Monitoring Tumor Response to Therapy (Clinical) 
Neoadjuvant chemotherapy (NACT) consists of drug therapy that is administered prior to 
surgery.  It is the standard of care for locally advanced breast cancer, which involves breast 
tumors that may be large, and may have spread to lymph nodes or tissue near the breast, but 
that have not spread beyond the breast region to other parts of the body.  NACT can reduce 
tumor size and allow for breast conserving surgery in patients who would have otherwise 
required mastectomy [47].  In addition, NACT provides an in vivo assessment of tumor 
responsiveness to therapy and has become a useful strategy for evaluating the biologic effects 
of new cancer therapies.  NACT also has the added effect of systemically treating any 
micrometastases that may be present in the body. 
Following NACT the patient undergoes surgery, at which point the pathological effect of 
the treatment can be assessed.  A complete pathological response (pCR) occurs when no 
residual tumor cells are observed in the pathological specimen obtained during surgery.  
Studies have shown that pCR correlates with the more traditional cancer endpoints of 5-year 
and 10-year disease-free-survival [48, 49].  The NSABP B18 study showed that women who 
achieved a pathologic complete response (pCR) with NACT have significantly improved disease 
free and overall survival [110].   
However, only 3-27% of women achieve a pCR after months of NACT [50].  These low 
response rates have motivated a number of studies looking to predict response to neoadjuvant 
chemotherapy, with the notion that detecting non-responders early in treatment would allow 






modality that is ideal for assessing early response to NACT.  Physical exam, mammogram, 
ultrasound, and magnetic resonance imaging (MRI) are based on measuring tumor size changes 
and are insensitive to early the vascular response of the tumor.  In a retrospective study of 141 
women, Chagpar et al. found that size estimates by palpation, US, and mammography were 
only moderately correlated with residual tumor size following NACT (reported correlation 
coefficients of 0.42, 0.42, and 0.41 respectively) [51].  Similarly, Schott et al. evaluated 41 
patients with physical exam, mammogram, US, and MRI and found the sensitivity of each 
modality in detecting a pCR was 50, 50, 25, and 25%, respectively [111].  PET-CT, has shown 
promise in predicting response to NACT; however, in addition to the high cost ($1000 per study) 
[52], successive PET-CT exposes the patient to radioactive isotopes and ionizing radiation. 
 Given the success of the pre-clinical study discussed in Chapter 10, we hypothesize that 
early changes in DOT parameters can be used to predict individual patient response to NACT.    
As it is fast, less expensive, and requires neither ionizing radiation nor exogenous contrast, 
serial DOT measurements during NACT can be used to track tumor changes more frequently 
than other imaging modalities.  Preliminary optical imaging studies have shown promising 
results in small patient groups and suggest that optical techniques may be able to identify 
responsive tumors within the first week of treatment [54-56, 112]. 
11.1 Clinical Protocol 
A HIPAA-compliant, Columbia IRB-approved (IRB-AAAI0480) pilot study of 20 women began 
recruitment at the Columbia University Medical Center in June 2011.  The inclusion criteria is 






diagnosed invasive breast cancer deemed eligible to receive neoadjuvant chemotherapy with 
weekly taxane followed by dose-dense doxorubicin and cyclophosphamide.  Patients should 
have a tumor size ≥ 1 cm by clinical measurement, bra cup size > B, and be scheduled to 
undergo NACT with 12 cycles of weekly paclitaxel (80mg/m2) (T) followed by 4 cycles of 
doxorubicin (60mg/m2) and cyclophosphamide (600 mg/m2)(AC) given biweekly.   
Upon or prior to enrollment, each study participant underwent a targeted physical exam 
including height, weight, blood pressure, pulse, and breast exam including bra cup size as 
reported by the patient.  Measurement of the breast tumor size was documented using 
standardized calipers with the patient lying in the supine position with the ipsilateral arm 
placed behind the head (or in the same position on all subsequent exams).  Baseline imaging 
(MRI and mammogram) and diagnostic breast tumor core biopsy for future analysis of Ki-67 
and microvessel density were also obtained. 
During the baseline visit, each participant underwent DOT imaging for determination of 
oxy-hemoglobin ([HbO2]), deoxy-hemoglobin ([Hb]), and scattering (μs’) content in the breasts.  
DOT imaging was performed at six time points:  
 Baseline (prior to treatment) 
 Week 2 (before cycle 3 of paclitaxel) 
 Week 4 (before cycle 5 of paclitaxel) 
 Week 0 AC (prior to starting AC treatment) 







Before surgery mammography and breast MRI were repeated. Fig. 11-1 shows the timing of the 
various components of the study. 
 
Figure 11-1.  Timing of NACT treatment, physical exams, MRI, and DOT imaging. 
 
11.2 Optical Imaging Protocol 
All diffuse optical imaging measurements were performing with the digital optical imaging 
system described in Chapters 2 through 7.  The translating ring breast-fiber interface described 
in Section 8.2 was designed specifically for this experiment in order to perform longitudinal 
measurements of the absolute optical properties of the breast.  Fig. 11-2 shows a photograph 
of a patient being imaged with diffuse optical tomography.  At each imaging time point 1,000 
frames of data were collected from the patient. A stable region of fifty frames was selected and 
the average and standard deviation for each source-detector measurement was computed. Any 
source-detector pairs with a signal to noise ratio (SNR) below 15 dB were excluded from the 
reconstruction to reduce noise artifacts. Three-dimensional reconstructions were obtained 






[93].  However, in this case the algorithm reconstructs absolute values of the chromophore 
concentrations (in this case [Hb], [HbO2], and scattering).  Absolute reconstructions are similar 
to the differential reconstructions described in Section 9-3, except for that in this case the 
baseline is an Intralipid reference, and the images of the subject’s breasts are reconstructed 
relative to that reference.  Since the optical properties of the Intralipid reference are known, 
we can compute the actual optical properties of the breast.   
 
Figure 11-2.  Photograph of diffuse optical tomography imaging of a study participant. 
 
 
A reference image was performed immediately following the patient imaging using a 
combination of 20% Intralipid (Baxter) and 1% India Ink (Higgins) diluted and mixed to yield 
similar optical properties to breast tissue (μa=0.12 cm
-1, μs’=8.13 cm
-1).  We chose to mix the 






during the reference measurement.  The Intralipid reference measurement was performed with 
identical settings to the patient (including the gain settlings controlling the amplification of the 
detect channels).  The Intralipid reference (1.5 L held in a clear plastic bag) was placed into the 
translating ring interface and 100 frames of data were acquired, of which 50 frames were 
selected as the baseline reference, an input to the reconstruction algorithm. 
The 3D reconstruction was performed on a finite element mesh with ~46,000 voxels, 
with more, smaller voxels placed near the sources and detectors. A unique mesh was created 
for each patient using the known geometry of the rings holding the sources and detectors. 
Since the rings for the patient interface are adjustable in the coronal direction, the position of 
the sources and detectors remains fixed in x and y, but varies in the z direction depending on 
the patient’s breast size. Therefore, a different mesh is generated for each patient according to 
the coronal translation of the rings. The mesh was extended 2 cm from the largest ring to 
account for the chest wall (see Fig. 8-4 for a sample mesh).  Sagittal slices showing the tumor 
location were selected from the tumor-bearing breast, and the same slice from the 
contralateral breast was also selected for visualization.  Images from all time points were 
plotted on the same scale for longitudinal analysis. 
11.3 Preliminary Imaging Results 
Included here are preliminary results for the initial patients who have enrolled in the study.  






Case Study 1 
A 47 year-old premenopausal woman enrolled as the first patient in the study in June 2011 and 
underwent NACT for poorly differentiated invasive ductal carcinoma at New York-Presbyterian 
Hospital.  Her baseline BMI was 27.3 with a bra size of 36B.  She obtained bilateral US and MRI 
images that confirmed that there was a mass in the right breast with approximate dimensions 
of 1.4 cm, and 2.3x1.5x2.0 cm determined by each imaging modality, respectively.  Fig. 11-3 
shows PET-CT, Mammogram, and US images obtained at baseline. 
 
Figure 11-3.  Case Study 1: Baseline PET-CT, mammogram, and US images. 
(a) An axial slice through the body with the tumor region in the breast shown an a highly 
enhancing node (bright yellow). 
(b) A craniocaudal (axial) mammogram of the right breast.  The red circle shows the malignant 
region. 









Figure 11-4.  Case Study 1: Graphical representation of tumor position in the breast. 
(a) View looking at the patient with the tumor located at 1 o’clock.  The grey circle represents the 
tumor, and the solid line shows the sagittal slice taken 1.7 cm from the nipple, thought the tumor 
region. 
(b) Sagittal view of the slice through the tumor. 
(c) Sagittal DOT image with the tumor region outlined with the black dashed line. 
 
Fig. 11-4 graphically illustrates the location of the tumor in the breast with the position 
of the sagittal axial slice selected 1 cm to the left of the nipple.  The same slice was selected for 
both the left breast (top three rows) and right breast (bottom three rows) at all time points, as 
shown in Fig. 11-5.  For each breast the images are organized as [HbO2] (topmost row), [Hb] 
(middle row), and μs’ (bottom row).  The scale goes from blue (low chromophore 
concentration) to red (high chromophore concentration), and is constant across both breasts, 
and all imaging time points.  At baseline, there is a region of high [HbO2], [Hb] and scattering in 
the right breast compared to the surrounding tissue (Fig. 11-5a).  The region of enhancement is 
located at approximately 12 o’clock and 4 cm from the nipple.  This correlates well with the 
mammogram and MRI tumor localization (11 o’clock and 6 cm for the nipple).  In our imaging 
geometry the patient leans into the rings, likely causing some minor coronal compression of the 
breast which likely results in the tumor appearing slightly closer to the nipple in the DOT 
images.   
After the first two cycles of paclitaxel (Fig. 11-5b/c) were administered the tumor could 
no longer be visualized and by Week 0 AC (Fig. 11-5d) the DOT images showed similar [HbO2], 
[Hb], and μs’ in both the left and right breast.  A smaller ring geometry was used for the pre-







Figure 11-5.  Case Study 1: DOT images of [HbO2], [Hb], and μs’ for the left (healthy, top three 
rows) and right (tumor bearing, bottom three rows) breast during NACT. 
Shown are images taken at (a) Baseline, (b) Week 2, (c) Week 4, (d) Week 0 AC, (e) Week 2 AC 







The change in optical parameters was quantified by averaging the chromophore values 
within a 1-cm-radius sphere around the tumor location in the DOT image.  The radius of 1 cm 
was selected to match the tumor size (2 cm diameter) at Baseline.  The quantified values for the 
[HbO2], [Hb], and μs’ are shown in Fig. 11-6.  Also shown in Fig. 11-6a is the largest tumor 
dimension taken from the caliper measurements.  The caliper measurements correlate with the 
observed DOT changes. This patient was very responsive to treatment, as visualized by the DOT 
imaging. 
 
Figure 11-6.  Case Study 1: Response to therapy over treatment as assessed by (a) caliper 
measurement, (b) [HbO2], (c) [Hb], and (d) scattering (μs’).   
Chromophore measurements are quantified as the average value over a 1-cm-radius sphere 







Case Study 2 
The second case study involves a 66 year-old postmenopausal woman who enrolled in the 
study in September 2011 and is undergoing NACT for a poorly differentiated invasive ductal 
carcinoma located in the right breast.  MRI images show a mass at 1 o’clock in the right breast 6 
cm from the nipple with dimensions of 2.3x1.5x2.0 cm.  Fig. 11-7 shows PET-CT, MRI, and US 
images obtained at baseline.   
 
Figure 11-7. Case Study 2: Baseline PET-CT, MRI, and US images. 
(a) An axial slice through the body with the tumor region in the breast shows a highly enhancing 
node (bright yellow). 
(b) An axial bilateral MRI.  The red circle shows the malignant region. 
(c) An US image of the tumor with a 1.3 cm diameter. 
 
 
Figure 11-8.  Case Study 2: Graphical representation of tumor position in the breast. 
(a) View looking at the patient with the tumor located at 1 o’clock.  The grey circle represents the 
tumor, and the solid line shows the sagittal slice taken 1 cm from the nipple, thought the tumor 
region. 
(b) Sagittal view of the slice through the tumor. 






Fig. 11-8 graphically illustrates the location of the tumor in the breast with the position 
of the sagittal axial slice selected 1 cm to the left of the nipple.  The same slice was selected for 
both the left breast (top three rows) and right breast (bottom three rows) at all time points, as 
shown in Fig. 11-9.  For each breast the images are organized as [HbO2] (top row), [Hb] (middle 
row), and μs’ (bottom row).  The scale goes from blue (low chromophore concentration) to red 
(high chromophore concentration), and is constant across both breasts, and all imaging time 
points.  There is a region of high [HbO2] and μs’ (and moderate [Hb]) in the right breast 
compared to the surrounding tissue and the contralateral breast at baseline (Fig. 11-9a).  The 
region of enhancement is located at approximately 1 o’clock and 3-4 cm from the nipple, again 
this correlates with the MRI localization when we consider the coronal compression of the 
breast in our imaging geometry.   
After the first two weeks of paclitaxel treatment (Fig. 11-9b/c) there is a dramatic 
decrease in the chromophores in the tumor region.  By Week 0 AC (Fig. 11-9d) the DOT images 
show a more homogenous chromophore distribution across the right breast, and there are 








Figure 11-9. Case Study 2: Sagittal DOT images of [HbO2], [Hb], and μs’ for the left (healthy) and 
right (tumor bearing) breast during NACT. 






As with Case Study 1, the change in optical parameters was quantified by averaging the 
chromophore values within a 1-cm-radius sphere around the tumor location in the DOT image.  
The radius of 1 cm was selected to approximate the tumor size (2 cm diameter) at Baseline.  
The quantified values for the [HbO2], [Hb], and μs’ are shown in Fig. 11-10.  Also shown in Fig. 
11-10a is the largest tumor dimension taken from the caliper measurements.  The caliper 
measurements generally correlate with the observed DOT changes. This patient was responsive 
to treatment, as visualized by the DOT imaging.  Interesting to note is that there is an increase 
in deoxy-hemoglobin in the tumor region at Week 4, corresponding to a decrease in oxy-
hemoglobin.  This may represent necrosis occurring in the tumor region during treatment. 
After week 4 the caliper measurements provide little information about the tumor 
response, while the DOT parameters continue to show meaningful changes.  Specifically, there 
is a persistent decrease in [Hb] from Week 4 to Week 2 AC and an observed rebound effect in 
[HbO2] over the same time.  This may reflect the changing oxygen saturation of the tumor 







Figure 11-10.  Case Study 2: Response to therapy over treatment as assessed by (a) caliper 
measurement, (b) [HbO2], (c) [Hb], and (d) scattering (μs’). 
Chromophore measurements are quantified as the average value over a 1-cm-radius sphere 
taken around the tumor location. 
 
11.4 Discussion 
We have developed instrumentation and methods for the visualization of breast tumors in 
longitudinal studies.  Our current techniques can extract [HbO2], [Hb] and scattering for use in 
studying the vascularization of advanced breast tumors in response to neoadjuvant 
chemotherapy.  
Our preliminary findings show that DOT can identify the tumor region at baseline by an 
increased [HbO2], [Hb], and scattering as compared to the surrounding healthy tissue.  
Increased [HbO2] and [Hb] are observed at baseline due to the higher levels of vascularization in 






(increased cell density) as well as the enlarged nuclei that are hallmarks of cancerous tissue.  
Increased [Hb], [HbO2], and scattering in tumor regions is well documented in literature [21, 
26].  The observed DOT measurements correlate well with the tumor dimensions obtained 
through caliper measurements, and suggest that as early as 2 to 4 weeks after beginning 
treatment DOT can predict that the tumor is responding to treatment.  These results agree with 
results from other clinical studies that show significant decreases in optical parameters in 
responding patients within weeks of initiating therapy [54, 56, 113]. 
In both case studies we observed a strong decrease in absorption and scattering within 
4 weeks of starting NACT.  Paclitaxel is a microtubule-damaging anti-cancer agent that is known 
to have anti-angiogenic properties [114, 115].  In these two case studies we see an almost 30% 
reduction in [HbO2] and a 10% reduction in [Hb], reflecting the decreased vascularization of the 
tumor region.  There is approximately 60% and 20% reduction in scattering over the NACT 
treatment for Case Study 1 and 2, respectively.  This decrease in scattering reflects the return to 
more normal tissue cellularity caused by the chemotherapy drugs.  Similar changes in [Hb], 
[HbO2], and scattering have been reported by Soliman et al. in a DOT study of 10 patients [56], 
and by Cerussi et al. in a diffuse optical spectroscopy study of 34 patients [54], and by Jiang et 
al. in a diffuse optical tomography study of 7 patients [112].  Soliman et al. showed that [Hb], 
[HbO2], and scattering changes can be used to differentiated between responders and non-
responders, while Cerussi et al. and Jiang et al. showed that only [Hb] and [HbT], respectively, 






able to add to these preliminary findings in an effort to understand which optical biomarkers 
are most sensitive to NACT response. 
 This study is ongoing and will ultimately aim to explore these promising preliminary 
results in a population of 20 patients.  The study will improve upon existing studies by including 
better pathological endpoints to evaluate the tumor responsiveness.  The biologic response will 
be assessed by Ki-67 reduction which is associated with cellular proliferation.  A reduction in Ki-
67 during NACT has been shown to correlate with clinical outcome [116].  DOT-measured 
hemoglobin concentrations have also been shown to correlate with Ki-67 [117].  This study will 
allow for the correlation between longitudinal changes in Ki-67 and DOT parameters through Ki-
67 assessment at baseline, surgery, and in some patients at mid-treatment.  In addition, prior 
studies have had non-uniform treatment schedules and chemotherapy agents, while our study 
controls for those factors. 
 DOT has a number of advantageous characteristics that make it well suited to therapy 
monitoring.  It’s non-ionizing, inexpensive, and portable technology makes it a clinically 
appealing solution for longitudinal measurements at the point of care.  The principle advantage 
that DOT has over other breast imaging modalities (US, MRI, and Mammography) is its 
sensitivity to the endogenous tumor changes in vascularity and cellularity.  Tumor hemoglobin 
content and scattering appear to be more sensitive and provide an earlier indication of tumor 






Chapter 12 : Wireless Handheld Optical Imaging Probe 
In chemotherapy monitoring applications, where the location of the tumor in the breast is 
already known, and is, in many cases, large and palpable, it may be possible to simplify the 
instrumentation for easier clinical use.  A number of handheld optical imaging probes have 
been developed for detecting breast tumors and monitoring tumor response to therapy [54, 
113, 118, 119].  However, all of them are either fiber or camera-based systems where the hand-
held portion of the probe connects to a much larger instrument.  In this chapter we present the 
design of a handheld device that miniaturizes the detection hardware so that all processing is 
performed at the detector and transmitted wirelessly to the host computer.  This design 
eliminates the need for optical fibers or a camera-based design and allows for a hand-held 
device whose small form factor and ease of use make it suitable for a number of clinical 
applications. 
Most of the current handheld probes for optical breast imaging detect light in 
reflectance geometry with a 0.5 to 3.5 cm source-detector separation in order to probe 
beneath the tissue surface.  They use a range of near-infrared wavelengths to determine the 
concentration of chromophores relevant to detecting tumors including oxy- and deoxy-
hemoglobin, lipid, water, and scattering.  Many of these probes operate in the frequency 
domain (FD), where the source light is modulated in intensity at frequencies between 100 and 
1000 MHz.  These systems can extract both the change in phase and amplitude from the 
detected light. Current handheld FD imaging systems require bundles of optical fibers to bring 






 Continuous-wave (CW) systems use illumination with constant (or radio-frequency 
modulated) light intensities and, as a result, only extract the change in amplitude of the light 
through the tissue. Although less information is collected as compared to FD systems, CW 
systems are much less expensive, allow for faster data acquisition, and the detection 
electronics can be miniaturized.  Recently, Xu et al. demonstrated a handheld CW system for 
pressure-induced dynamic breast imaging [113, 120]. Their approach integrates the detection 
electronics into the handheld portion of the device and relays the measured data to a laptop 
computer via a serial port. No wireless handheld breast imaging devices have been published to 
date.  
 In other areas, wireless optical imaging devices have recently been developed for 
wearable technologies [121, 122], and endoscopy [123, 124].  A wearable patch-like device 
designed by Muehlemann et al. uses 4 CW sources and 4 detectors with 2 wavelengths [121].  A 
flexible printed circuit board holds the illumination, detection, and wireless transmission 
electronics.  Similarly, a larger, but still portable wearable brain-imaging system developed by 
Atsumori et al. [122] uses 8 CW sources and 8 detectors with 2 wavelengths for imaging the 
frontal cortex.  Along with a portable pack that attaches to the subject's waist, the wireless 
system allows the subject to move around during imaging.  Both of these systems focus on 
differential imaging and use the modified Beer-Lambert law to look at relative changes in the 
concentration of oxy- and deoxy-hemoglobin.  In endoscopy, capsule-like wireless devices have 
been designed for spectral, fluorescent, and bright field imaging of the gastrointestinal tract 






charged couple device (CCD) sensors to perform qualitative imaging for identifying suspicious 
regions at the surface of the tissue.   
 Despite this progress, there are currently no wireless optical imaging devices that 
perform diffuse optical tissue measurements with absolute reconstruction of the 
concentrations of tissue chromophores, including the contribution of tissue scattering. Here we 
present the first prototype of such a device. Our new system is handheld, wireless, and can 
resolve actual optical properties of scattering, oxy- and deoxy-hemoglobin using four source 
wavelengths and two detectors at 2.3 Hz.  The device uses radio-frequency modulated 
illumination to eliminate background light and reduce noise artifacts.  Using digital detection 
techniques described earlier in Chapters 4 and 5, we are able to perform the majority of the 
signal detection and demodulation in the digital domain, which allows for the wireless 
transmission of the final signal amplitude.  The device is inexpensive, portable, runs off of a 9V 
D-type battery, and can seamlessly interface via Bluetooth to a host computer. A multispectral 
evolution algorithm uses the measured light intensity to calculate absolute values for tissue-
scattering, and concentrations of oxy- and deoxy-hemoglobin in tissue. 
12.1 Wireless Handheld Probe Design 
The instrument uses four near-infrared wavelengths of light to illuminate tissue.  The 
light passes through the sample and is absorbed and scattered as it travels to two detectors 
configured in reflectance geometry and located 1.8-2.4 cm and 2.7-3.3 cm away from the 







Figure 12-1. Wireless handheld probe source and detector layout. 
 
 The light is detected by a silicon photodiode and both quantized and demodulated by a 
microcontroller that passes the result back to the host computer via Bluetooth.  The instrument 
is powered by a 9V D-type battery.  A block diagram of the system is shown in Fig. 12-2. 
 
Figure 12-2.  System block diagram for the wireless handheld probe. 
 
 The current version of the device is a prototype that is enclosed by a plastic case 
measuring 11.5 x 16 x 2.5 cm.  This makes the device easy to hold and it can be brought in 
contact with a wide variety of tissue surfaces.  A photograph of the probe is shown in Fig. 12-3a.  







Figure 12-3.  Photograph of the handheld wireless probe. 




The input light is generated by 10 mW 5.6 mm-diameter laser diodes at wavelengths of 780 nm, 
808 nm, 850 nm, and 904 nm (L780P010, L808P010, L850P010, L904P010, ThorLabs).  The 
wavelengths are selected to provide a range of spectral information to reconstruct oxygenated 
hemoglobin ([HbO2]), deoxygenated hemoglobin ([Hb]) and scattering (μs’), while working 
within the limited selection of wavelengths available in this small package.  The laser diodes are 
driven by a 15 V Laser Diode Driver (iC-WKN, iC Haus).  Each wavelength has the ability to 






potentiometers.  The modulation signal is generated using a combination of a 1 kHz to 33 MHz 
Oscillator (LTC1799, Linear Technologies), a binary counter (M74HC4820, STMicroelectronics) 
and a low-pass filter (LTC1067, Linear Technologies). The power of the laser diode can be 
controlled using a 20 kΩ potentiometer that regulates the current to the laser driver.   
 The modulation of the input light provides several advantages including superior noise 
rejection (including ambient light) as well as the ability to illuminate the tissue simultaneously 
with multiple wavelengths.  Due to the fact that the speed of this particular system is limited by 
the processing power of the microcontroller, the probe is configured to sequentially illuminate 
the target which each wavelength.  However, future iterations of this design involving a more 
powerful microcontroller could simultaneously illuminate the sample with all wavelengths, 
modulated at different frequencies, thereby improving the frame rate by a factor of 4.  
Light Detection 
Light is detected using a silicon photodiode (SiPD) (S1337-33BR, Hamamatsu) and a trans-
impedance amplifier (TIA).  The amplifier has 4 possible gain settings including 10 kV/A, 100 
kV/A, 1 MV/A, and 10 MV/A.  For laser power between 1 and 5 mW, the closer detector (d1) 
uses the 1 MV/A setting for most applications, while the further detector (d2) uses the 10 MV/A 
setting.  The 1 MV/A and 10 MV/A gain settings utilize a bandwidth-extension technique 
previously described in Section 4.2.  Following the TIA, the signal is high-pass filtered to remove 
any DC offset.  The signal is also passive low-pass filtered to prevent aliasing at the analog-to-
digital converter (ADC).  In the final stage the signal is offset to 1.5V to fully optimize the 0 to 3 






 The microcontroller used in this design (ADUC7020, Analog Devices) has a built-in 12-bit 
analog-to-digital converter (ADC).  The ADC logic is configured to sample at 75 kHz and to 
acquire 150 samples for each measurement.  Upon acquisition, the microcontroller performs 
digital lock-in detection to extract the amplitude from the detected sinusoidal signal.  This 
algorithm, previously outlined in Section 5.6, uses averaging filters combined with modulation 
and sampling constraints to digitally extract the amplitude while reducing noise.  The 
demodulated amplitude is transmitted to the Bluetooth Module via a universal asynchronous 
receiver/transmitter (UART) interface. 
 The Bluetooth Module (RN-41, Roving Networks) was selected for this instrument due 
to its small form factor (13.4 x 25.8 x 2.0 mm) and low power consumption (<100 mA @ 3 V).  
The RN-41 Bluetooth Module provides secure communication with 128-bit encryption, error 
correction for guaranteed packet transfer, and a Class 1 antenna that provides up to 100m of 
wireless range.  Any Bluetooth-capable computer can pair with the Bluetooth Module (by 
providing the correct pairing code) and communicate via a virtual serial communication port to 
a LabVIEW user interface.   
Power Supply 
All power to the device is supplied by a 9 V D-type battery.  This could easily be replaced with 
any battery that can provide more than 120 mA at 3 V.  Care was taken in selecting components 
for the device that operate at 3 V so that only one voltage rail is required for the device 
operation.  A low-dropout voltage regulator takes any input voltage between 3 and 12 V and 






12.2 System Performance 
With no incident light on the detector the dark noise of the system is 160 µV.  This is far below 
the typical values recorded for tissue of between 0.05 and 1 V.  The largest possible input value 
is 3 V peak-to-peak, giving the device a dynamic range of 85 dB for the single 10 MV/A gain 
setting.  From measurements made on a tissue-like optical phantom, the SNR was between 36 
dB and 51 dB.  This range is due in part to the differences in absorption at the various 
wavelengths. 
 The system speed is currently limited by the time required to demodulate the acquired 
signal.  It takes 2 ms to acquire 150 samples followed by 52 ms to demodulate the data and 
send it to the Bluetooth module.  This 54 ms acquisition time must be repeated for each of the 
four wavelengths and each of the detectors, ultimately giving a sampling speed of 2.3 Hz.  It 
takes the laser diodes approximately 5 ms to settle following switching.  This settling time is 
coordinated to take place during the time that the microcontroller is demodulating the data 
from the previous wavelength.  A summary of the probe’s parameters and performance is 
shown in Table 12-1. 
Table 12-1. Summary of the wireless handheld probe parameters and performance. 
Parameter Value 
Wavelengths 4: 780 nm, 805 nm, 850 nm, 904 nm 
Detectors 2 
Mode CW 
Frame Rate 2.3 Hz 
Dynamic Range 85 dB 
Dark Noise 160 µV 
SNR ~50 dB 
Power Consumption 120 mA @ 3 V 








12.3 Evolutionary Reconstruction Algorithm 
The wireless handheld probe provides measurements of the light that scattered through the 
light and returned to the detector at the surface, as shown in Fig. 12-4. 
 
Figure 12-4.  Diagram of light propagation in a back-reflection geometry. 
Photons that are emitted from the source into the medium scatter and return to a detector 
located d away from the source. As the source-detector separation increases, the photons that 
arrive at the detector are more likely to have travelled deeper into the sample (in z). 
 
By performing reflectance measurements at multiple locations on the surface of the medium 
with multiple wavelengths we can compute the optical properties of the tissue.  The diffuse 
reflectance depends solely on the absorption coefficient a, the reduced scattering coefficient 
s', and the source-detector separation d. Under the assumption of a semi-infinite 
homogeneous medium, there is a closed-form analytic solution for the spatially resolved 
reflectance.  It is given by Farrell et al. [125] as: 
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Here µeff is the effective attenuation coefficient (
'3eff a s   ), t' is the total transport 
coefficient (t'= µa+s') and A is the internal reflection parameter [126] that takes into account 
the refractive index mismatch at the air-tissue interface. 
The common approach to find a and s' is to fit the analytic solution (Eq. 12.1) to the 
measured values of R(d), which makes use of the linear correlation between R(d) and d. In other 
words, a plot of log(d2R(d)) versus d can be used to estimate eff. To separate a and s', 
Patterson et al. [127] used the absolute overall diffuse reflectance over the entire surface, 
whereas Farrell et al. [125] exploited the reflectance at small d to obtain s', while Liu et al. 
[128] used the intercept of d2R(d) versus d to estimate s', and Matcher et al. [129] simply use 
time-resolved techniques to assume s'. Once a and s' are obtained at multiple wavelengths, 
the results are then combined to obtain the chromophore concentrations (e.g. [HbO2] and 
[Hb]). Clinical applications of this technique can be found in literature [130-134].   
Although the slope-based approach is widely used, it is highly sensitive to noise. Small 
errors in the measurement can lead to a large error in the slope obtained through a least 
squares fitting procedure. To reduce this error, one can increase the number of data points by 
increasing the number of detectors, which in turn leads to an increase in the size of a probe, a 
solution that is not preferred in the design of hand-held probes. To overcome the difficulties 
with the slope-based approach, we employ a multispectral evolutionary algorithm that uses 
data from all wavelengths simultaneously to estimate the optical properties. 
Evolution algorithms imitate the principles of evolution and heredity in nature for 






population of individuals Pk=(x1, … , xn)k that can recombine and mutate to create offspring.  On 
each iteration, the offspring is evaluated against an objective function only a subset of the 
offspring is selected as the population for the next iteration Pk+1=(x1, … , xn)k+1.  Once the 
objective function has reached an acceptably small value, that offspring is identified as the 
solution to the problem. 
12.4 Phantom Measurements 
Experimental studies on an optical phantom were performed to validate the handheld probe. 
Using a liquid phantom we explored the relationship between the expected value of absorption 
and scattering and our reconstructed value. To reconstruct the absolute values of absorption 
and scattering parameters in the medium, we normalized the target measurement data to a 
reference medium with known optical properties.  Measurements were made at the surface of 
an 8 cm × 8 cm × 8 cm box filled with 500 ml of 30 different solutions. Each solution consisted 
of an aqueous mixture made up of Intralipid (Baxter Intralipid 20% Fat Emulsion), black ink 
(Higgins India Ink), and near-infrared dye (Epolight 2735, Epolin Inc.).  We chose Intralipid for its 
well-documented optical properties and prior use in phantom studies to mimic tissue optical 
properties [135, 136].  Likewise, black India ink is commonly used in optical phantoms and is a 
water-soluble absorber that has a flat absorption spectrum in our wavelength range.  Epolight 
2375 is a water-soluble near-infrared dye that has peak absorption at 970 nm, and therefore 
displays a different spectral response from India ink in the near-infrared range. The ranges for 






 In the first experiment we used a reference solution of 3.2% by volume (32 ml/l) of 
Intralipid 20% with no added ink.  This provides a medium where the absorption is 
predominantly due to water, which results in higher absorption at higher wavelengths 
(expected µa: 0.023, 0.019, 0.042, 0.068 cm
-1 @ 780, 808, 850, 904) [17].  The scattering in the 
medium is due to the Intralipid scattering and decreases at higher wavelengths (expected µs': 
6.74, 6.48, 6.12, 5.70 cm-1 @ 780, 808, 850, 904 nm) [135, 136].  We increased the reduced 
scattering coefficient by increasing the concentration of Intralipid from 3.4% (34 ml/l) to 5.2% 
(52 ml/l) in increments of 0.2% (2 ml/l) resulting in a µs' ranging from ~6-10 cm
-1.  Note that an 
increase in the Intralipid concentration does not change the absorption of the solution.  In Fig. 
12-5a we show both the theoretical (solid and dashed lines) and the experimentally-derived 
values for µa for varying concentrations of Intralipid. As expected, µa shows no dependence on 
the Intralipid concentration and the calculated values for absorption closely match the 
expected values for water absorption.  Conversely, Fig. 12-5b shows that µs' increases linearly 
with the increasing Intralipid concentration due to the increased concentration of scatterers.  








Figure 12-5.  Phantom experiment using the wireless probe to measure increasing absorption 
and scattering. 
Reconstructed values of (a) a and (b) s' for linearly increasing amounts of Intralipid added to 
the phantom; and reconstructed values of (c) a and (b) s' for linearly increasing amounts of Ink 
added to the phantom. 
 
 For the second experiment we used a reference solution of 4.8% (48 ml/l) Intralipid and 
0.024 ml/l of our ink dilution.  In this case the absorption is due to both water and ink (expected 
µa: 0.042, 0.038, 0.060, 0.086 cm
-1 @ 780, 808, 850, 904 nm) while scattering is due to Intralipid 
(expected µs': 9.84, 9.46, 8.93, 8.31 cm
-1 @ 780, 808, 850, 904 nm).   We increased the 
absorption coefficient by increasing the ink concentration by 0.024 ml/l per step from 0.048 
ml/l to 0.24 ml/l (resulting in an increase in µa' of ~0.0192 cm






the ink concentration does not significantly affect the scattering properties of the medium.  The 
results are shown in Fig. 12-5c/d where the theoretical values of absorption and scattering are 
shown by the solid and dashed lines and the experimentally derived values are shown by the 
markers.  In Fig. 12-5c, µa shows a linear relationship to the ink concentration with an average 
relative error of 3%.  The increased ink concentration does not affect the scattering of the 
solution, as reflected by Fig. 12-4d, where µs' is constant across the various concentrations of 
ink.  Similar to the first experiment the scattering is underestimated by 7% on average, an effect 
that appears accentuated at the longer wavelengths.  This may be due to the fact that, although 
black ink is commonly considered to be a perfect absorber, it may have a scattering component 
that can lead to an underestimation of scattering [137]. 
In order to explore the probe’s ability to accurately separate two chromophores (such as 
oxy- and deoxy-hemoglobin), we performed measurements on a series of liquid optical 
phantoms with varying amounts of ink (Black India Ink) and dye (Epolight 2735, 0.05 g in 50 ml 
deionized water). In each experiment, we used a low and high absorbing solution to calibrate 
the probe. In the first experiment, we measured a solution of 4% Intralipid (40 ml/l), 0.5 ml/l of 
dye, and 1.5 ml/l to 3.5 ml/l of ink in steps of 0.5 ml/l (Phantom 1 through 5). The expected and 
measured values of the ink and dye volumes are shown in Fig. 12-6a. In the second experiment, 
we measured a solution of 4% Intralipid (40 ml/l), 1 ml/l of a 1% ink dilution, and 1 ml/l to 3 
ml/l of dye in steps of 0.5 ml/l (Phantom 6 through 10). The expected and measured values of 
the ink and dye volumes are shown in Fig. 12-6b. Note that increasing the ink or dye 






measured values for the scattering parameter A are shown for the increasing ink (Fig. 12-6c) 
and increasing dye (Fig. 12-6d) experiments. The results shown in Fig. 12-6 demonstrate that 
the probe can distinguish between two different optically absorbing chromophores. The small 
error in deriving the precise ink and dye volumes is due to the fact that the wavelengths used in 
the probe are optimized for differentiating oxy- and deoxyhemoglobin, not for differentiating 
the spectra of ink and dye. 
 
Figure 12-6.  Reconstructed volumes of ink (grey) and dye (black) in Intralipid solution for (a) 
linearly increasing amounts of ink and (b) linearly increasing amounts of dye. Also shown is the 
reconstructed scattering A for each experiment (c/d). Dashed lines represent the actual values, 








We have presented a new hand-held wireless device for diffuse optical tissue spectroscopy.  
The prototype was created for less than $400 and presents an inexpensive, portable, and user-
friendly device for clinical optical measurements.  The size of the device is currently suited for 
hand-held operation, but could be further scaled down in size by selecting smaller component 
footprints, a smaller battery, and denser board layout.  Furthermore, while the device can 
image at 2.3 Hz, which is suitable for most dynamic imaging experiments, the speed could be 
increased by selecting a more powerful microcontroller and using simultaneous illumination by 
multiple wavelengths. Using four wavelengths and two detector positions we have 
demonstrated that we can accurately resolve absolute measurements of absorption and 
scattering using a multispectral evolutionary reconstruction algorithm. 
 This device will facilitate future clinical studies exploring the optical signatures of tumor 
regions in the breast, but is not limited to breast imaging.  Indeed, this device provides a fast 
and easy way to make static and dynamic measurements on many other tissues, including, for 
example, brain or limbs, without the need for specific interfaces for each application.    The 
ease of use, portability, and low cost of this device will complement many existing clinical 
optical studies by providing real-time measurements, and will create opportunities for new 









Chapter 13 : Summary and Future Work 
13.1 Summary 
This thesis focuses on the development of a new optical tomography system for dynamic and 
static imaging of breast cancer.  The system uses digital detection techniques combined with a 
master-slave digital-signal-processor (DSP) architecture.  The digital demodulation and timing 
control of the system enable frame rates of 1.7 – 111 Hz.  The ability to store a unique gain bit 
setting for each source-detector pair provides a large dynamic range (160 dB) that is important 
for imaging the breast.  The instrument has 32 sources and 64 detectors per breast, and can 
image at four wavelengths (765, 808, 827, and 905 nm).   Two fiber-breast interfaces were used 
for clinical studies: an articulating-finger breast interface for dynamic imaging and a translating 
ring breast interface for longitudinal studies for absolute measurements. 
  The contrast derived from the difference in optical absorption and scattering by various 
tissue chromophores (namely oxygenated and deoxygenated hemoglobin) can be used to 
create three-dimensional maps that provide insight into the physiology of the tissue.  In cancer, 
the increased vasculature that forms around a growing tumor can be used to identify suspicious 
tissue.  In addition, tumor vasculature is poorly formed, shunted, and dilated, features that 
cause a tumor tissue to respond differently to a stimulus.  We conducted two clinical studies 
and one pre-clinical study exploiting this biological source of optical contrast. 
 In a study of 21 subjects, we explored dynamic features that can be used to identify 
breast masses during the hemodynamic response of the breast to a breath hold.  Specifically, 






with breast cancer.  In addition, during the recovery period from the breath hold, the tumor can 
be visualized by an increased presence of deoxygenated hemoglobin.  Exponential fitting of the 
transient response suggests that the source of this contrast in the recovery period comes from 
the slower washout rate of deoxygenated hemoglobin from the tumor region.  This slow 
washout rate is due to the disorganized tumor vasculature. 
 In a pre-clinical study involving 22 mice we used DOT to differentiate between 
responsive tumors and non-responsive tumors within 5 days of anti-angiogenic drug treatment.  
A significant decrease in total hemoglobin was observed in the responsive, treated mice as 
early as one day after treatment, while untreated, and treated non-responsive mice showed an 
increase in total hemoglobin over the 5 days.  These changes in total hemoglobin correlated 
with changes in microvessel density (observed by lectin perfusion imaging) and relative blood 
volume (observed by MRI T2 relaxometry). 
 Based on the results of the pre-clinical therapy-monitoring study, as well as the growing 
need for a technique to improve the effectiveness of neoadjuvant chemotherapy in breast 
cancer, we designed a clinical study using DOT to predict individual patient response to 
neoadjuvant breast cancer therapy.  Case studies of two breast cancer patients suggest that 
DOT can predict the patient’s response to therapy as early as two weeks after beginning 
treatment.  In both cases, a strong reduction in absorption due to decreased vasculature in the 
tumor region is observed as early as 2 weeks after commencing treatment, representing the 






also observed, reflecting changes in tumor cellularity.  These preliminary results will be further 
explored in an ongoing study of 20 patients undergoing NACT. 
 The clinical use of the digital optical breast imaging system led to the design of a 
complementary handheld probe for fast, simple, local optical measurements.  This compact 
wireless probe can make dynamic measurements at 2.4 Hz or static measurements.  Its design 
requires contact with a 4 cm section of tissue, removing the need for a complex fiber-breast 
interface and enabling a large variety of clinical studies.  Phantom experiments with the device 
show that it can resolve optical properties of absorption and scattering with good accuracy. 
 Overall, this thesis has focused on the design and clinical translation of new digital 
instrumentation for optical tomography.  We have seen promising results in studies using the 
device for breast cancer detection and therapy monitoring.  It is our hope that these results 
provide the basis for further studies refining the techniques and clinical use of DOT for 
improvements in breast cancer management.  
13.2 Future Work 
Instrumentation 
The digital optical tomography system has been in clinical use at the Herbert Irving 
Comprehensive Cancer Center (HICCC) for 3 years.  Over the past six months, staff at the HICCC 
have been trained and are now proficient at operating the system.  Training clinicians to 
operate the system opens up a larger range of clinical studies and use of the device.   This 
process can be further facilitated in the future by improving the software user interface to 






 Chapter 8 described two fiber-breast interfaces with different approaches for making 
contact with the breast.  Further improvement to these interfaces can significantly improve the 
quality of the DOT images by providing better breast-fiber contact over the entire breast 
volume for patients of all breast sizes and body types.  Software-controlled positioning of the 
interface would be an ideal extension of the existing system, with motors to control the precise 
positioning of the interface.  The importance and difficultly of designing clinically 
implementable fiber-breast interfaces across a broad range of patient sizes should not be 
underestimated in future DOT breast imaging studies. 
 From a technical standpoint, there are a few enhancements to the system that could 
improve its clinical use and operation.  These improvements are outlined in detail in Section 
9.10. 
Dynamic Breast Imaging 
There are many other aspects of breast cancer management in which DOT may be able to 
improve patient outcomes.  The study described in Chapter 9 showed that dynamic DOT can be 
used to visualize breast tumors.  In addition, it also showed promising trends in using dynamic 
signatures of tumors to differentiate benign from malignant pathologies.  While a more 
controlled, larger, prospective study would be required to fully investigate these trends, DOT 
may have a complementary role to mammography as a secondary screening tool.  It is also 
possible that dynamic DOT may provide information about the tumor vasculature which could 






 Dynamic contrast mechanisms can provide additional information about tumor 
vascularity.  However, in many cases, the biological mechanism causing the optical contrast is 
not clear.  Preliminary attempts to understand the source of contrast during a breath hold have 
been performed by creating a 3-compartment Windkessel vascular model, as described in 
Appendix N.  This model can be further enhanced to validate and complement the experimental 
results of dynamic imaging. 
DOT Monitoring of Neoadjuvant Chemotherapy 
There is a significant need in the neoadjuvant chemotherapy setting to find new ways to predict 
and monitor response to therapy.  DOT is perfectly suited to this application, as it is fast, non-
ionizing, and sensitive to the early changes in the tumor physiology.  The study described here 
showed promising results in two case studies, where the tumor response could be visualized by 
decreases in hemoglobin and scattering within two weeks.  This study is ongoing and will 
hopefully provide the basis for a number of other investigations into the use of DOT in 
optimizing treatment schedules and therapy selection with the goal of improving patient 
outcomes. 
 In addition to the longer NACT study described here, there are a number of 2-week 
studies that explore the short term tumor response to treatment prior to surgery.  DOT imaging 
of these studies would provide a quantitative in vivo assessment of the tumor response.  These 
studies not only generate additional clinical information to guide patient care, but also provide 






for more rapid results and could provide an ideal setting for testing new DOT instrumentation 
and protocols. 
DOT in Pre-Clinical Applications 
While clinical translation of this tool is one of the more exciting aspects of this work, the value 
of DOT in pre-clinical studies should not be ignored.  In fact, the ability to conduct small-animal 
studies to complement and parallel the clinical therapy monitoring studies is a strong benefit of 
optical imaging.  Pre-clinical studies can also allow for the refinement of the imaging 
techniques, including the imaging protocols, optical references, and reconstruction algorithms.  
Pre-clinical studies benefit not only from a well-controlled setting, but also from a wide range of 
well-characterized tumor models and treatments.   
In our study of bevacizumab-treated renal tumors we observed an overall decrease in 
total hemoglobin over the 5 days.  However, individual mice showed varying rebound effects 
which may reflect vascular normalization in response to treatment.  Tumors are known to find 
alternate pathways in response to anti-angiogenic treatment in order to continue vascular 
development.  DOT would enable further exploration of these effects, especially in studies 
looking at combinations of anti-angiogenic treatments. 
Wireless Handheld Probe 
Optical imaging is an inexpensive, non-ionizing, compact technology that can provide 
physiologically-relevant information about tissue at the point of care.  Designing portable, 
widely useable technologies such as the wireless handheld imaging probe described in Chapter 






work here focused on the design of the handheld probe for breast imaging, but the probe is not 
limited to breast tissue.  There is interest in also applying the use of this probe to skin imaging, 
particularly in observing the behavior of pediatric hemangiomas.  Although the technology and 
acquired data is significantly simplified from the DOT instrumentation described in Chapters 2 
through 9, the handheld probe complements more sophisticated DOT imaging studies and 
opens up a wide range of new applications. 
13.2 Conclusions   
Over the past 15 years the field of diffuse optical tomography has progressed from theoretical 
applications to bench top demonstrations and, more recently, into the clinic.  With increasing 
interest in using safe, lower-cost imaging techniques, DOT continues to find clinical applications 
where its sensitivity to tissue physiology makes it a valuable medical tool.  DOT can provide 
physiologically-relevant information for detecting, characterizing, and monitoring tumors in 
both clinical and pre-clinical settings.  In particular, optical imaging shows particular promise in 
breast cancer applications.  The role of optical imaging in breast cancer management will be 
better understood in coming years by the research community through studies ranging from 
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APPENDIX A – DDS BOARD BOM, SCHEMATIC, AND BOARD LAYOUT 
A1. Bill of Materials 
# Qty Ref 
Part 
Desc. 






0.01uF SMT-0805 CERAMIC 10% 50V X7R AVX: 08055C103KAT2A          
2 2 C5, C24 27pF SMT-1206 Ceramic, 50V, NP0 Yageo: 1206CG270J9B200         
3 2 C6, C25 47pF SMT-1206 Ceramic, 5%, 50V, NP0 AVX: 12065A470JAT2A           
4 2 C7, C26 39pF SMT-1206 Ceramic, 5%, 50V, NP0 AVX: 12065A390JAT2A            
5 2 C8, C27 22pF SMT-1206 Ceramic, 5%, 50V, NP0 BC: VJ1206A220JXACW1BC    
6 2 C9, C28 2.2pF SMT-1206 Ceramic, ±0.25pF, 50V, NP0 AVX: 12065A2R2CAT2A          
7 2 C10, C29 12pF SMT-1206 Ceramic, 5%, 50V NP0 Yageo: 1206CG120J9B200           
8 2 C11, C30 8.2pF SMT-1206 Ceramic, ±0.5pF, 50V, NP0 Yageo: 1206CG829D9B200         
9 10 
C12, C19, C31, 
C38, C69, C71, 
C73, C75, C79, 
C82 






0.1uF SMT-0603 CERM CHIP, 25V,  X7R, 10% Panasonic: ECJ-1VB1E104K       
11 2 C47,C52 10nF SMT-1206 CERM .01UF 10% 50V X7R AVX: 12065C103KAT2A    
12 14 
C43,C44,C48,C49,
C70, C72, C74, 
C76,C80, C83, 
C87, C88, C89, 
C90 
0.1uF SMT 0805 CERM, 10%, 50V X7R  Kemet: C0805C104K5RACTU 
13 1 C66 1uF SMT-1206 Ceramic, 25V, 10%, X7R Kemet: C1206C105K3RACTU    
14 1 C68 10uF SMT 0805 Ceramic, 6.3V, 20%, X5R Panasonic: ECJ-2FB0J106M       
15 1 IC1 
 
SOIC-8 
Slew enhanced, Feedback 
Amp 
Elantec: EL5203IS            
16 2 IC2, IC3 
 
SOIC-8 
Low distortion, Rail-to-Rail 
Amp 
Analog Devices: AD8027AR            
17 4 IC5, IC6, IC9, IC10 
 
SSOP-16 
Active RC Filter Chip, 4th 
Order 
Linear: LTC1563 
18 1 IC8 
 
TO-220 LDO REG FIXED 5V 1.5A  Linear Technology: LT1086CT-5                     
19 1 J1 
 
  CONN DIN PLUG 64POS RT  AMP/Tyco:  650945-5   
20 2 L1, L4 82nH 
L2520(100
8) 
MULTILAYER 0.082UH 1008 TDK:  NLV25T-082J-PF    
21 4 L2, L3, L5, L6 68nH 
L2520(100
8) 
MULTILAYER 0.068UH 1008 TDK:  NLV25T-068J-PF    
22 2 R1, R9 1.3k SMT-0805 1/8W 1% Yageo: RC0805FR-071K3L 
23 2 R2, R10 3.9k SMT_0805 1/8W 1% Rohm: MCR10EZHF3901             
24 4 R3, R4, R11,R12 25 Ohm  SMT-0805 Thick Film, 1/8W 1% Yageo: RC0805FR-0724R9L                 
25 4 R5, R6, R13, R14 50 Ohm  SMT-0805 Thick Film, 1/8W 1% Yageo: RC0805FR-0749R9L 
26 4 R7, R8, R15, R16 
100 
Ohm 
SMT-0805 Thick film, 1/4W 1% Yageo: 9C08052A1000FKHFT 
27 2 R17, R35 3.3k SMT-1206 1/4W 1% Yageo: RC1206FR-073K3L 
28 2 R18, R36   SMT-1206 Thick film, 1/4W 1% Yageo: RC1206FR-0715KL 
29 4 
R19, R21, R37, 
R39 
187k SMT 0805 1/8 W, 1% Yageo: 9C08052A1873FKHFT 






31 2 R27, R45 249k SMT 0805 1/8 W, 1% Yageo: RC0805FR-07249KL 
32 4 
R28, R30, R46, 
R48 
261k SMT 0805 1/8 W, 1% Yageo: 9C08052A2613FKHFT 
33 2 R20, R38 226k SMT 0805 1/8 W, 1% Yageo: 9C08052A2263FKHFT 
34 4 
R23, R25, R41, 
R43 
221k SMT 0805 1/8 W, 1% Yageo: 9C08052A2213FKHFT 
35 4 
R24, R26, R42, 
R44 
174k SMT 0805 1/8 W, 1% Yageo: 9C08052A1743FKHFT 
36 2 R29, R47 165k SMT 0805 1/8 W, 1% Yageo: 9C08052A1653FKHFT 




Thru-Hole 3/8" SQ CERM SL MT Bourns: 3299W-1-103        
38 1 R31 2.0k SMT-1206 1/4W 5%  Yageo: 9C12063A2001JLHFT 
39 2 R33, R51   SMT-1206 1/4W 1% Yageo: RC1206FR-071KL 
40 2 R34, R52 1.78k SMT-1206 1/4W 1% Yageo: 9C12063A1781FKHFT     
41 2 R49, R53 
49.9 
Ohm 
SMT-1206 1/4W 1% Yageo: RC1206FR-0749R9L     
42 2 R54, R55 
0.0 
Ohm 
SMT-1206 1/4W 5% Yageo: 9C12063A0R00JLHFT     
43 2 U1, U2 DDS TQFP-80 DDS CMOS 80-LQFP Analog Devices: AD9854AST    
44 2 U8, U9 
 
SOT-223 2.0 Amps Analog Dev:  ADP3338AKCZ-3.3  
45 1 U6 
 
SOT23-5 200 mA, Low Dropout Linear Technology: LT1964ES5-5                     
46 1 U3 
 

























APPENDIX B – INPUT UNIT MICROCONTROLLER CODE 
// ddsdriver.C 
 
#include <REG52.H>             /* special function register declarations for the intended 8051 derivative   */ 
#include <intrins.h>             /* call to invoke _nop_()(one cpu circle,100ns) for time delay*/ 
 
sbit WR1 = P1^0; 
sbit UDCLK1 = P1^2; 
sbit WR2 = P1^1; 
sbit UDCLK2 = P1^3; 
sbit WR3 = P1^4; 
sbit UDCLK3 = P1^6; 
sbit WR4 = P1^5; 
sbit UDCLK4 = P1^7; 
sbit RST = P3^7; 
int i; 
 
void main (void)  //  The main C function.  Program execution starts here after stack initialization. 
{ 
 // time delay 
 for (i = 0;i < 1000;i++)// Time delay 
  _nop_(); 
  
 // Initializing four DDS 
 UDCLK1 = 1; 
 UDCLK2 = 1; 
 UDCLK3 = 1; 
 UDCLK4 = 1;  
  
 WR1 = 1; 
 WR2 = 1; 
 WR3 = 1; 
 WR4 = 1; 
 
 // Resetting four DDS 
 RST = 0; 
 for (i = 0;i < 1000;i++)// Time delay 
  _nop_();  
  
 RST = 1; 
 for (i = 0;i < 1000;i++)// Time delay 
  _nop_(); 
 
 RST = 0; 
for (i = 0;i < 100000;i++)// Time delay 
  _nop_();  // _nop_() is used to guarantee that the timing requirement of the DDS is met. 
 
  
 // Choosing the operation mode and the source of update clock 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x1f; // Address for corresponding register  
 P2 = 0x00; // Single tone and external update clock 
  
 _nop_(); _nop_();_nop_();_nop_(); _nop_(); 
 WR1 = 0; // Writing I/O buffer 
 WR2 = 0; 
 WR3 = 0; 
 WR4 = 0;  
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 






 WR2 = 1; 
 WR3 = 1; 
 WR4 = 1; 
  
 // Bypassing inverse sinc function 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x20; // Address for corresponding register 
 P2 = 0x40; 
  
 _nop_(); _nop_();_nop_();_nop_();_nop_(); 
 WR1 = 0; // Writing I/O buffer 
 WR2 = 0; 
 WR3 = 0; 
 WR4 = 0;  
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 1; 
 WR2 = 1; 
 WR3 = 1; 
 WR4 = 1; 
 
// Setting up the frequency tuning words 5000hz->20c49ba5e3 for DDS I 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x09; // Address for corresponding register 
 P2 = 0xe3; 
 
 _nop_(); _nop_();_nop_();_nop_();_nop_(); 
 WR1 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x08; // Address for corresponding register 
 P2 = 0xa5; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x07; // Address for corresponding register 
 P2 = 0x9b; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x06; // Address for corresponding register 
 P2 = 0xc4; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR1 = 1; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x05; // Address for corresponding register 
 P2 = 0x20; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 







 WR1 = 1; 
  
// Setting up the frequency tuning words 7000hz->2de00d1b71 for DDS II 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x09; // Address for corresponding register 
 P2 = 0x71; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x08;// Address for corresponding register 
 P2 = 0x1b; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x07; // Address for corresponding register 
 P2 = 0x0d; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x06; // Address for corresponding register 
 P2 = 0xe0; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x05; // Address for corresponding register 
 P2 = 0x2d; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
     WR2 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR2 = 1; 
 
// Setting up the frequency tuning words 5000hz->20c49ba5e3 for DDS III 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x09; // Address for corresponding register 
 P2 = 0xe3; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x08; // Address for corresponding register 








 WR3 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x07; // Address for corresponding register 
 P2 = 0x9b; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x06; // Address for corresponding register 
 P2 = 0xc4; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x05; // Address for corresponding register 
 P2 = 0x20; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
     WR3 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR3 = 1; 
 
// Setting up the frequency tuning words 7000hz->2de00d1b71 for DDS IV 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x09; // Address for corresponding register 
 P2 = 0x71; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x08; // Address for corresponding register 
 P2 = 0x1b; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x07; // Address for corresponding register 
 P2 = 0x0d; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x06; // Address for corresponding register 








 WR4 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 1; 
  
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 P3 = 0x05; // Address for corresponding register 
 P2 = 0x2d; 
 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
    WR4 = 0; // Writing I/O buffer 
 _nop_();_nop_();_nop_();_nop_();_nop_(); 
 WR4 = 1; 
 
// Update the four DDS 
 for (i = 0;i < 1000;i++) // Time delay 
  _nop_();  
  
 UDCLK1 = 0; 
 UDCLK2 = 0; 
 UDCLK3 = 0; 
 UDCLK4 = 0; 
  
 for (i = 0;i < 1000;i++) // Time delay 
  _nop_(); 
  
 UDCLK1 = 1; // Externally updating both DDS 
     UDCLK2 = 1; 
 UDCLK3 = 1; 
 UDCLK4 = 1; 
 
   for (i = 0;i < 1000;i++) // Time delay 
  _nop_();  
  
 UDCLK1 = 0; 
 UDCLK2 = 0; 
 UDCLK3 = 0; 
 UDCLK4 = 0; 
 
 while(1); 






APPENDIX C – INPUT UNIT BACKPLANE BOM, SCHEMATIC, AND BOARD LAYOUT 
C1.  Bill of Materials 
Item Ref Part 
Desc. 
Package Specification Manufacturer/Source: PN 
1 R7, R8 0 Ohm SMT-1206 Thick film, 1/4W 5% Yageo: 9C12063A0R00JLHFT 
2 R2 33 Ohm SMT-1206 Thick film, 1/4W 1% Yageo: RC1206FR-0733RL 
3 R5, R6 50 Ohm SMT-1206 Thick Film, 1/4W 1% Yageo: RC1206FR-0749R9L 
4 R1, R3 10k SMT-1206 Thick film, 1/4W 1% Yageo: 9C12063A1002FKHFT 
5 R4 2k SMT-1206 Thick film, 1/4W 5% Yageo: 9C12063A2001JLHFT 
6 C1, C3, C6, C8, 
C9, C12, C13, 
C14, C16 
0.01uF SMT-0805 CERAMIC 10% 50V X7R AVX: 08055C103KAT2A 
7 C15 0.047uF SMT-0805 CERM .047UF 10% 50V 
X7R 
AVX: 08055C473KAT2A 
8 C2, C4, C11, 
C18, C19, C24 
0.1uF SMT 0805 CERM, 10%, 50V X7R Kemet: C0805C104K5RACTU 
9 C5, C7, C10, 
C17, C20, C21, 
C25 
10uF EIA-3216 Tantalum, 10V 10% AVX: TAJA106K010R 
10 C22, C23 250uF Radial FC CPOL, 25V  
11 IC6  SOL-14 Schmitt Trigger Hex, 
Inverter 
 
12 IC2  SOL-14 Quad, And gate  
13 IC1  QSOP-16 2:1 Mux  
14   SOIC-8 MPU Supervisor 3.08 WD  
15 U8  SOT-223 3.3V 2A Power Regulator  
 
Analog Dev:  ADP3338AKCZ-3.3 
16 IC4  PLCC44 Microcontroller Atmel: AT89S8252 
17 U$57  DIL08-4 10 MHz Chrystal Oscillator 
CMOS PROG 3.3V 0E 
Epson: SG-8002DC-MPT 
18 JP1  DIL-3 CONN HEADER VERT 3POS 
.100 TIN 
AMP/Tyco:  640452-3 
19 SW1  Gull-Wing SPST Switch TACT MOM 
SLD G-WING SMD 
C&K: KT11P2SM 
20 IC5  TO-220 LDO REG FIXED 5V 1.5A Linear Technology: LT1086CT-5 
21 U1  SOIC-8 IC RECEIVER ECL DIFF 3.3V 
8SOIC 
ON Semi: MC100LVEL16D 
22 Switch 
Connector 
 DIL-3 CONN HEADER VERT 3POS 
.100 TIN 
 























APPENDIX D  – LASER DIODE SPECIFICATIONS 





































APPENDIX E – DETECTION UNIT TIA AND RC HIGH-PASS FREQUENCY RESPONSE 


















APPENDIX F – DETECTOR BOARD BOM, SCHEMATIC, AND BOARD LAYOUT 
F1.  Detection BOM 
























































68nF 1210 CAP .068UF 16V PPS FILM 
1210 2% 
Digi-Key PCF1187CT-ND 





10uF 3216-18  CAP TANTALUM 10UF 16V 
10% SMD 
Digi-Key 478-1655-1-ND 















0.01uF 805 CAP 10000PF 50V CERAMIC 
X7R 0805 
Digi-Key 399-1158-1-ND 








14 C200,C203,C207 100pF 805 CAP CERAMIC 100PF 50V NP0 
0805 
Digi-Key 399-1122-1-ND 
15 D1,D2  SMB RECTIFIER GPP 400V 1A SMB Digi-Key S1GB-FDICT-ND 
16 FC1,FC2,FC3,FC4,FC5,FC6
,FC7,FC8 
  FIBER PLUG NIRx  















































4.7k 1206 RES 4.70K OHM 1/4W 1% 
1206 SMD 
Digi-Key 311-4.70KFRCT-ND 


























































187k 603 RES 187K OHM 1/0W 1% 
0603 SMD 
Digi-Key 311-187HRCT-ND 






4,R166,R189,R206 0603 SMD 
38 R99,R105,R134,R140,R17
4,R176,R205,R214 
15 1206 RES 15.0 OHM 1/4W 1% 1206 
SMD 
Digi-Key 311-15.0FRCT-ND 
39 R217 0 402 RES ZERO OHM 1/16W 5% 
0402 SMD 
Digi-Key P0.0JCT-ND 
40 R218,R219,R220 100 805 RES 100 OHM 1/8W 5% 0805 
SMD 
Digi-Key P100ACT-ND 









 8-SOIC IC LP INSTRUMENTATION 

















 8-SOIC IC OPAMP R-R IN/OUT HS 8-
SOIC 
Digi-Key AD8028ARZ-ND 
47 U57,U58  8-SOIC IC REF PREC LONOISE 2.50V 
8-SOIC 
Digi-Key ADR421BRZ-ND 
48 U59,U61  48-LQFP IC ADC 16BIT CMOS 5V 48-
LQFP 
Digi-Key AD7665ASTZRLCT-ND 
49 U60  14-SOIC IC QUAD 2IN POS OR GATE 
14-SOIC 
Digi-Key 296-1059-1-ND 
50 U62,U63  8-SOIC IC 5.0V 250MA LDO REG 8-
SOIC 
Digi-Key 296-2730-5-ND 
51 U64  TO-220 IC POS VOLT REG 8V 500MA 
TO-220 
Digi-Key 296-11136-5-ND 
52 U65  SOT-23-5 IC 100MA LDO LINEAR REG 
SOT23-5 
Digi-Key 296-15295-1-ND 
53 U66  TO-220 IC 8V NEGATIVE REGULATOR 
TO220F 
Digi-Key NJM79M08FA-ND 
54 U67  8-SOIC IC 3.3V 500MA LDO REG 8-
SOIC 
Digi-Key 296-2776-5-ND 





56 U69,U71,U73  16-SOL IC REGISTER SHIFT 8-BIT 16-
SOL 
Digi-Key TC74VHC595FNF-ND 




































APPENDIX G – DSP CODE 
G1.  Main.c 
#include "def21161.h"  
#include "Experiment_Parameters.h" 





int src = 0; // # of sources 
int det = 0; // # of detectors 
int wl_set = 0; // # of wavelength sets 
int im_cnt = 0; // # of image count 
 
double IDA[DETECTORS*SAMPLES/2] = {0};// incoming ADC data to for one source,16 detectors, 150 samples(1st det) .. 150 samples(last det)  
double IDB[DETECTORS*SAMPLES/2] = {0};// incoming ADC data for one source, 16 detectors 
double OUTPUT_W1[DETECTORS] = {0};//demodulated date for wavelength 1 
double OUTPUT_W2[DETECTORS] = {0};//demodulated date for wavelength 2 
 















 im_cnt = 0; 
  
 Initialize_DSP();// initialize registers upon starting up 
 Initialize_DMA();// initialize DMA register 
  
#ifdef MASTER_DSP // MASTER code 
  
 sysreg_bit_set(sysreg_IMASK, IRQ0I); 
  
interrupt(SIG_IRQ0,irqINTR); 
 interrupt(SIG_EP0I,ep0INTR);//EXT.port buffer 0 interrupt 
 interrupt(SIG_EP1I,ep1INTR);//EXT.port buffer 1 interrupt 
 interrupt(SIG_SP0I,sp0INTR);// sport0 interrupt 
  
 interrupt(SIG_SP1I,sp1INTR);// sport1 interrupt 





 while(1) { 








#else //SLAVE code 
 while(1) { 
  int flgfive = *(volatile int *)IOFLAG & 0x00000002; 






G2.  Initialize_DSP.c 
#include "Experiment_Parameters.h" 






#ifdef MASTER_DSP  
 // configure flag lines direction 
 *(volatile int *)IOFLAG = FLG5O | FLG9O; //select flag5,9 as output 
 *(volatile int *)IOFLAG &= ~FLG5; // output low, default 
 *(volatile int *)IOFLAG &= ~FLG9; // output low, default 
   
 // Configure interrupt registers 
 //sysreg_bit_clr(sysreg_MODE1, IRPTEN); // disable global interrupt  
  
 sysreg_bit_set(sysreg_MODE2, IRQ0E);  // set IRQ0 interrupts as edge-sensitive 
#endif  
 sysreg_bit_clr(sysreg_MODE1, NESTM);  // disable interrupt nesting 
  
 // Configure serial port register 
 *(volatile int *)DIV0 = 0;//clear serial port0 divisor register 
 *(volatile int *)DIV1 = 0x001f0007;//select the FS divisor for internal FS. the FS frequency under this  
                                      //value is about 12. (see page 10-36) 
 *(volatile int *)SPCTL0 = SLEN16 | CKRE | FSR | LAFS; // initialize SPORT0 register 
// enable 16 bit word length  
       // use rising edge for sampling data, 
        // require frame sync 
 // late FS  
 *(volatile int *)SPCTL1 = DDIR | SLEN32 | CKRE | FSR | LAFS | IFS; // enable transmit buffers (output port), 
        // choose and late transmit frame sync. 
        // use internal Frame sync 
        // require frame sync 
        // use rising edge for sampling data 




{            
 // initialize external port 0 DMA . 
 *(volatile int *)DMAC10 = MASTER|MSWF|PMODE6|TRAN; 
// disable external handshake mode, enable master  
   // mode (DSP is master),MSW first during packing, 8 bit external 
   // to 32/64 bit internal packing,  
   // transmit data from internal memory for the  
   // DMA channel 10 external port FIFO buffer. 
  






 *(volatile int *)SYSCON |= HBW16; // set host bus width to 16 bit 
 *(volatile int *)DMAC11 = HSHAKE | MASTER | PMODE1;// enable handshake mode, enable master    
  // mode (DSP is master),LSW first during packing, 16 bit external 
     // to 32/64 bit internal packing,  
     // receive data from external memory for the  
     // DMA channel 10 external port FIFO buffer. 
     // initialize serial port 0 DMA 
     // initialize serial port 1 DMA 
} 
 
G3.  myIRQ.c 













void ep0INTR()// External port 0 uploads demodulated imaging data to DAQ 
{ 
 *(volatile int*)DMAC10&= ~DEN;;//disable EXT. port 0 DMA   
} 
 
void ep1INTR()// External poart 1 downloads imaging parameter and gainbits from DAQ 
{ 
// sysreg_bit_clr(sysreg_IMASK, EP1I);;//clear the DMA1 interrupt  
 *(volatile int*)DMAC11&= ~DEN;//disable EXT. port 1 DMA 
} 
 
void sp0INTR()// serial port 0 receives modulated imaging data 
// DMA is automatically disabled 
{ 
 
 sysreg_bit_clr(sysreg_IMASK, SP0I);;//disable SPORT0 interrupt 
 *(volatile int *)SPCTL0&= ~SPEN_A;// disable serial port 0A 
 *(volatile int *)SPCTL0&= ~SPEN_B;// disable serial port 0B 
 *(volatile int *)SPCTL0&= ~SDEN_A;// disable serial port 0A DMA 




void sp1INTR()// serial port 1 sends gainbit data to CPLD 
// DMA is automatically disabled 
{ 
 sysreg_bit_clr(sysreg_IMASK, SP1I);;//disable SPORT1 interrupt  
 *(volatile int *)SPCTL1&= ~SPEN_A;// disable serial port 1A 
 *(volatile int *)SPCTL1&= ~SPEN_B;// disable serial port 1B 
 *(volatile int *)SPCTL1&= ~SDEN_A;// disable serial port 1A DMA 
 *(volatile int *)SPCTL1&= ~SDEN_B;// disable serial port 1B DMA 
} 
 
void tmINTR()//timer interrupt 
{ 






 sysreg_bit_clr(sysreg_IMASK, TMZHI);// disable timer interrupt with high priority 
 timer_off();//disable timer 
} 
 
G4.  Pc_instruction.c 
#include "def21161.h"  
#include "Experiment_Parameters.h" 
 














  while(1)// hold until flag2=1 
  { 
   if ( poll_flag_in(DIO_PLD0,5) == 1 ) break;// CPLD sends out 1 while in standby 
  }; 
  
  //if flag0=0 and flag1=0 then turn on LED and keep rolling 
  if ( poll_flag_in(DIO_PC0,5) == 0 && poll_flag_in(DIO_PC1,5) == 0 ) 
  { 
   Turn_on_LED(); 
   break; 
  }; 
  
  // if flag0=1 and flag1=0 then get imaging parameters from PC 
  if ( poll_flag_in(DIO_PC0,5) == 1 && poll_flag_in(DIO_PC1,5) == 0 ) getImpar(); 
   
  // if flag0=0 and flag1=1 then download gainbits from PC 
  if ( poll_flag_in(DIO_PC0,5) == 0 && poll_flag_in(DIO_PC1,5) == 1 ) downGbit(); 
   
  // if flag1=1 and flag1=1 then take new image 






G5.  LED.c 















 *(volatile int *)IOFLAG &= ~FLG9; // output low 
} 
 
G6.  ImParameters.c 
#include "def21161.h"  
#include "Experiment_Parameters.h" 
#include <processor_include.h>  
#include <sysreg.h> 
 
extern int src;// # of sources 
extern int det;// # of detectors 




// Labview sends the source/detector information to the DSP 
// This subroutine sets up the data transfer between the PC and DSP using a small DMA  
// sequence.  
 *(volatile int*)IIEP1 = (int) (&src);//DMA Ch11 Index Register set to address of src 
 *(volatile int*)IMEP1 = 0x1;//DMA Ch11 Modify Register = 1 
 *(volatile int*)CEP1 = 0x1; //DMA Ch11 Count Register = 1 
 *(volatile int*)GPEP1 = 0; //DMA Ch11 General Purpose Register = 0 
 *(volatile int*)EIEP1 = 0x0C000000; //DMA Ch11 External Index Register = 0x0C000000 
 *(volatile int*)EMEP1 = 0x1; //DMA Ch11 External Modify Register = 1 
 *(volatile int*)ECEP1 = 0x2; //DMA CH11 External Count Register = 2  
 *(volatile int*)CPEP1 = 0;//DMA CH11 Chain Pointer Register = 0 (no chaining) 
 
  
 //sysreg_bit_set(sysreg_IMASK, EP1I); // enable DMA 11 interrupt 
 *(volatile int*)DMAC11 |= DEN;//0x01; // DEN=1 // Enable DMA channel 11 
 
 while(1) { 
   if(sysreg_bit_tst(sysreg_IRPTL, EP1I)) { 
    sysreg_bit_clr(sysreg_IRPTL, EP1I); 
    *(volatile int*)DMAC11 &= ~DEN; 
    break;  //this bit shows if the interrupt has fired 
   } 
  } 
 // Splits the data word into variables src (16 LSB) and det (16 MSB) 
  
 while(1) //Make sure that we're not requesting an IRQ anymore so that we can return to standby 
 { 
  if ( poll_flag_in(DIO_PC0,5) == 0 ) break; 
 } 
  
 int temp; 
 temp = src; 
 src = src & 0x0000003F; // clear 16 MSB of src (plus additional 8MBS for now) 
  
 //Extract the number wavelength sets embedded in the source number 
 if((temp & 0x00000040) > 0) { wl_set = 2; } 
 else { wl_set = 1; } 
  
 det = temp >> 0x10; // right shit temp by 16 bits, set det to the 16 MSB of src 








G7.  Gain_Bit.c 
#include "def21161.h"  
#include "Experiment_Parameters.h" 




extern int src; // # of sources 
extern int det; // # of detectors 
extern int wl_set; // # of wavelength sets 
 
void downGbit(void) //Ext. Port Buffer 1 DMA  
{ 
 if ( poll_flag_in(DIO_PC1,5) == 0 ) 




  // compute the size of memory used for gain bits 
  int total_word32 = ceil(SOURCES * wl_set * det * GAINBITS / 32); 
  int count_size = det * GAINBITS / 32; 
    
  *(volatile int*)DMAC11 &= ~DEN; 
    
  // setup transer channels over the external port  
  *(volatile int*)IIEP1 = (int) (&GB);//DMA Ch11 Index Register set to address  
  *(volatile int*)IMEP1 = 0x1;//DMA Ch11 Modify Register = 1 
  *(volatile int*)CEP1 = total_word32*2; //DMA Ch11 Count Register = total_word32 * 2 for left and right 
  *(volatile int*)GPEP1 = 0; //DMA Ch11 General Purpose Register = 0 
  *(volatile int*)EIEP1 = 0x0C000000; //DMA Ch11 External Index Register = 0x0C000000 
  *(volatile int*)EMEP1 = 0x1; //DMA Ch11 External Modify Register = 1 
  *(volatile int*)ECEP1 = 4 * total_word32; //DMA CH11 External Count Register = 2 x total_word32, because the buffer is 
16 bits. 
 
  *(volatile int*)EP1I = 1;// enable DMA 11 interrupt 
  *(volatile int*)DMAC11 |= DEN; // Enable DMA channel 11 transfer of gainbits from Labview to DSP - also enable chaining 
 
  while(1) { 
   if(sysreg_bit_tst(sysreg_IRPTL, EP1I)) { 
    sysreg_bit_clr(sysreg_IRPTL, EP1I); 
    *(volatile int*)DMAC11 &= ~DEN; 
    break;  //this bit shows if the interrupt has fired 
   } 
  } 
   
  // Make sure to disable any dma on the sport1 channel so that we can 
  // first put the cpld into gb and send the # of sources 
  *(volatile int*)SPCTL1 &= (~SDEN_A & ~SDEN_B & ~SENDN & ~SPEN_B & ~SPEN_A); 
   
   
  // configure the DMA for serial port 1A 
  *(volatile int*)II1A = (int)GB; 
  *(volatile int*)GP1A = 0;// DMA General purpose register =0 
  *(volatile int*)CP1A = 0;// DMA chain pointer register=0 
  *(volatile int*)IM1A = 0x1;// DMA internal modify register=1 
  *(volatile int*)C1A = total_word32; // DMA internal counter register 
   
  // configure the DMA for serial port 1B 
  *(volatile int*)II1B = (int)GB + total_word32; 
  *(volatile int*)GP1B = 0;// DMA General purpose register =0 
  *(volatile int*)CP1B = 0;// DMA chain pointer register=0 






  *(volatile int*)C1B = total_word32; // DMA internal counter register 
   
   
  // Tell CPLD to go to gainbit state by setting FS for a word at port 1A (data = 0).     
     
  sysreg_bit_clr(sysreg_IMASK, SP1I); // enable sport 1 interrupt 
  *(volatile int*)SPCTL1 &= ~FS_BOTH;// enable sport 1A 
  *(volatile int*)TX1A = 0; 
  *(volatile int*)SPCTL1 |= SPEN_A;// enable sport 1A 
   
  poll_flag_in(DIO_PLD1,0); // wait for CPLD to confirm it is in gainbit state (flag3 pulses high) 
   
   
  // send src # and wl_set# to CPLD before sending gainbit through 1A 
  sysreg_bit_clr(sysreg_IMASK, SP1I); // enable sport 1 interrupt      
  *(volatile int*)SPCTL1 |= SPEN_A;// enable sport 1A 
  *(volatile int*)TX1A = (src*wl_set) | ((wl_set-1) << 0x07); 
    
  poll_flag_in(DIO_PLD1,0); 
   
  int src_pos = 0; 
     
  while ( src_pos < src*wl_set) 
  { 
  
   *(volatile int*)SPCTL1 &= (~SDEN_A & ~SDEN_B); 
   *(volatile int*)SPCTL1 |= (SENDN | SPEN_A | SPEN_B); 
    
   // configure the DMA for serial port 1A 
   *(volatile int*)II1A = (int)GB + src_pos*count_size;  
   *(volatile int*)GP1A = 0;// DMA General purpose register =0 
   *(volatile int*)CP1A = 0;// DMA chain pointer register=0 
   *(volatile int*)IM1A = 0x1;// DMA internal modify register=1 
   *(volatile int*)C1A = count_size; // DMA internal counter register 
   
   // configure the DMA for serial port 1B 
   *(volatile int*)II1B = (int)GB + total_word32 + src_pos*count_size;  
   *(volatile int*)GP1B = 0;// DMA General purpose register =0 
   *(volatile int*)CP1B = 0;// DMA chain pointer register=0 
   *(volatile int*)IM1B = 0x1;// DMA internal modify register=1 
   *(volatile int*)C1B = count_size; // DMA internal counter register 
    
   src_pos++; 
    
   // send gainbits 
   //sysreg_bit_set(sysreg_IMASK, SP1I); // enable sport 1 interrupt  
   *(volatile int*)SPCTL1 |= (SDEN_A | SDEN_B);// LSB first, enable sport1 and its DMA for both A and B  
   //idle();// wait for interrupt; 
    
   poll_flag_in(DIO_PLD1,0); 
   
  } 
   
  poll_flag_in(DIO_PLD0,2);  //wait for CPLD to get into standby state (flag2=1)  
  
   
  while(1) //Make sure that we're not requesting an IRQ anymore so that we can return to standby 
  { 
   if ( poll_flag_in(DIO_PC1,5) == 0 ) break; 









G8.  Imaging.c 





extern int im_cnt;// # of image count 
extern int IDA[]; // incoming ADC data 
extern int IDB[]; // incoming ADC data 
extern double OUTPUT_W1;// demodulated date for wavelength 1 
extern double OUTPUT_W2;// demodulated date for wavelength 2 
extern int src; // # of sources 
extern int det; // # of detectors 
extern int wl_set; // # of wavelength sets 
 





 im_cnt++; // for each frame 
  
 // set general purpose register and chain pointer registers for DMA serial port 0 
 *(volatile int *)GP0A = 0; 
 *(volatile int *)GP0B = 0; 
 *(volatile int *)CP0A = 0; 
 *(volatile int *)CP0B = 0; 
 
 *(volatile int *)C0A = 16*SAMPLES;//32 src * 32 det * 150 samples / 2 
 *(volatile int *)C0B = 16*SAMPLES;// 
   
 // set internal modify register = 1 
 *(volatile int *)IM0A = 1; 
 *(volatile int *)IM0B = 1; 
  
 // set internal index register -> IDA 
 *(volatile int *)II0A = (int) (&IDA); 
 
 // set internal index register -> IDB 
 *(volatile int *)II0B = (int) (&IDB); 
  
  
 *(volatile int*)DMAC10 &= ~DEN; //Disable DMA channel 10 until we're ready 
 //configure Ext. Port Buffer 0 for sending demodulated data to PC 
 *(volatile int*)IIEP0 = (int) (&OUTPUT_W1);//DMA Ch10 Index Register set to address of OUTPUT_W1 
 *(volatile int*)IMEP0 = 0x1;//DMA Ch10 Modify Register = 1 
 *(volatile int*)CEP0 = DETECTORS * 0x2; //DMA Ch10 Count Register = 2*32 
 *(volatile int*)GPEP0 = 0; //DMA Ch10 General Purpose Register = 0 
 *(volatile int*)EIEP0 = 0x08000000; //DMA Ch10 External Index Register = 0x0C000000,/us2 cleared, write to FIFO 
 *(volatile int*)EMEP0 = 0x1; //DMA Ch10 External Modify Register = 1 
 *(volatile int*)ECEP0 = DETECTORS * 0x8; //DMA CH10 External Count Register = 4*32  
  
 sysreg_bit_clr(sysreg_IRPTL, EP0I | SP0I | TMZHI); 
  
 int src_pos = 0; 
 int count_val = 0;  
 
#ifdef MASTER_DSP //only the Master DSP needs to control the CPLD (put it into imaging state, start the timer) 
 // set timer for the settling time 
 timer_off();  
 //timer_set (0x7A120, 0x7A120);// 5ms 






 //timer_set (0x927C0, 0x927C0); // 6ms 
 sysreg_bit_clr(sysreg_IMASK, TMZLI); 
   
 // DSP notify CPLD to start passing the first source imaging data 
 *(volatile int *)IOFLAG |= FLG5;// send imaging request to CPLD 
 
 while ( src_pos < src*wl_set) 
 { 
   
  while(1) 
  { 
   if ( poll_flag_in(DIO_PLD1,5) == 1 )  
   { 
    break;// FLAG3 tells DSP to start the timer (switch settled)  
   } 
  } 
  sysreg_bit_set(sysreg_IMASK, SP0I | TMZHI); // enable timer interrupt with high priority and enable sport 0 interrupt 
  timer_set (0xAAE60, 0xAAE60); 
  timer_on();// start timer 
 
#else 
 while ( src_pos < 2*SOURCES) //when it is the slave running it just waits for the CPLD to be finished 
 {    //the CPLD knows # of sources it needs to send, but Slave DSP doesn’t  
     //(max # of iterations is 32 sources * 2 wavelength sets) 
  sysreg_bit_set(sysreg_IMASK, SP0I); // enable sport 0 interrupt 
#endif   
  //Send out the data to the PC from the previous source while we're waiting for the timer to expire 
  //This takes ~1.7ms, fast enough that it will complete before the 5ms timer 
  if(src_pos > 0) { 
   deModulation(); 
    
   //Configure the External DMA register to send WL1 data 
   *(volatile int*)IIEP0 = (int) (&OUTPUT_W1);//DMA Ch10 Index Register set to address of OUTPUT_W1 
   *(volatile int*)CEP0 = DETECTORS; //DMA Ch10 Count Register = 32 
   *(volatile int*)ECEP0 = DETECTORS * 0x4; //DMA CH10 External Count Register = 4*32 (Each 32-bit word is 
broken up into 4 8-bit writes) 
   *(volatile int*)EIEP0 = 0x08000000; //DMA Ch10 External Index Register = 0x0C000000,/us2 cleared, write to 
FIFO 
   *(volatile int*)DMAC10 |= DEN; //Enable DMA channel 10, send WL1 data to buffer 
   
   while(1) { 
    if(sysreg_bit_tst(sysreg_IRPTL, EP0I)) { 
     sysreg_bit_clr(sysreg_IRPTL, EP0I); 
     *(volatile int*)DMAC10 &= ~DEN; 
     break;  //this bit shows if the interrupt has fired 
    } 
   } 
   
   //Configure the External DMA register to send WL2 data 
   *(volatile int*)IIEP0 = (int) (&OUTPUT_W2);//DMA Ch10 Index Register set to address of OUTPUT_W1 
   *(volatile int*)CEP0 = DETECTORS; //DMA Ch10 Count Register = 32 
   *(volatile int*)ECEP0 = DETECTORS * 0x4; //DMA CH10 External Count Register = 4*32 (Each 32-bit word is 
broken up into 4 8-bit writes)  
   *(volatile int*)EIEP0 = 0x08000000; //us2 cleared, write to FIFO 
   *(volatile int*)DMAC10 |= DEN; //Enable DMA channel 10, send WL1 data to buffer 
   
   while(1) { 
    if(sysreg_bit_tst(sysreg_IRPTL, EP0I)) { 
     sysreg_bit_clr(sysreg_IRPTL, EP0I); 
     *(volatile int*)DMAC10 &= ~DEN; 
     break;  //this bit shows if the interrupt has fired 
    } 
   } 







  // Reconfigure the SPORT0 DMA registers so that they're ready to go again 
  *(volatile int *)II0A = (int) (&IDA); // set internal index register -> IDA 
  *(volatile int *)II0B = (int) (&IDB); // set internal index register -> IDB  
  *(volatile int *)C0A = 16*SAMPLES;//32 det * 150 samples / 2 (A&B streams) 
  *(volatile int *)C0B = 16*SAMPLES;// 
 
  
  *(volatile int *)SPCTL0 |= ( SPEN_A | SDEN_A | SPEN_B | SDEN_B );// enable sport0, start taking in ADC data 
   
  //Wait for the Sport interrupt to let us know we've received the data 
#ifdef MASTER_DSP   
  while(1) { 
   count_val = *(volatile int *)C0A; //A and B have the same sync, so once one of them 
   if(count_val == 0) {  // when count_val==0 then we know they are both done.  This could be done more 
elegantly with SPOI, but I couldn’t get the interrupt to trigger properly. 
   //if(sysreg_bit_tst(sysreg_IRPTL, SP0I)) { 
    sysreg_bit_clr(sysreg_IRPTL, SP0I | TMZHI); 
    *(volatile int *)SPCTL0 &= ~( SPEN_A | SDEN_A | SPEN_B | SDEN_B ); 
    break;  //this bit shows if the interrupt has fired 
   } 
   else if(count_val == 4*SAMPLES) { 
    *(volatile int *)IOFLAG &= ~FLG5;// now that CPLD has understood, stop sending IMST 
   } 
  } 
  
#else 
  while(1) { 
   count_val = *(volatile int *)C0A; //A and B have the same sync, so once one of them 
   if(count_val == 0) {   
   //if(sysreg_bit_tst(sysreg_IRPTL, SP0I) || poll_flag_in(DIO_PLD0,5) == 1) { 
    sysreg_bit_clr(sysreg_IRPTL, SP0I); 
    *(volatile int *)SPCTL0 &= ~( SPEN_A | SDEN_A | SPEN_B | SDEN_B ); 
    break;  //this bit shows if the interrupt has fired 
   } 
  } 
   
#endif   
     
  src_pos = src_pos+1; 
  if ( poll_flag_in(DIO_PLD0,5) == 1 ) break;// FLAG2 tells DSP that data acquisition is complete because we're 
back in standby. 
   
 }; 
  
 //We still have one source worth of data to send back to the PC 
 deModulation(); 
    
 //Configure the External DMA register to send WL1 data 
 *(volatile int*)IIEP0 = (int) (&OUTPUT_W1);//DMA Ch10 Index Register set to address of OUTPUT_W1 
 *(volatile int*)CEP0 = DETECTORS; //DMA Ch10 Count Register = 2*32 
 *(volatile int*)ECEP0 = DETECTORS * 0x4; //DMA CH10 External Count Register = 8*32  
 *(volatile int*)EIEP0 = 0x08000000; //DMA Ch10 External Index Register = 0x0C000000,/us2 cleared, write to FIFO 
 *(volatile int*)DMAC10 |= DEN; //Enable DMA channel 10, send WL1 data to buffer 
   
 while(1) { 
  if(sysreg_bit_tst(sysreg_IRPTL, EP0I)) { 
   sysreg_bit_clr(sysreg_IRPTL, EP0I); 
   *(volatile int*)DMAC10 &= ~DEN; 
   break;  //this bit shows if the interrupt has fired 
  } 
 } 
   






 *(volatile int*)IIEP0 = (int) (&OUTPUT_W2);//DMA Ch10 Index Register set to address of OUTPUT_W1 
 *(volatile int*)CEP0 = DETECTORS; //DMA Ch10 Count Register = 2*32 
 *(volatile int*)ECEP0 = DETECTORS * 0x4; //DMA CH10 External Count Register = 8*32  
 *(volatile int*)EIEP0 = 0x08000000; // us2 cleared, write to FIFO 
 *(volatile int*)DMAC10 |= DEN; //Enable DMA channel 10, send WL1 data to buffer 
  
 while(1) { 
  if(sysreg_bit_tst(sysreg_IRPTL, EP0I)) { 
   sysreg_bit_clr(sysreg_IRPTL, EP0I); 
   *(volatile int*)DMAC10 &= ~DEN; 
   break;  //this bit shows if the interrupt has fired 
  } 
 } 
  
 *(volatile int *)IOFLAG &= ~FLG5; 
} 
 
G9.  Demodulation.c 
#include "def21161.h"  
#include "Experiment_Parameters.h" 
#include <matrix.h>  
#include <math.h>  
#include "Ref_sig.h" 
 
extern int IDA[]; 
extern int IDB[]; 
extern double OUTPUT_W1[]; 
extern double OUTPUT_W2[]; 
extern double RI5k7k[][]; 




 int j;// index for samples  
 int i;// index for det 
  
 double scaling = 13107; //((2^16)-1)/5 : divide by this factor to turn the number into a voltage; 
  
 //Inphase Reference Matrix 
 double *m1 = (double *) (&RI5k7k); 
  
 //Quadrature Reference Matrix 
 double *m2 = (double *) (&RQ5k7k); 
  
 //Sample Matrix 
 double datMat[SAMPLES]; 
 double *m0 = (double *) (&datMat); 
  
 //Mixed Matrix 
 double XMat[COLOURS][1];// inphase 
 double YMat[COLOURS][1];// quadrature 
 double *m3 = (double *) (&XMat), *m4 = (double *) (&YMat); 
  
 //This hash is required in order to resort the detectors back into their correct order (undoes the muxing from chip select, etc). 
 int Det_Hash[DETECTORS] = {2, 0, 10, 8, 18, 16, 26, 24, 3, 1, 11, 9, 19, 17, 27, 25, 6, 4, 14, 12, 22, 20, 30, 28, 7, 5, 15, 13, 23, 21, 31, 
29}; 
  
 // compute chain A (port A data) 







  //get the sample matrix 
  for ( j = 0; j < SAMPLES ; j++) 
   datMat[j] = (double) IDA[1+16*j]; 
  //datMat[j] = (double) IDA[i+16*j]; // Extract the samples from the given detector (always spaced 16 entries apart) 
   
  //multiply the matrices 
  matmmlt (m3, m1, m0, COLOURS, SAMPLES, 1);//inphase mix 
  matmmlt (m4, m2, m0, COLOURS, SAMPLES, 1);//quadrature mix     
   
  //take the square root of the real part squared plus the imag. part squared to get the amplitude.  
 OUTPUT_W1[Det_Hash[i]] = sqrtf( (XMat[0][0] - 2.5) * (XMat[0][0]-2.5) + (YMat[0][0]-2.5) * (YMat[0][0]-2.5) ) / SAMPLES / scaling; 
  OUTPUT_W2[Det_Hash[i]] = sqrtf( XMat[1][0] * XMat[1][0] + YMat[1][0] * YMat[1][0] ) / SAMPLES / scaling; 
 
 };   
  
 int det_div_2 = DETECTORS/2; 
     
 // compute chain B (port B data) 
 for ( i = det_div_2; i < DETECTORS ; i++ ) 
 { 
  //get the sample matrix 
  for ( j = 0; j < SAMPLES ; j++) 
   datMat[j] = (double) IDA[1+16*j]; 
   //datMat[j] = (double) IDB[i-det_div_2+16*j]; // Extract the samples from the given detector (always spaced 
16 entries apart) 
   
  //multiply the matrices 
  matmmlt (m3, m1, m0, COLOURS, SAMPLES, 1);//inphase mix 
  matmmlt (m4, m2, m0, COLOURS, SAMPLES, 1);//quadrature mix     
    
  //take the square root of the real part squared plus the imag. part squared to get the amplitude.  
  OUTPUT_W1[Det_Hash[i]] = sqrtf( XMat[0][0] * XMat[0][0] + YMat[0][0] * YMat[0][0] ) / SAMPLES / scaling; 






G10.  ExperimentParameters.h 
#define MASTER_DSP  // Define whether we are compiling master or slave code 
 
#define PCI    0x20000       //bit 17 - enables per-chain interupts   
#define GAINBITS    3   
#define SOURCES        32 
#define DETECTORS      32   // two DSPs on each board, so 64/2=32 
#define SAMPLES   150 
#define COLOURS 2    //number of wavelengths per set 
#define DIO_PC0   0 
#define DIO_PC1   1 
#define DIO_PLD0  2 
#define DIO_PLD1  3 
#define DIO_IMST  FLG5 








APPENDIX H – CPLD CODE 
H1.  CPLD_breast_imager_master.pld 
/* *************** INPUT PINS *********************/ 
PIN 12  = en;   /* Enable */  
PIN 83  = clk;   /* PLD Clock */ 
 
PIN 75  = timexp; /* Timer from DSP*/ 
 
PIN 20  = TF;   /* DSP Transmit Frame */  
PIN 21  = TDA;   /* DSP Transmit Data A */  
PIN 22  = TDB;   /* DSP Transmit Data B */  
PIN 35 = IMST;  /* Imaging Start from DSP - active low*/ 
 
/* TEMP DEBUG PINS */ 
PIN 27 = dbg1; 
PIN 28 = dbg2; 
PIN 39 = dbg3; 
PIN 40 = dbg4; 
PIN 41 = dbg5; 
 
/* *************** OUTPUT PINS ********************* */ 
PIN 70 = FG2;  /* Control line to DSP 1 */ 
PIN 15  = FG3;  /* Control line to DSP 2 */ 
 
PIN 17  = fr;   /* FIFO read signal */ 
PIN 81  = !fw;   /* FIFO write signal */ 
PIN 79  = !ffrst;   /* FIFO reset signal */ 
PIN 68  = frt;   /* FIFO retransmit signal */ 
PIN 69  = GBL;  /* Output to left-breast shift register */ 
PIN 74 = GBR;  /* Output to right-breast shift register */ 
PIN 16  = ssclk;   /* To be AND gated with clock and then becomes shift register input clock */ 
PIN 24  = srclk;   /* To be AND gated with clock and then becomes shift register output clock */ 
PIN 25 = scl;  /* Clear the shift register */ 
 
PIN 18 = cnvst;  /* Convert State - Used to switch between ADC cores */ 
 
PIN 80  = A0;   /* Channel address bit sent to every ADC */ 
PIN 56  = cs1;   /* Chip select signal for cards 1&2&3&4 */ 
PIN 54  = cs2;   /* Chip select signal for cards 5&6&7&8 */ 
PIN 57  = cs3;   /* Chip select signal for cards 9&10&11&12 */ 
PIN 55  = cs4;   /* Chip select signal for cards 13&14&15&16 */ 
 
PIN 29  = PS0;  /* Output to optical switch */ 
PIN 30  = PS1;  /* Output to optical switch */ 
PIN 31  = PS2;  /* Output to optical switch */ 
PIN 33  = PS3;  /* Output to optical switch */ 
PIN 34  = PS4;  /* Output to optical switch */ 
PIN 36  = PS5;  /* Output to optical switch */ 
PIN 37  = PS6;  /* Output to optical switch */ 
 
 
/* *************** PINNODES ********************* */ 
/* Main State Machine Variables */ 
PINNODE = M1; 
PINNODE = M0; 
 
/* Inputs from the DSP - TF is the frame synchronizer and TDA and TDB are the data lines. */ 






PINNODE = TF_1; 
PINNODE = TDA_0; 
PINNODE = TDA_1; 
PINNODE = TDA_2; 
PINNODE = TDA_3; 
PINNODE = TDA_4; 
PINNODE = TDA_5; 
PINNODE = TDA_6; 
PINNODE = TDA_7; 
PINNODE = TDA_8; 
PINNODE = TDB_0; 
PINNODE = IMST_0; 
 
/* Gainbit State Machine Variables */ 
PINNODE = G2; 
PINNODE = G1; 
PINNODE = G0; 
 
/* Signal to increment the source counter */ 
PINNODE = src_cntr; 
 
/* Holds the number of sources programmed at the beginning of the gainbit state */ 
PINNODE = src0; 
PINNODE = src1; 
PINNODE = src2; 
PINNODE = src3; 
PINNODE = src4; 
PINNODE = src5; 
PINNODE = src6; 
PINNODE = wl_sets; 
 
/* Counts which source we are programming the gainbits for */ 
PINNODE = gsc0; 
PINNODE = gsc1; 
PINNODE = gsc2; 
PINNODE = gsc3; 
PINNODE = gsc4; 
PINNODE = gsc5; 
PINNODE = gsc6; 
 
/* Imaging State Machine Variables */ 
PINNODE = IM0; 
PINNODE = IM1; 
PINNODE = IM2; 
 
/* Finished Imaging (all samples, sources, and cs) */ 
PINNODE = f_img; 
 
/* Counters for source positions, samples, and the sample enable (whether to allow the sample counter to run */ 
PINNODE = srcpos_cntr; 
PINNODE = smpl_cntr; 
PINNODE = smpl_en; 
 
/* Flopped version of the TIMEXP input from the DSP */ 
PINNODE = time; 
 
/* Conversion state counters - counts to 70 cycles (time for the ADC to convert) */ 
PINNODE = cwc0; 
PINNODE = cwc1; 
PINNODE = cwc2; 
PINNODE = cwc3; 
PINNODE = cwc4; 
PINNODE = cwc5; 







PINNODE = f_cnvt; /*Finished the conversion state 70 cycle delay*/ 
 
/* Sample Counter counts to 300 (150 samples for each detector A0=0 and A0=1) */ 
PINNODE = csmp0; 
PINNODE = csmp1; 
PINNODE = csmp2; 
PINNODE = csmp3; 
PINNODE = csmp4; 
PINNODE = csmp5; 
PINNODE = csmp6; 
PINNODE = csmp7; 
PINNODE = csmp8; 
 
PINNODE = f_smpl; /* Goes high when csmp has counted to 300 */ 
 
/* Send Data Counter - counts to 126 */ 
PINNODE = sdc0; 
PINNODE = sdc1; 
PINNODE = sdc2; 
PINNODE = sdc3; 
PINNODE = sdc4; 
PINNODE = sdc5; 
PINNODE = sdc6; 
 
PINNODE = f_sd; /*Finished sending all 126 bits of data - 16 bits per detector, 2 detectors per ADC and 4 cs)*/ 
 
PINNODE = ls; /* Goes high when imaging data has been sent for every source */ 
 
/* Source position counter - keeps track while imaging, which source positions have been completed */ 
PINNODE = spc0; 
PINNODE = spc1; 
PINNODE = spc2; 
PINNODE = spc3; 
PINNODE = spc4; 
PINNODE = spc5; 
PINNODE = spc6; 
 
/*flag3 and flag3_d are in order to spread out the FG3 output to the DSP to make it longer, thus giving it a higher chance of the DSP catching it 
*/ 
PINNODE = flag3; 
PINNODE = flag3_d; 
 
/*Optical Switch Timer Counters*/ 
PINNODE = swtch_cntr0; 
PINNODE = swtch_cntr1; 
PINNODE = swtch_cntr2; 
PINNODE = swtch_cntr3; 
PINNODE = swtch_cntr4; 
PINNODE = swtch_cntr5; 
PINNODE = swtch_cntr6; 
PINNODE = swtch_cntr7; 
PINNODE = swtch_cntr8; 
PINNODE = swtch_cntr9; 
 
/*For expanding the read clock pulse*/ 
PINNODE = fr1; 
PINNODE = fr2; 
PINNODE = fr3; 
 
/*Optical Switch stobe counters & state machine pinnodes */ 
PINNODE = T0; 
PINNODE = T1; 






PINNODE = strobe_counter; 
PINNODE = strobe_init; 
PINNODE = switch_cntr_hold; 
 
/* *************** MAIN STATE MACHINE ***************** */ 
 
field MSM = [M1..0]; 
$define initial 'b'00 
$define standby 'b'01 
$define gainbit 'b'10 
$define imaging 'b'11 
 
[M1..0].ck = clk; 
 
SEQUENCED MSM { 
 
 present initial if (!en)    next initial; 
    if (en & !IMST_0)  next standby; 
 
 present standby if (!en)    next initial; 
   if (en & !TF_0 & TF_1 & !TDA_1)  next gainbit out ffrst out flag3; 
   if (en & IMST_0 )    next imaging out flag3; 
   default     next standby; 
  
 present gainbit if (!en)    next initial; 
   if (en & f_gb)    next standby; 
   if (en & !f_gb)    next gainbit; 
  
 present imaging if (!en)    next initial; 
   if (en & f_img)    next standby; 
   if (en & !f_img)   next imaging; 
 
} 
ffrst.ck = clk; 
FG2.ck = clk; 
FG2.d = en & !M1 & M0; 
 
flag3.ck = clk; 
 
flag3_d.ck = clk; 
flag3_d.d = flag3; 
 
FG3.ck = clk; 
FG3.d = flag3 # flag3_d; 
 
IMST_0.d = IMST; 
IMST_0.ck = clk; 
 
TF_0.d = TF; 
TF_1.d = TF_0; 
TDA_0.d = TDA; 
TDB_0.d = TDB; 
[TDA_1..8].d = [TDA_0..7]; 
[TF_0..1].ck = clk; 
[TDA_0..8].ck = clk; 
TDB_0.ck = clk; 
 
/* *************** GAINBIT STATE MACHINE ***************** */ 
 
field GBSM = [G2..0]; 
$define gb_init  'b'000 
$define gb_getsrc 'b'001 
$define gb_cnt96 'b'010 






$define gb_fifo 'b'100 
$define gb_loop 'b'101 
$define gb_undef1 'b'110 
$define gb_undef2 'b'111 
 
[G2..0].ck = clk; 
 
SEQUENCED GBSM { 
 
 present gb_init  if (en & M1 & !M0 & ffrst)  next gb_getsrc out flag3; 
    default    next gb_init; 
  
 present gb_getsrc  if (!en # !M1 # M0)   next gb_init; 
    if (en & M1 & !M0 & f_getsrc)  next gb_cnt96 out flag3 out src_cntr; 
    default    next gb_getsrc; 
 
 present gb_cnt96  if (!en # !M1 # M0)   next gb_init; 
    if (en & M1 & !M0 & f_gb_upload) next gb_fifo out scl out srclk; 
    default    next gb_cnt96 out scl; 
  
 present gb_fifo  if (!en # !M1 # M0)   next gb_init; 
    default    next gb_loop out fw; 
 
 present gb_loop  if (!en # !M1 # M0)   next gb_init; 
    if (en & M1 & !M0 & f_gb)  next gb_init out flag3; 
    default    next gb_cnt96 out flag3 out src_cntr; 
 
 present gb_undef1      next gb_init; 
  




f_getsrc = !TF_0 & TF_1 & !G2 & !G1 & G0; 
 
fw.ck = clk; 
 
src_cntr.ck = clk; 
 
 
/* Counter for keeping track of how many sources have been programmed for the experiment */ 
[src0..6].ck = clk; 
src0.d = TDA_1 & f_getsrc # src0 & !f_getsrc; 
src1.d = TDA_2 & f_getsrc # src1 & !f_getsrc; 
src2.d = TDA_3 & f_getsrc # src2 & !f_getsrc; 
src3.d = TDA_4 & f_getsrc # src3 & !f_getsrc;  
src4.d = TDA_5 & f_getsrc # src4 & !f_getsrc; 
src5.d = TDA_6 & f_getsrc # src5 & !f_getsrc; 
src6.d = TDA_7 & f_getsrc # src6 & !f_getsrc; 
wl_sets.ck = clk; 
wl_sets.d = TDA_8 & f_getsrc # wl_sets & !f_getsrc; 
 
/* Counter for keeping track of the source number (to make sure we have shifted in gain bits for every source) */ 
[gsc0..6].ck = clk; 
 
append gsc0.d = !gsc0 & src_cntr & M1 & !M0; 
append gsc0.d = gsc0 & !src_cntr & M1 & !M0; 
append gsc1.d = !gsc1 & gsc0 & src_cntr & M1 & !M0; 
append gsc1.d = gsc1 & !src_cntr & M1 & !M0; 
append gsc1.d = gsc1 & !gsc0 & M1 & !M0; 
append gsc2.d = !gsc2 & gsc1 & gsc0 & src_cntr & M1 & !M0; 
append gsc2.d = gsc2 & !src_cntr & M1 & !M0; 
append gsc2.d = gsc2 & !gsc0 & M1 & !M0; 






append gsc3.d = !gsc3 & gsc2 & gsc1 & gsc0 & src_cntr & M1 & !M0; 
append gsc3.d = gsc3 & !src_cntr & M1 & !M0; 
append gsc3.d = gsc3 & !gsc0 & M1 & !M0; 
append gsc3.d = gsc3 & !gsc1 & M1 & !M0; 
append gsc3.d = gsc3 & !gsc2 & M1 & !M0; 
append gsc4.d = !gsc4 & gsc3 & gsc2 & gsc1 & gsc0 & src_cntr & M1 & !M0; 
append gsc4.d = gsc4 & !src_cntr & M1 & !M0; 
append gsc4.d = gsc4 & !gsc0 & M1 & !M0; 
append gsc4.d = gsc4 & !gsc1 & M1 & !M0; 
append gsc4.d = gsc4 & !gsc2 & M1 & !M0; 
append gsc4.d = gsc4 & !gsc3 & M1 & !M0; 
append gsc5.d = !gsc5 & gsc4 & gsc3 & gsc2 & gsc1 & gsc0 & src_cntr & M1 & !M0; 
append gsc5.d = gsc5 & !src_cntr & M1 & !M0; 
append gsc5.d = gsc5 & !gsc0 & M1 & !M0; 
append gsc5.d = gsc5 & !gsc1 & M1 & !M0; 
append gsc5.d = gsc5 & !gsc2 & M1 & !M0; 
append gsc5.d = gsc5 & !gsc3 & M1 & !M0; 
append gsc5.d = gsc5 & !gsc4 & M1 & !M0; 
append gsc6.d = !gsc6 & gsc5 & gsc4 & gsc3 & gsc2 & gsc1 & gsc0 & src_cntr & M1 & !M0; 
append gsc6.d = gsc6 & !src_cntr & M1 & !M0; 
append gsc6.d = gsc6 & !gsc0 & M1 & !M0; 
append gsc6.d = gsc6 & !gsc1 & M1 & !M0; 
append gsc6.d = gsc6 & !gsc2 & M1 & !M0; 
append gsc6.d = gsc6 & !gsc3 & M1 & !M0; 
append gsc6.d = gsc6 & !gsc4 & M1 & !M0; 
append gsc6.d = gsc6 & !gsc5 & M1 & !M0; 
 
 
/* Determine whether or not we are finished programming the gainbits for all of the enabled sources */ 
f_gb = !(  (src0 $ gsc0) # (src1 $ gsc1) # (src2 $ gsc2) # (src3 $ gsc3) # 
   (src4 $ gsc4) # (src5 $ gsc5) # (src6 $ gsc6) # !G0 # G1 # !G2); 
 
/* Outputs to the shift registers */ 
scl.ck = clk; 
 
GBL.d = en & TDA_0 & !G2 & G1 & !G0; 
GBR.d = en & TDB_0 & !G2 & G1 & !G0; 
GBR.ck = clk; 
GBL.ck = clk; 
 
ssclk.d = en & TF_0 & !G2 & G1 & !G0; 
ssclk.ck = !clk; 
srclk.ck = !clk; 
/* Since both ssclk and srclk are ANDed with the clock after leaving the CPLD, we shift them by half a clock cycle to give more stability to the 
system. 
 
/* Finished uploading the gainbits whenever the DSP stops sending them */ 
/* NOTE - no checking done by CPLD to make sure correct number of gainbits were transferred */ 
f_gb_upload = !TF_0 & TF_1 & !G2 & G1 & !G0; 
 
 
/* *************** IMAGING STATE MACHINE ***************** */ 
/* NOTE: The strobe_init signal is what actually tells the switch to move positions.  */ 
/* The srcpos_cntr is just keeping track of the next position */ 
 
field IMSM = [IM2..0]; 
$define i_init   'b'000 /* Initial state */ 
$define i_wait   'b'001  /* State where the optical source is updating (~5ms) */ 
$define i_update  'b'010  /* State where the DSP is updating its settings - is this state needed?. */ 
$define i_cnvrt  'b'011  /* Give the ADC time to convert the signals from analog to digital (~70 clocks) */ 
$define i_sndta  'b'100  /* Send the data to the DSP - 150 samples per detector/source combo */ 
$define i_finish1 'b'101  /* Finished state */ 
$define i_finish2 'b'110 







[IM2..0].ck = clk; 
 
SEQUENCED IMSM { 
 
 present i_init  if (!en # !M1 # !M0)  next i_init; 
    if (en & M1 & M0)  next i_switch;  
  /*the first time through the switch is already in the right spot - don't need to change positions*/ 
     
 present i_switch if (!en # !M1 # !M0)   next i_init; 
    if (en & M1 & M0)  next i_wait out strobe_init; 
 
 present i_wait  if (!en # !M1 # !M0)  next i_init; 
    if (en & M1 & M0 & time)  next i_update out srcpos_cntr; 
    default    next i_wait  out flag3;  
   /*outputing flag3 the entire time we are in i_wait tells the DSP to start the 5ms timer*/ 
 
 present i_update if (!en # !M1 # !M0)   next i_init; 
    if (en & M1 & M0)  next i_cnvrt out smpl_en; 
    default    next i_update; 
 
 present i_cnvrt  if (!en # !M1 # !M0)  next i_init; 
    if (en & M1 & M0 & f_cnvt) next i_sndta out smpl_cntr out smpl_en; 
    default    next i_cnvrt out smpl_en; 
 
 present i_sndta  if (!en # !M1 # !M0)  next i_init; 
    if (en & M1 & M0 & f_sd & ! f_smpl) next i_cnvrt out smpl_en; 
    if (en & M1 & M0 & f_sd & f_smpl & !ls) next i_switch; 
    if (en & M1 & M0 & f_sd & f_smpl & ls) next i_finish1 out f_img; 
    default     next i_sndta out smpl_en; 
 
 present i_finish1       next i_finish2; 
 




f_img.ck = clk; 
srcpos_cntr.ck = clk; 
smpl_cntr.ck = clk; 
smpl_en.ck = clk; 
strobe_init.ck = clk; 
 
/* Fifo Retransmit - Set low for one cycle after imaging state is completed */ 
!frt.d = ((IM2 & !IM1 & IM0) # (IM2 & IM1 & !IM0)); 
frt.ck = clk; 
 
/* Convert State signal to ADC */ 
!cnvst.d = !IM2 & IM1 & IM0; 
cnvst.ck = clk; 
 
/* Fifo Read Signal - output to the Gainbit Fifo */ 
fr1.d =  !((!IM2 & !IM1 & IM0) # (!IM2 & IM1 & !IM0) # (!IM2 & IM1 & IM0) # (IM2 & !IM1 & !IM0)); 
fr1.ck = clk; 
 
/*Need to expand the read pulse to avoid glitches*/ 
fr2.ck = clk; 
fr2.d = fr1; 
fr3.ck = clk; 
fr3.d = fr2; 
fr.d = fr1 # fr2 # fr3; 
fr.ck = clk; 
 






time.d = timexp; 
time.ck = clk; 
 
/* Counter for the conversion state (counts for 70 cycles) */ 
 
[cwc0..6].ck = clk; 
 
append cwc0.d = !cwc0 & !IM2 & IM1 & IM0; 
append cwc1.d = !cwc1 & cwc0 & !IM2 & IM1 & IM0; 
append cwc1.d = cwc1 & !cwc0 & !IM2 & IM1 & IM0; 
append cwc2.d = !cwc2 & cwc1 & cwc0 & !IM2 & IM1 & IM0; 
append cwc2.d = cwc2 & !cwc0 & !IM2 & IM1 & IM0; 
append cwc2.d = cwc2 & !cwc1 & !IM2 & IM1 & IM0; 
append cwc3.d = !cwc3 & cwc2 & cwc1 & cwc0 & !IM2 & IM1 & IM0; 
append cwc3.d = cwc3 & !cwc0 & !IM2 & IM1 & IM0; 
append cwc3.d = cwc3 & !cwc1 & !IM2 & IM1 & IM0; 
append cwc3.d = cwc3 & !cwc2 & !IM2 & IM1 & IM0; 
append cwc4.d = !cwc4 & cwc3 & cwc2 & cwc1 & cwc0 & !IM2 & IM1 & IM0; 
append cwc4.d = cwc4 & !cwc0 & !IM2 & IM1 & IM0; 
append cwc4.d = cwc4 & !cwc1 & !IM2 & IM1 & IM0; 
append cwc4.d = cwc4 & !cwc2 & !IM2 & IM1 & IM0; 
append cwc4.d = cwc4 & !cwc3 & !IM2 & IM1 & IM0; 
append cwc5.d = !cwc5 & cwc4 & cwc3 & cwc2 & cwc1 & cwc0 & !IM2 & IM1 & IM0; 
append cwc5.d = cwc5 & !cwc0 & !IM2 & IM1 & IM0; 
append cwc5.d = cwc5 & !cwc1 & !IM2 & IM1 & IM0; 
append cwc5.d = cwc5 & !cwc2 & !IM2 & IM1 & IM0; 
append cwc5.d = cwc5 & !cwc3 & !IM2 & IM1 & IM0; 
append cwc5.d = cwc5 & !cwc4 & !IM2 & IM1 & IM0; 
append cwc6.d = !cwc6 & cwc5 & cwc4 & cwc3 & cwc2 & cwc1 & cwc0 & !IM2 & IM1 & IM0; 
append cwc6.d = cwc6 & !cwc0 & !IM2 & IM1 & IM0; 
append cwc6.d = cwc6 & !cwc1 & !IM2 & IM1 & IM0; 
append cwc6.d = cwc6 & !cwc2 & !IM2 & IM1 & IM0; 
append cwc6.d = cwc6 & !cwc3 & !IM2 & IM1 & IM0; 
append cwc6.d = cwc6 & !cwc4 & !IM2 & IM1 & IM0; 
append cwc6.d = cwc6 & !cwc5 & !IM2 & IM1 & IM0; 
 
f_cnvt.d = cwc6 & !cwc5 & !cwc4 & !cwc3 & cwc2 & cwc1 & !cwc0; /*70*/ 
f_cnvt.ck = clk; 
 
 
/* Counting the number of samples (counts to 300 - 150 for each ADC address 0 and 1) */ 
[csmp0..8].ck = clk; 
append csmp0.d = !csmp0 & smpl_cntr & smpl_en; 
append csmp0.d = csmp0 & !smpl_cntr & smpl_en; 
append csmp1.d = !csmp1 & csmp0 & smpl_cntr & smpl_en; 
append csmp1.d = csmp1 & !smpl_cntr & smpl_en; 
append csmp1.d = csmp1 & !csmp0 & smpl_en; 
append csmp2.d = !csmp2 & csmp1 & csmp0 & smpl_cntr & smpl_en; 
append csmp2.d = csmp2 & !smpl_cntr & smpl_en; 
append csmp2.d = csmp2 & !csmp0 & smpl_en; 
append csmp2.d = csmp2 & !csmp1 & smpl_en; 
append csmp3.d = !csmp3 & csmp2 & csmp1 & csmp0 & smpl_cntr & smpl_en; 
append csmp3.d = csmp3 & !smpl_cntr & smpl_en; 
append csmp3.d = csmp3 & !csmp0 & smpl_en; 
append csmp3.d = csmp3 & !csmp1 & smpl_en; 
append csmp3.d = csmp3 & !csmp2 & smpl_en; 
append csmp4.d = !csmp4 & csmp3 & csmp2 & csmp1 & csmp0 & smpl_cntr & smpl_en; 
append csmp4.d = csmp4 & !smpl_cntr & smpl_en; 
append csmp4.d = csmp4 & !csmp0 & smpl_en; 
append csmp4.d = csmp4 & !csmp1 & smpl_en; 
append csmp4.d = csmp4 & !csmp2 & smpl_en; 
append csmp4.d = csmp4 & !csmp3 & smpl_en; 
append csmp5.d = !csmp5 & csmp4 & csmp3 & csmp2 & csmp1 & csmp0 & smpl_cntr & smpl_en; 






append csmp5.d = csmp5 & !csmp0 & smpl_en; 
append csmp5.d = csmp5 & !csmp1 & smpl_en; 
append csmp5.d = csmp5 & !csmp2 & smpl_en; 
append csmp5.d = csmp5 & !csmp3 & smpl_en; 
append csmp5.d = csmp5 & !csmp4 & smpl_en; 
append csmp6.d = !csmp6 & csmp5 & csmp4 & csmp3 & csmp2 & csmp1 & csmp0 & smpl_cntr & smpl_en; 
append csmp6.d = csmp6 & !smpl_cntr & smpl_en;append csmp6.d = csmp6 & !csmp0 & smpl_en; 
append csmp6.d = csmp6 & !csmp1 & smpl_en; 
append csmp6.d = csmp6 & !csmp2 & smpl_en; 
append csmp6.d = csmp6 & !csmp3 & smpl_en; 
append csmp6.d = csmp6 & !csmp4 & smpl_en; 
append csmp6.d = csmp6 & !csmp5 & smpl_en; 
append csmp7.d = !csmp7 & csmp6 & csmp5 & csmp4 & csmp3 & csmp2 & csmp1 & csmp0 & smpl_cntr & smpl_en; 
append csmp7.d = csmp7 & !smpl_cntr & smpl_en; 
append csmp7.d = csmp7 & !csmp0 & smpl_en; 
append csmp7.d = csmp7 & !csmp1 & smpl_en; 
append csmp7.d = csmp7 & !csmp2 & smpl_en; 
append csmp7.d = csmp7 & !csmp3 & smpl_en; 
append csmp7.d = csmp7 & !csmp4 & smpl_en; 
append csmp7.d = csmp7 & !csmp5 & smpl_en; 
append csmp7.d = csmp7 & !csmp6 & smpl_en; 
append csmp8.d = !csmp8 & csmp7 & csmp6 & csmp5 & csmp4 & csmp3 & csmp2 & csmp1 & csmp0 & smpl_cntr & smpl_en; 
append csmp8.d = csmp8 & !smpl_cntr & smpl_en; 
append csmp8.d = csmp8 & !csmp0 & smpl_en; 
append csmp8.d = csmp8 & !csmp1 & smpl_en; 
append csmp8.d = csmp8 & !csmp2 & smpl_en; 
append csmp8.d = csmp8 & !csmp3 & smpl_en; 
append csmp8.d = csmp8 & !csmp4 & smpl_en; 
append csmp8.d = csmp8 & !csmp5 & smpl_en; 
append csmp8.d = csmp8 & !csmp6 & smpl_en; 
append csmp8.d = csmp8 & !csmp7 & smpl_en; 
 
/* Address select to ADC */ 
A0.d = csmp0; 
A0.ck = clk; 
f_smpl.d = csmp8 & !csmp7 & !csmp6 & csmp5 & !csmp4 & csmp3 & csmp2 & !csmp1 & !csmp0; /*300*/ 
f_smpl.ck = clk; 
 
/* Counter for sending the data from ADC to DSP */ 
[sdc0..6].ck =clk; 
append sdc0.d = en & !sdc0 & IM2 & !IM0 & !IM1; 
append sdc1.d = en & !sdc1 & sdc0 & IM2 & !IM0 & !IM1; 
append sdc1.d = en & sdc1 & !sdc0 & IM2 & !IM0 & !IM1; 
append sdc2.d = en & !sdc2 & sdc1 & sdc0 & IM2 & !IM0 & !IM1; 
append sdc2.d = en & sdc2 & !sdc0 & IM2 & !IM0 & !IM1; 
append sdc2.d = en & sdc2 & !sdc1 & IM2 & !IM0 & !IM1; 
append sdc3.d = en & !sdc3 & sdc2 & sdc1 & sdc0 & IM2 & !IM0 & !IM1; 
append sdc3.d = en & sdc3 & !sdc0 & IM2 & !IM0 & !IM1; 
append sdc3.d = en & sdc3 & !sdc1 & IM2 & !IM0 & !IM1; 
append sdc3.d = en & sdc3 & !sdc2 & IM2 & !IM0 & !IM1; 
append sdc4.d = en & !sdc4 & sdc3 & sdc2 & sdc1 & sdc0 & IM2 & !IM0 & !IM1; 
append sdc4.d = en & sdc4 & !sdc0 & IM2 & !IM0 & !IM1; 
append sdc4.d = en & sdc4 & !sdc1 & IM2 & !IM0 & !IM1; 
append sdc4.d = en & sdc4 & !sdc2 & IM2 & !IM0 & !IM1; 
append sdc4.d = en & sdc4 & !sdc3 & IM2 & !IM0 & !IM1; 
append sdc5.d = en & !sdc5 & sdc4 & sdc3 & sdc2 & sdc1 & sdc0 & IM2 & !IM0 & !IM1; 
append sdc5.d = en & sdc5 & !sdc0 & IM2 & !IM0 & !IM1; 
append sdc5.d = en & sdc5 & !sdc1 & IM2 & !IM0 & !IM1; 
append sdc5.d = en & sdc5 & !sdc2 & IM2 & !IM0 & !IM1; 
append sdc5.d = en & sdc5 & !sdc3 & IM2 & !IM0 & !IM1; 
append sdc5.d = en & sdc5 & !sdc4 & IM2 & !IM0 & !IM1; 
append sdc6.d = en & !sdc6 & sdc5 & sdc4 & sdc3 & sdc2 & sdc1 & sdc0 & IM2 & !IM0 & !IM1; 
append sdc6.d = en & sdc6 & !sdc0 & IM2 & !IM0 & !IM1; 






append sdc6.d = en & sdc6 & !sdc2 & IM2 & !IM0 & !IM1; 
append sdc6.d = en & sdc6 & !sdc3 & IM2 & !IM0 & !IM1; 
append sdc6.d = en & sdc6 & !sdc4 & IM2 & !IM0 & !IM1; 
append sdc6.d = en & sdc6 & !sdc5 & IM2 & !IM0 & !IM1; 
f_sd.d = sdc6 & sdc5 & sdc4 & sdc3 & sdc2 & sdc1 & !sdc0;  
 
/*126*/ 
f_sd.ck = clk; 
 
/* Logic for the chip selects (active low select) */ 
!cs1.d = !sdc6 & !sdc5 & IM2 & !IM0 & !IM1 & en; 
!cs2.d = !sdc6 & sdc5 & IM2 & !IM0 & !IM1 & en; 
!cs3.d = sdc6 & !sdc5 & IM2 & !IM0 & !IM1 & en; 
!cs4.d = sdc6 & sdc5 & IM2 & !IM0 & !IM1 & en; 
[cs1..4].ck = clk; 
 
/* Signal that determines when all of the enabled sources have been imaged */ 
!ls.d = (src0 $ spc0) # (src1 $ spc1) # (src2 $ spc2) # (src3 $ spc3) # (src4 $ spc4) # (src5 $ spc5) # (src6 $ spc6); 
ls.ck = clk; 
 
/* Counter for source positions */ 
[spc0..6].ck = clk; 
append spc0.d = !spc0 & srcpos_cntr & M1 & M0; 
append spc0.d = spc0 & !srcpos_cntr & M1 & M0; 
append spc1.d = !spc1 & spc0 & srcpos_cntr & M1 & M0; 
append spc1.d = spc1 & !srcpos_cntr & M1 & M0; 
append spc1.d = spc1 & !spc0 & M1 & M0; 
append spc2.d = !spc2 & spc1 & spc0 & srcpos_cntr & M1 & M0; 
append spc2.d = spc2 & !srcpos_cntr & M1 & M0; 
append spc2.d = spc2 & !spc0 & M1 & M0; 
append spc2.d = spc2 & !spc1 & M1 & M0; 
append spc3.d = !spc3 & spc2 & spc1 & spc0 & srcpos_cntr & M1 & M0; 
append spc3.d = spc3 & !srcpos_cntr & M1 & M0; 
append spc3.d = spc3 & !spc0 & M1 & M0; 
append spc3.d = spc3 & !spc1 & M1 & M0; 
append spc3.d = spc3 & !spc2 & M1 & M0; 
append spc4.d = !spc4 & spc3 & spc2 & spc1 & spc0 & srcpos_cntr & M1 & M0; 
append spc4.d = spc4 & !srcpos_cntr & M1 & M0; 
append spc4.d = spc4 & !spc0 & M1 & M0; 
append spc4.d = spc4 & !spc1 & M1 & M0; 
append spc4.d = spc4 & !spc2 & M1 & M0; 
append spc4.d = spc4 & !spc3 & M1 & M0; 
append spc5.d = !spc5 & spc4 & spc3 & spc2 & spc1 & spc0 & srcpos_cntr & M1 & M0; 
append spc5.d = spc5 & !srcpos_cntr & M1 & M0; 
append spc5.d = spc5 & !spc0 & M1 & M0; 
append spc5.d = spc5 & !spc1 & M1 & M0; 
append spc5.d = spc5 & !spc2 & M1 & M0; 
append spc5.d = spc5 & !spc3 & M1 & M0; 
append spc5.d = spc5 & !spc4 & M1 & M0; 
append spc6.d = !spc6 & spc5 & spc4 & spc3 & spc2 & spc1 & spc0 & srcpos_cntr & M1 & M0; 
append spc6.d = spc6 & !srcpos_cntr & M1 & M0; 
append spc6.d = spc6 & !spc0 & M1 & M0; 
append spc6.d = spc6 & !spc1 & M1 & M0; 
append spc6.d = spc6 & !spc2 & M1 & M0; 
append spc6.d = spc6 & !spc3 & M1 & M0; 
append spc6.d = spc6 & !spc4 & M1 & M0; 
append spc6.d = spc6 & !spc5 & M1 & M0; 
 
/* Logic to control the optical switch */ 
[swtch_cntr0..9].ck = clk; 
 
/* Counts to 510, timing for strobe */ 
append swtch_cntr0.d = !swtch_cntr0 & strobe_counter; 






append swtch_cntr1.d = swtch_cntr1 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr2.d = !swtch_cntr2 & swtch_cntr1 & swtch_cntr0 & strobe_counter; 
append swtch_cntr2.d = swtch_cntr2 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr2.d = swtch_cntr2 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr3.d = !swtch_cntr3 & swtch_cntr2 & swtch_cntr1 & swtch_cntr0 & strobe_counter; 
append swtch_cntr3.d = swtch_cntr3 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr3.d = swtch_cntr3 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr3.d = swtch_cntr3 & !swtch_cntr2 & strobe_counter; 
append swtch_cntr4.d = !swtch_cntr4 & swtch_cntr3 & swtch_cntr2 & swtch_cntr1 & swtch_cntr0 & strobe_counter; 
append swtch_cntr4.d = swtch_cntr4 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr4.d = swtch_cntr4 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr4.d = swtch_cntr4 & !swtch_cntr2 & strobe_counter; 
append swtch_cntr4.d = swtch_cntr4 & !swtch_cntr3 & strobe_counter; 
append swtch_cntr5.d = !swtch_cntr5 & swtch_cntr4 & swtch_cntr3 & swtch_cntr2 & swtch_cntr1 & swtch_cntr0 & strobe_counter; 
append swtch_cntr5.d = swtch_cntr5 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr5.d = swtch_cntr5 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr5.d = swtch_cntr5 & !swtch_cntr2 & strobe_counter; 
append swtch_cntr5.d = swtch_cntr5 & !swtch_cntr3 & strobe_counter; 
append swtch_cntr5.d = swtch_cntr5 & !swtch_cntr4 & strobe_counter; 
append swtch_cntr6.d = !swtch_cntr6 & swtch_cntr5 & swtch_cntr4 & swtch_cntr3 & swtch_cntr2 & swtch_cntr1 & swtch_cntr0 & 
strobe_counter; 
append swtch_cntr6.d = swtch_cntr6 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr6.d = swtch_cntr6 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr6.d = swtch_cntr6 & !swtch_cntr2 & strobe_counter; 
append swtch_cntr6.d = swtch_cntr6 & !swtch_cntr3 & strobe_counter; 
append swtch_cntr6.d = swtch_cntr6 & !swtch_cntr4 & strobe_counter; 
append swtch_cntr6.d = swtch_cntr6 & !swtch_cntr5 & strobe_counter; 
append swtch_cntr7.d = !swtch_cntr7 & swtch_cntr6 & swtch_cntr5 & swtch_cntr4 & swtch_cntr3 & swtch_cntr2 & swtch_cntr1 & 
swtch_cntr0 & strobe_counter; 
append swtch_cntr7.d = swtch_cntr7 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr7.d = swtch_cntr7 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr7.d = swtch_cntr7 & !swtch_cntr2 & strobe_counter; 
append swtch_cntr7.d = swtch_cntr7 & !swtch_cntr3 & strobe_counter; 
append swtch_cntr7.d = swtch_cntr7 & !swtch_cntr4 & strobe_counter; 
append swtch_cntr7.d = swtch_cntr7 & !swtch_cntr5 & strobe_counter; 
append swtch_cntr7.d = swtch_cntr7 & !swtch_cntr6 & strobe_counter; 
append swtch_cntr8.d = !swtch_cntr8 & swtch_cntr7 & swtch_cntr6 & swtch_cntr5 & swtch_cntr4 & swtch_cntr3 & swtch_cntr2 & 
swtch_cntr1 & swtch_cntr0 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr2 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr3 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr4 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr5 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr6 & strobe_counter; 
append swtch_cntr8.d = swtch_cntr8 & !swtch_cntr7 & strobe_counter; 
append swtch_cntr9.d = !swtch_cntr9 & swtch_cntr8 & swtch_cntr7 & swtch_cntr6 & swtch_cntr5 & swtch_cntr4 & swtch_cntr3 & 
swtch_cntr2 & swtch_cntr1 & swtch_cntr0 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr0 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr1 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr2 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr3 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr4 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr5 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr6 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr7 & strobe_counter; 
append swtch_cntr9.d = swtch_cntr9 & !swtch_cntr8 & strobe_counter; 
 
/* switch_cntr_hold goes high when counter reaches 788 ~26usec */ 
switch_cntr_hold.ck = clk; 
switch_cntr_hold.d = swtch_cntr9 & swtch_cntr8 & !swtch_cntr7 & !swtch_cntr6 & !swtch_cntr5 & swtch_cntr4 & !swtch_cntr3 & swtch_cntr2 








/* *************** STATE MACHINE FOR STROBE ***************** */ 
field T1SM = [T1..0]; 
$define t1_idle  'b'00 
$define t1_cnt_hold 'b'01 
$define t1_error 'b'10 
$define t1_error2 'b'11 
[T1..0].ck = clk; 
strobe.ck = clk; 
strobe_counter.ck = clk; 
 
SEQUENCED T1SM { 
 
 present t1_idle  if (strobe_init) next t1_cnt_hold out strobe_counter; 
    default  next t1_idle; 
  
 present t1_cnt_hold if (switch_cntr_hold) next t1_idle; 
    default  next t1_cnt_hold out strobe_counter  out strobe;  
  
 
 present t1_error    next t1_idle; 
 present t1_error2   next t1_idle; 
} 
 
/* Cycle through source positions from 1 to 32 and 1or2 wavelength sets */ 
[PS6..0].ck = clk; 
 
PS0.d = !strobe; 
 
/*Depending on how many wavelength sets we're using (1 or 2) we may or may not want to do the A1/A2 selection */ 
PS1.d = spc0 & wl_sets; /*(A1/A2 selection on switch = wavelength selection)*/ 
PS2.d = (spc1 & wl_sets) # (spc0 & !wl_sets); /*(Data0 for B1..B32 selection) */ 
PS3.d = (spc2 & wl_sets) # (spc1 & !wl_sets); /*(Data1 for B1..B32 selection) */ 
PS4.d = (spc3 & wl_sets) # (spc2 & !wl_sets); /*(Data2 for B1..B32 selection) */ 
PS5.d = (spc4 & wl_sets) # (spc3 & !wl_sets); /*(Data3 for B1..B32 selection) */ 










H2.  CPLD_breast_imager_slave.pld 
/* *************** INPUT PINS *********************/ 
 
PIN 83 = clk; /* PLD Clock */ 
PIN 56 = cs1;  /* chip select 1 */ 
PIN 54 = cs2;  /* chip select 2 */ 
PIN 57 = cs3;  /* chip select 3 */ 
PIN 55 = cs4;  /* chip select 4 */ 
 
PIN 4  = ind1a;  /* Input from ADC 1A */ 
PIN 5  = ind2a;  /* Input from ADC 2A */ 
PIN 6  = ind3a;  /* Input from ADC 3A */ 
PIN 8  = ind4a;  /* Input from ADC 4A */ 
PIN 9  = ind5a;  /* Input from ADC 5A */ 
PIN 10  = ind6a;  /* Input from ADC 6A */ 
PIN 11  = ind7a;  /* Input from ADC 7A */ 
PIN 15  = ind8a;  /* Input from ADC 8A */  
 
PIN 16  = ind1b;  /* Input from ADC 1B */ 
PIN 17  = ind2b;  /* Input from ADC 2B */ 
PIN 18  = ind3b;  /* Input from ADC 3B */ 
PIN 20  = ind4b;  /* Input from ADC 4B */ 
PIN 21  = ind5b;  /* Input from ADC 5B */ 
PIN 22  = ind6b;  /* Input from ADC 6B */ 
PIN 24  = ind7b;  /* Input from ADC 7B */ 
PIN 25  = ind8b;  /* Input from ADC 8B */ 
  
 
PIN 27  = ind1c;  /* Input from ADC 1C */ 
PIN 28  = ind2c;  /* Input from ADC 2C */ 
PIN 29  = ind3c;  /* Input from ADC 3C */ 
PIN 30  = ind4c;  /* Input from ADC 4C */ 
PIN 31  = ind5c;  /* Input from ADC 5C */ 
PIN 33  = ind6c;  /* Input from ADC 6C */ 
PIN 34  = ind7c;  /* Input from ADC 7C */ 
PIN 35  = ind8c;  /* Input from ADC 8C */ 
 
PIN 36  = ind1d;  /* Input from ADC 1D */ 
PIN 37  = ind2d;  /* Input from ADC 2D */ 
PIN 39  = ind3d;  /* Input from ADC 3D */ 
PIN 40  = ind4d;  /* Input from ADC 4D */ 
PIN 41  = ind5d;  /* Input from ADC 5D */ 
PIN 44  = ind6d;  /* Input from ADC 6D */ 
PIN 46  = ind7d;  /* Input from ADC 7D */ 
PIN 48  = ind8d;  /* Input from ADC 8D */ 
 
 
/* *************** OUTPUT PINS ********************* */ 
 
PIN 60  = outd1a;  /* Ouput Data to DSP 0A */ 
PIN 61  = outd1b;  /* Ouput Data to DSP 0B */ 
PIN 63  = outd2a;  /* Ouput Data to DSP 1A */ 
PIN 64  = outd2b;  /* Ouput Data to DSP 1B */ 
PIN 65  = outd3a;  /* Ouput Data to DSP 2A */ 
PIN 67  = outd3b;  /* Ouput Data to DSP 2B */ 
PIN 68  = outd4a;  /* Ouput Data to DSP 3A */ 
PIN 69  = outd4b;  /* Ouput Data to DSP 3B */ 
PIN 58  = sync; /* Sync output for Data to DPSs */ 
 
/* *************** PINNODES ************************ */ 
 






PINNODE = sp2; 
PINNODE = sp3; 
PINNODE = sp4; 
 
/* *************** DATA MUXING ********************* */ 
 
sp1.d = !cs1; 
sp2.d = !cs2; 
sp3.d = !cs3; 
sp4.d = !cs4; 
[sp1..4].ck = clk; 
 
sync.d = sp1 # sp2 # sp3 # sp4; 
sync.ck = clk; 
 
/* Right Side */ 
outd1a.d = sp1 & ind1c # sp2 & ind3c # sp3 & ind5c # sp4 & ind7c; 
outd1b.d = sp1 & ind2c # sp2 & ind4c # sp3 & ind6c # sp4 & ind8c; 
 
outd2a.d = sp1 & ind1d # sp2 & ind3d # sp3 & ind5d # sp4 & ind7d; 
outd2b.d = sp1 & ind2d # sp2 & ind4d # sp3 & ind6d # sp4 & ind8d; 
 
 
/*Left Side */ 
outd3a.d = sp1 & ind1a # sp2 & ind3a # sp3 & ind5a # sp4 & ind7a; 
outd3b.d = sp1 & ind2a # sp2 & ind4a # sp3 & ind6a # sp4 & ind8a; 
 
outd4a.d = sp1 & ind1b # sp2 & ind3b # sp3 & ind5b # sp4 & ind7b; 
outd4b.d = sp1 & ind2b # sp2 & ind4b # sp3 & ind6b # sp4 & ind8b; 
 
outd1a.ck = clk; 
outd1b.ck = clk; 
outd2a.ck = clk; 
outd2b.ck = clk; 
outd3a.ck = clk; 
outd3b.ck = clk; 
outd4a.ck = clk; 






APPENDIX I – GLUE LOGIC BOARD BOM, LAYOUT, and SCHEMATIC 
I1.  Bill of Materials 






C33,C36 0.1u 805 
CAP 0.1uF 50V CERAMIC 
X7R 0805 Digi-key 399-1170-1-ND 
2 C17,C18 0.47u 805 
CAP CER .56UF 25V X7R 
0805 Digi-key 399-3492-1-ND 
3 C21,C24 10u 
3216-18 
(EIA) 
CAP TANTALUM 10UF 16V 
10% SMD Digi-key 495-2236-1-ND 
4 C25,C27,C35,C37 10u 805 
CAP 10UF 6.3V CERAMIC 
X5R 0805 Digi-key PCC2225CT-ND 
5 C34,C38 100p 805 
CAP CERAMIC 100PF 50V 
NP0 0805 Digikey 399-1121-1-ND 
6 J1,J2 
  
CONN DIN PLUG 96POS RT 
ANG PCB Digi-Key A1279-ND 
7 R1,R2 10k 805 
RES 10.0K OHM 1/8W 1% 
0805 SMD Digi-key RHM10.0KCRCT-ND 
8 R3,R4 100 805 
RES 100 OHM 1/8W 1% 




IC 16BIT SCHOTTKY DIODE 








DIODE SCHOTTKY BARRIER 




IC OCT BUS XCVR/SHIFTER 




IC QUAD 2-INPUT OR GATE 




IC QUAD BUS BUFF GATE 




IC HEX SCHMITT-TRIG INV 




IC QUAD 2IN NAND GATE 




IC QUAD 2-IN NAND GATE 






IC BUS SWITCH 2-BIT LP 




IC QUAD D F/F W/CLEAR 16-




IC 5.0V 150MA LDO REG 8-




IC REG LDO 200MA 3.3V 8-




IC 5.0V 250MA LDO REG 8-
























APPENDIX J – MASTER DSP BOARD BOM, SCHEMATIC, AND BOARD LAYOUT 
J1.  Bill of Materials 











0.01 uF 0805 (2012) 






0.1 uF 0805 (2012) 















0.22 uF 0805 (2012) 
CAP CER .22UF 50V 10% X7R 
0805 
Digi-Key 490-1670-1-ND 
5 2 C68,C72 0.047 uF 1206 
CAP CERM .047UF 10% 50V X7R 
1206 
Digi-Key 478-1550-1-ND 
6 2 C77,C82 0.33 uF 0805 (2012) CAP CER .33UF 50V X7R 0805 Digi-Key 490-3327-1-ND 
7 1 C80 1000 pF 1206 (3216) 
CAP CERAMIC 1000PF 50V NP0 
1206 
Digi-Key 399-1218-1-ND 




LED RED ULTRA BRIGHT GW 
SMD 
Digi-Key P513CT-ND 






LED AMBER GULL WING SMD Digi-Key P512CT-ND 






LED GRN GW-TYPE SMD NO 
HDR/TRLR 
Digi-Key P504CT-ND 
11 1 D7 SL22/54 SMD SCHOTTKY DIODE 20V 2A SMB Digi-Key SL22/54GICT-ND 
12 1 D9 S2A-TP DO-214AA  RECTIFIER SIL 2A 50V DO-214AA Digi-Key S2A-TPMSCT-ND 
13 1 FB1 
 
603 
FERRITE CHIP 600 OHM 200MA 
0603 
Digi-Key 490-1023-1-ND 
14 2 FB2,FB3 600 1206 (3216) 
FERRITE 500MA 600 OHM 1206 
SMD 
Digi-Key 240-2415-1-ND 
15 1 FB4  2020 
CHOKE COMMON MODE 1000 
OHM 2020 
Digi-Key 490-1072-1-ND 
16 1 F1  SMD POLYSWITCH 2.50A HOLD SMD Digi-Key SMD250FCT-ND 
17 2 J1,J2  
 
CONN DIN PLUG 96POS RT ANG 
PCB 
Digi-Key A1254-ND 
18 4 J3,J4,J5,J6  
 
CONN HEADER VERT .100 12POS 
15AU 
Digi-Key A26575-ND 
19 1 J7  
 
CONN HEADER FMAL 12PS.1" DL 
GOLD 
Digi-Key S7109-ND 
20 2 J8,J9  
 
CONN HEADER VERT .100 14POS 
15AU 
Digi-Key A26577-ND 
21 1 J10  
 
CONN HEADER VERT .100 6POS 
15AU 
Digi-Key A26569-ND 
22 2 RN1,RN2  16-SOIC 
















RES 10K OHM 1/8W 5% 0805 
SMD 
Digi-Key P10KACT-ND 
24 2 R6,R11 10 805 
RES 10 OHM 1/8W 5% 0805 
SMD 
Digi-Key P10ACT-ND 
25 4 R25,R26,R27,R30 680 805 
RES 680 OHM 1/8W 5% 0805 
SMD 
Digi-Key P680ACT-ND 
26 1 R29 3.9 805 
RES 3.9 OHM 1/8W 5% 0805 
SMD 
Digi-Key P3.9ACT-ND 
27 1 R34 100k 1206 
RES 100K OHM 1/4W 5% 1206 
SMD 
Digi-Key P100KECT-ND 
28 2 R35,R36 0 402 
RES ZERO OHM 1/16W 5% 0402 
SMD 
Digi-Key P0.0JCT-ND 
29 2 SW1,SW2  
 
SWITCH TACT 2.36MM SILVR G-
WING 
Digi-Key CKN1848CT-ND 
30 4 U1,U2,U7,U8  54-TSOP 64MB SDRAM COMPONENT Digi-Key 557-1091-1-ND 
31 2 U3,U9  225BGA 





32 2 U4,U10  
32PLCC-
THRU-HOLE 
IC SOCKET 32POS PLCC THRU-
HOLE 
Digikey 3M3211B1-ND 
33 1 U5  14-SOIC 
IC QUAD 2-IN NAND GATE 14-
SOIC 
Digi-Key 296-1694-1-ND 
34 4 U6,U36,U42,U50  14-TTSOP 














36 1 U17  84-PLCC IC CPLD 15NS LOW V 84PLCC Digi-Key 
ATF1508ASV-
15JU84-ND 
37 1 U21  24-SSOP 
IC OCT BUS XCVR/SHIFTER 24-
SSOP 
Digi-Key 296-8514-1-ND 
38 4 U22,U23,U25,U26  8-SOIC 





39 2 U28,U31  20-SSOP IC OCTAL F-F TRI-STATE 20-SSOP Digi-Key 296-8530-1-ND 
40 1 U29  TQFP 3.3V DUAL 8Kx9 SYNC FIFO AVNET 72V851L10PFG 
41 1 U30  48-SSOP 
IC 16BIT DUAL OCTAL TXRX 48-
SSOP 
Digi-Key 296-14781-1-ND 
42 1 U32  14-SOIC 
IC QUAD 2-INPUT OR GATE 14-
SOIC 
Digi-Key 296-1235-1-ND 
43 1 U35  14-SOIC 
IC QUAD 2-INPUT AND GATE 14-
SOIC 
Digi-Key 296-1697-1-ND 
44 2 U38,U41  8-SOIC 
IC SUPERVISOR MPU 3.08 WD 
8SOIC 
Digi-Key ADM708TARZ-ND 
45 1 U39  20-SOIC IC 16-BIT TERM ARRAY 20-SOIC Digi-Key 296-1726-5-ND 
46 2 U43,U46  D²Pak/A 
IC REG LDO POS 3.3V 3.0A 
D2PAK/A 
Digi-Key 497-3423-1-ND 
47 1 U44  D²Pak/A IC REG LDO 5.0V 3.0A P2PAK/A Digi-Key 497-3476-1-ND 
48 1 U45  D²Pak/A 
IC 3A LDO 1.8V REGULATOR 
D2PAK/A 
Digi-Key 497-1500-1-ND 
49 1 U47  
Through 
Hole 
IC SOCKET PLCC 84POS GOLD Digi-Key AE7338-ND 
50 2 U48,U49  32-PLCC 
IC FLASH MEM 4MBIT 90NS 32-
PLCC 
AVNET M29W040B90K1E 
51 1 X1  
8-DIP Half 
Size 
OSC 3.3V PROG CMOS TRI ST 
50PPM 
Digi-Key CPPC4-LT5PT-ND 
52 1 X2  SMD 
OSC 25.0000MHZ 3.3V +/-
50PPM SMD 
Digi-Key SE3621CT-ND 
53 2 C99,C100 15pF 1206 (3216) 








54 1 J11 
  
CONN HEADER VERT 2POS .100  Digikey A26564-ND 






























APPENDIX K – SLAVE DSP BOARD BOM, SCHEMATIC, AND BOARD LAYOUT 
K1.  Bill of Materials 













































































































Key P513CT-ND Panasonic - SSG LN1261CALTR 







Key P512CT-ND Panasonic - SSG LN1461CTR 






























Commercial Co. S2A-TP 





































RT ANG PCB 
Digi-














































Key P10KACT-ND Panasonic ERJ-6GEYJ103V 
21 R4,R8 10 805 




Key P10ACT-ND Panasonic ERJ-6GEYJ100V 
22 
R22,R23,R24, 






Key P680ACT-ND Panasonic ERJ-6GEYJ681V 





Key P3.9ACT-ND Panasonic ERJ-6GEY3R9V 






Key P100KECT-ND Panasonic - ECG ERJ-8GEYJ104V 






Key P0.0JCT-ND Panasonic - ECG ERJ-2GE0R00X 


















21161NKCA-100 Analog Devices ADSP-21161NKCA-100 




PLCC AVNET M29W040B90K1E 
ST 
Microelectronics M29W040B90K1E 
29 U5  14-SOIC 






















ND Toshiba TC74LCX14FT(EL,M) 









Electronics Inc A-CCS84-G 
32 U12  84-PLCC 






15JU84-ND ATMEL ATF1508ASV-15JU84 







ND Pericom PI74FCT244CTSE 
34 U14  TQFP 
3.3V DUAL 
8Kx9 SYNC 
FIFO AVNET 72V851L10PFG IDT 72V851L15PA 

















Key ADM708TARZ-ND Analog Devices ADM708TARZ 









38 U21,U24  D²Pak/A 








39 U22  D²Pak/A 







40 U23  D²Pak/A 




































Key CKN1848CT-ND ITT Industries KT11P2SM34LFS 
























































APPENDIX L – DETECTOR UNIT BACKPLANE BOM, LAYOUT, AND SCHEMATIC 
L1.  Bill of Materials 









CONN DIN RECEPT 96POS 
VERT PCB 
Digikey A29014-ND 
2 cPCI Connector  PCS 
Straight solder PCB mount 
female connector 
Positronic Inc. PCIH47F300A1 
3 X1  
Through 
Hole 
CONN TERM BLOCK 6POS 
5.08MM PCB 
Digikey 277-1251-ND 
4 J1  
Through 
Hole 
CONN HEADER 4POS 7.5MM 
VERT TIN 
Digikey WM18475-ND 
5 FAN1,FAN2  
Through 
Hole 






5 Ohm TO-220 
RES 5.000 OHM 15W 1% SMD 
TO-220 
Digikey FPS2-T2205.000CT-ND 
7 12V_PWR_RES 50 Ohm TO-220 
RES 50.000 OHM 15W 1% 
SMD TO-220 
Digikey FPS2-T22050.000CT-ND 
8 R1,R2,R3,R5,R6 10k 
0805 
SMD 
RES 10K OHM 1/8W 5% 0805 
SMD 
Digikey P10KACT-ND 
9 R4 300 Ohm 
2512 
SMD 

















POWER ENT MOD W/FILTER 
8A M5 2PL 
Digikey 486-1301-ND 
13 
Fuse Drawer for 
Power Entry 
Module 
  FUSE DRAWER Shurter Inc. 4301.1401 
14 
Fuses for Power 
Entry Module  
 FUSES Shurter Inc. 34.1525 
15 
Compact PCI 
Power Module  
 6U CompactPCI Power Supply Chroma cPWR-59041 
16 Enclosure 
  


























APPENDIX M – LABVIEW BLOCK DIAGRAMS 
M1.  Data Acquisition 
 







Preparation for reading a single frame of data.  Lower left corner writes DIO_PC0 and DIO_PC1 to 1 to instruct 
mDSP to begin data acquisition. 
 
 
For each frame of data the LabVIEW unpacks the 8-bit packets in Data_converter_mx.vi and then reorganizes the 







Data_converter_mx.vi is responsible for organizing the 8-bit packets received on the data bus and formatting them 
into 32-bit floating point data points for each source, detector, and wavelength. 
 
 
Data acquired from the DAQ is converted into the appropriate arrays and then written to 4 files (one for each 
wavelength) and also ouput to the Data Acquisition plot.  Only the selected wavelength and detectors are 









When the data acquisition is complete, and the correct number of frames have been acquired, the LabVIEW 
instructs the mDSP to leave the imaging state by seting DIO_PC0 and DIO_PC1 low. 
 
M2.  Gain Bit Programming 
 
When the ‘CONFIRM’ button is pressed, the LabVIEW uploads the current gain bits to the mDSP, waits, and then 








Automatic gain settings are calculated when the ‘AUTO’ button is pressed.  This code starts with the lowest gain 
setting and then keeps increasing the gain until the data detected for a given channel falls within the acceptable 
range (as set by the Imaging Parameters tab).  When a channel has found an acceptable gain setting, it preserves 











APPENDIX N – WINDKESSEL VASCULAR MODEL 
To understand the physiological mechanism that causes an increase in blood volume in the 
breast during the breath hold, we created a three-compartment vascular model for the breast.  
Vascular models have been used to understand the biological mechanisms for dynamic optical 
contrast in the brain [N1, N2].   
 
Figure N-1.  Analog electrical equivalent for a 3-compartment Windkessel model of the vascular 
system. 
 
Fig. N-1 shows the analog electrical equivalent of the 3-compartment (arterial, capillary, 
venous) Windkessel model of the vascular system.  Each vascular compartment is modeled with 
two resistors and a capacitor, while the arterial and venous blood pressures are modeled by 
voltage sources.  The resistors account for the vascular resistance to blood flow, while the 
capacitors model the vascular compliance and ability to store blood.  The voltage sources cause 
a current to flow through the electrical equivalent circuit, representing the flow of blood.  The 
blood volume in a given compartment is equal to the difference between the flow out and the 
flow into that compartment. Table 9-2 shows the resistance and capacitance values used for 








Table N-1.  Descriptions and values of the parameters used in the 3-compartment vascular model. 
Parameter Description Value 
Pa Arterial blood pressure 60 mmHg 
Pv Venous blood pressure 25 mmHg 
Ra1 Input resistance of the arterial vasculature 0.0075 mmHg/s/ml 
Ra2 Output resistance of the arterial vasculature 0.038 mmHg/s/ml 
Rc1 Input resistance of the capillary vasculature 12.1 mmHg/s/ml 
Rc2 Output resistance of the capillary vasculature 2.42mmHg/s/ml 
Rv1 Input resistance of the venous vasculature 2.43 mmHg/s/ml 
Rv2 Input resistance of the venous vasculature 0.013 mmHg/s/ml 
Ca Capacitance of the arterial vasculature 0.91 ml/mmHg 
Cc Capacitance of the capillary vasculature  2.7 ml/mmHg 
Cv Capacitance of the venous vasculature 13.3 ml/mmHg 
 
The breath hold is implemented in the Windkessel model as an increase in venous blood 
pressure (Pv) by 5 mmHg, simulating the increase in thoracic pressure impeding the venous 
return.  The parameters in Table N-1 are those used to model healthy breast tissue.  To model 
tumor vasculature we increase the capillary resistances (Rc1 and Rc2) by 10 times and decrease 
the capillary compliance (Cc) by 2 times.  The results of the breath hold simulation performed 
using a Windkessel model in response to a breath hold, as run using a Simulink (MATLAB, 







Fig. N-2.  Similunk 3-compartment windkessel model. 
The results of the model are shown in Fig. N-3.    The blue line represents the % change 
in total blood volume for a healthy breast in response to a breath hold, while the blue response 
represents the response of a tumor-bearing breast.  Similar to the clinical results shown in 
Chapter 9, the greatest contrast between the tumor and healthy vasculature occurs in the 
recovery period following the breath hold. Further improvements to this model could account 
for oxygen consumption by the tissue, and provide insight into the transient response of 
oxygenated and deoxygenated hemoglobin as opposed to just total blood volume.  In addition, 






rate, blood pressure, and oxygen saturation could strengthen this work and provide a greater 
understanding of the biological mechanism from which we derive the optical contrast during a 
breath hold. 
 
Figure N-3.  Plot showing the % change in blood volume for a healthy breast vascular model and a 
tumor vascular model.  
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